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SUMMARY 
 
Vitamin D Receptor (VDR) belongs to the superfamily of nuclear receptors that are in total 48 
ligand-activated transcription factors that bind to the DNA and are involved in the regulation 
of gene expression. The active form of vitamin D3, hormone 1α,25-dihydroxyvitaminD3 
(1α,25(OH)2D3), is a natural ligand for VDR. The generally described physiological functions 
of 1α,25(OH)2D3-activated VDR target genes are stimulation of metabolism as well as 
differentiation and inhibition of inflammation and cellular proliferation. In this study we focus 
primarily on the target genes of VDR that could potentially have a positive role in cancer 
prevention. Microarrays were performed of  human non-malignant prostate RWPE1 cells after 
4 h and 24 h treatment with 100 nM 1α,25(OH)2D3 and among several hundred responsive 
genes, we identified multiple members of the kallikrein (KLK) gene family as putative 
primary VDR targets. The KLKs are serine proteases that have been shown to be deregulated 
in various cancers. The 15 genes in the KLK family cluster together on human chromosome 
19 span roughly 270 kB. KLK6 was the most responsive gene (16-fold induction after 4h 
treatment), followed by its neighboring KLK5, KLK7, KLK8 and KLK9. This effect of 
1α,25(OH)2D3 was confirmed by real-time quantitative PCR and loss-of-function 
experiments. Interestingly, the VDR-mediated induction of the KLK genes was less 
pronounced in the cancer than in non-malignant prostate cells. In addition, we analyzed the 
genomic sequence of the KLK cluster in silico and identified a number of putative VDR 
binding sites (VDREs) as well as putative insulator CTCF binding sites. Chromatin regions 
containing putative binding sites were analyzed by chromatin immunoprecipitation assays to 
assess their functionality in RWPE1 cells. Six VDREs were associated with VDR whereas 
validation of detected CTCF binding sites showed increased occupancy of CTCF upon 
1α,25(OH)2D3 stimulation. These results allow describing the changes in chromatin 
architecture on the KLK locus after VDR activation. Taken together, our study shows that 
1α,25(OH)2D3-activated VDR has an impact on the regulation of the whole KLK gene cluster 
in prostate cells. 
  
  
TABLE OF CONTENTS  
 
 
1. INTRODUCTION………………………………………………………………………......2 
1.1. Chromatin architecture and its relevance in regulation of gene expression .......................2 
1.1.1 Control of chromatin structure ................................................................................3 
1.1.2 Chromatin loop formation .......................................................................................4 
1.2. The nuclear receptor superfamily .....................................................................................7 
1.2.1 Classification ..........................................................................................................7 
1.2.2. Role of nuclear receptors........................................................................................8 
1.2.3. General structure of nuclear receptors .................................................................. 10 
1.2.4. Mechanism of action ............................................................................................ 12 
1.2.5. Interaction with co-regulators ............................................................................... 13 
1.3. Vitamin D and the vitamin D receptor (VDR) ................................................................ 15 
1.3.1. The history of Vitamin D ..................................................................................... 15 
1.3.2. Vitamin D metabolism ......................................................................................... 15 
1.3.3. Discovery of the Vitamin D Receptor................................................................... 16 
1.3.4. Principles of VDR action ..................................................................................... 17 
1.3.5. Protein-protein interactions that mediate VDR transactivation .............................. 18 
1.3.6. 1α,25(OH)2D3 and its analogs .............................................................................. 21 
1.3.7. 1α,25(OH)2D3  effects in biological processes ...................................................... 21 
1.3.7.1 Functions of the VDR in calcium homeostasis ................................................... 22 
1.3.7.2. Functions of the VDR in the immune system..................................................... 22 
1.3.7.3. Functions of the VDR in cell cycle and cancer .................................................. 23 
1.4.1. Phenomenon of cancer ......................................................................................... 25 
1.4.2. Prostate cancer (PCa) genesis ............................................................................... 26 
1.4.3. PCa and inflammation .......................................................................................... 26 
1.4.4. The cancer hallmarks distinguished in PCa .......................................................... 27 
1.4.5. Vitamin D and its function in non-malignant prostate cells ................................... 30 
1.4.6. VDR and PCa epidemiology ................................................................................ 30 
1.4.7. Role of VDR in prostate cancer development ....................................................... 31 
1.4.7.1. The anti-proliferative function of the VDR ........................................................ 31 
1.4.7.2. Anti-angiogenic functions of VDR .................................................................... 33
  
 
1.4.7.3. Anti-metastatic function of the VDR ................................................................. 33 
1.4.8. Clinical studies of vitamin D in PCa..................................................................... 33 
1.5. The Kallikrein gene family ............................................................................................ 35 
1.5.1. General overview on the Kallikrein gene family ................................................... 35 
1.5.2. Organization and structure of the KLKs and their genes ....................................... 35 
1.5.3. Regulation of kallikrein genes .............................................................................. 37 
1.5.4. The role of KLKs in cancer .................................................................................. 38 
1.5.5. Signaling pathways and other functions ............................................................... 40 
2. OBJECTIVES ..................................................................................................................... 42 
3. MATERIALS AND METHODS ........................................................................................ 43 
3.1. Cell culture .................................................................................................................... 43 
3.2. Total RNA extraction and cDNA synthesis .................................................................... 43 
3.3. Microarray analysis ....................................................................................................... 44 
3.4. Real-time quantitative PCR ............................................................................................ 44 
3.5. siRNA silencing ............................................................................................................. 45 
3.6. Chromatin immunoprecipitation (ChIP) assays .............................................................. 45 
3.7. PCR of chromatin templates .......................................................................................... 46 
3.8. RNA degradation rate experiment .................................................................................. 47 
3.9. Gene annotation analysis ............................................................................................... 47 
3.10. The in silico screening analysis .................................................................................... 47 
4. RESULTS ........................................................................................................................... 48 
4.1. Profiling of VDR target genes in non-malignant prostate cells ....................................... 48 
4.2. Physiological role of VDR in non-malignant prostate cells............................................. 54 
4.3. Regulation of the KLK genes in non-malignant and malignant prostate epithelial         
cells by VDR ................................................................................................................. 57 
4.4. Effect of VDR silencing on the central region of the KLK gene family ........................... 61 
4.5. The early VDR-dependent, dynamic response of KLK6 gene expression in                   
non-malignant prostate cell line ..................................................................................... 64 
4.6. Identification of putative binding sites for VDR within the human KLK cluster.............. 67 
4.6.1. In silico screening for putative VDREs in the human KLK cluster based on  
datasets tracks ................................................................................................................ 67 
4.6.2. Recruitment of VDR to the TSS regions of KLK genes ........................................ 70 
4.6.3. Identification of functional VDREs in close proximity to the KLK6 promoter ...... 71
  
 
4.7. Association of VDR and H4Ac with the KLK6 promoter in malignant prostate cells ...... 75 
4.8. Distribution of CTCF binding sites and their activity within the KLK locus ................... 77 
4.9. Effect of CTCF silencing on 1α,25(OH)2D3 stimulation ................................................. 79 
4.10. The correlation between KLK substrates and VDR action. ........................................... 81 
5. DISCUSSION ..................................................................................................................... 84 
5.1. Identification of VDR-regulated genes in human prostate cells ...................................... 84 
5.2. Selectively regulated genes from the KLK cluster in prostate cells ................................. 85 
5.3. Organization of the KLK gene locus, and implications of the VDR in its regulation ....... 87 
5.4. Role of insulators in the KLK cluster .............................................................................. 90 
5.5. Potential functions of VDR and KLKs in human non-malignant prostate cells ............... 92 
5.6. Conclusions ................................................................................................................... 94 
5.7. Future perspective .......................................................................................................... 95 
6. REFERENCES ................................................................................................................... 97 
7. APPENDIX I-III ............................................................................................................... 110 
  
1. Introduction 
 
 2 
1. INTRODUCTION 
1.1. Chromatin architecture and its relevance in regulation of gene 
expression 
 
Chromatin refers to the complex of DNA and proteins that form the chromosomes during cell 
division. It plays a crucial role in the cell-specific gene regulation. Its organization structure is 
directly involved in the process of allowing or denying transcription factors access to DNA. 
The basic units of chromatin structure are the nucleosomes. Each of them is composed of four 
histones proteins wrapped by 147 base pairs (bp) of DNA and is separated from the 
neighboring nucleosome by linker DNA. Their disassembly and reassembly abilities are 
necessary for the proper maintenance of the genome (Deal, 2010). Consequently, 
nucleosomes are involved in DNA packaging and accessibility, which is basically directly, 
related to two chromatin states of relaxation (euchromatin) and of compaction 
(heterochromatin). In the open state of the chromatin the promoter and enhancers of a certain 
gene are available for the transcription complexes whereas they are inaccessible in the densely 
packed, heterochromatin state (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chromatin organization. 
The DNA of a cell is located in the nucleus and organized in chromatin, the material of 
chromosomes. The nucleosome, the basic unit of the chromatin, comprises 147 bp of DNA 
wrapped around the core of histones. Euchromatin is associated with an open state of the 
chromatin that is permissive for transcription, whereas heterochromatin is compact and 
inaccessible for the factors involved in transcription (Taken form Sha, 2009). 
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1.1.1 Control of chromatin structure 
There are at least three processes that are responsible for regulation and assembly of the 
chromatin: DNA methylations, histone modifications and adenosine-tri-phosphate (ATP)-
dependent chromatin remodeling (Ho, 2010).  
DNA methylation is a mechanism of transcription repression that occurs via addition of a 
methyl group to the cytosine (C) in cytosine guanine (GC)-rich regions, called CpG islands. 
This modification on a promoter or enhancer induces histone deacetylation and chromatin 
remodeling resulting in the inactivation of the gene. In addition, abnormal DNA methylation 
serves as a marker of cancer (Schones, 2008). 
Post-translational histone modifications are crucial for chromatin organization. They 
modulate nucleosome stability and therefore control DNA accessibility and gene 
transcription. Several modifications have been described, including acetylation and 
methylation of the N-terminal histone tails (Suganuma, 2008). Acetylation, which is reflected 
by the presence of acetyl groups in histones H3 and H4, increases chromatin flexibility, while 
deacetylation is correlated with locally compacted chromatin. Acetylation is controlled by two 
kinds of enzymes. Histone acetyltransferases (HATs), like steroid receptor co-activator 1 
(SRC1/p160) modify histones by adding acetyl groups to their tails, which correlates to the 
open state of the chromatin, and is a marker for active transcription. The second group, the 
histone deacetylases (HDACs), on the contrary remove acetyl groups from targeted histones 
and are associated with transcriptional repression (Wu, 2009). Histone methylation is 
characterized by the presence or removal of a methyl group from the histone tails. The methyl 
group is delivered by histone methyltransferases (HMTs) and removed by histone 
demethylases (HDMs) (Chi, 2010). Histone H3 methylation has been observed at many lysine 
(K) sites e.g. H3K4, K9 and K27 with four different states: unmethylated, monomethylated, 
dimethylated and trimethylated. Each of the states has a different impact on the gene 
expression. For instance, H3K4 trimethylation (H3K4me3) is associated with an open state of 
chromatin and its highest level has been observed at the transcription start sites (TSSs) of the 
active genes. Interestingly, the H3K4 dimethylation (H3K4me2) is related not only to the TSS 
but also to the enhancers that modulate gene expression. In contrast, H3K27 trimethylation 
(H3K27me3) is correlated with condensed chromatin and gene silencing. In addition, 
methylation and acetylation may also neutralize the positive charge of histones and by that 
reduce the interactions with the negatively charged DNA. Consequently nucleosomes may be 
repositioned allowing the recruitment of regulatory complexes, including transcription factors 
(TFs), to interact with the DNA (Chi, 2010).  
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Interestingly, if a binding site is located at nucleosome-free regions or between positioned 
nucleosomes, transcription factors may access it easily. However, if the regulatory sequence is 
hidden “inside” the nucleosome TF association requires engagement of chromatin remodeling 
complexes (Cairns, 2009). These are specific units that use the energy of ATP hydrolysis to 
regulate nucleosome mobility by destabilization, restructuring or even their ejection. Thus, 
recruited complexes like SWItch Sucrose NonFermentable (SWI/SNF)-like ATPases or 
brahma-associated factor (BAF) may enable TFs to access to respective binding sites on 
DNA, in order to recruit co-activators as well as the general transcription machinery. 
Therefore, they are crucial for rapid induction of gene expression (Weake, 2010). There are 
more than 30 SWI/SNF-like ATPase subunits involved in chromatin remodeling complexes, 
which suggests that the function of this class of proteins is very broad and specific (Wu, 
2009). Intriguingly, SWI/SNF “remodellers” contain a domain that may bind to acetylated 
histone tails and promote their targeting or activity of gene promoters (Cairns, 2009). 
Interestingly, Chodavarapu et al. have shown that nucleosome positioning influences DNA 
methylation, i.e. the level of methylation was higher on nucleosome-bound DNA than in 
flanking regions (Chodavarapu, 2010). Moreover, He et al. noticed that changes in 
nucleosome occupancy are associated with the presence of enhancers. They performed 
genome-wide analyses, which reveled that upon androgen stimulation of a prostate cancer cell 
line, nucleosomes present at androgen receptor binding sites are dismissed not only from the 
TSS regions but also from enhancers. In addition, histone modifications were linked with 
those observations, since H3K4me2 was very efficient for detection of TF binding to TSSs 
and enhancers (He, 2010). 
 
1.1.2 Chromatin loop formation 
Enhancers can be marked by H3K27ac, H3K9ac, H3K4 monomethylation (H3K4me) and 
H3K4me2 but not by H3K4me3. They contribute to gene transcriptional activation from 
upstream or downstream, in distance or close proximity to the TSS of the targeted genes 
(Heintzman, 2007). Together with other regulatory elements like insulators, silencers and 
locus control regions (LCR), enhancers are mainly situated in great distances, up to hundreds 
of kilobases (kb) away from the TSS of targeted gene. Two ways of distant transcriptional 
regulation have been discovered, the spreading and the looping. The spreading model 
suggests that the initial signal starts at an enhancer and is passed along on the chromatin fiber 
to the promoter that finally results in modulation of gene expression. The expanse can also be 
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reduced by formation of chromatin loops, which bring enhancer and promoter together to the 
active gene. The proteins associated with loop formation are under investigation and may 
involve transcription factors, nuclear receptors, insulators, chromatin remodelers and possibly 
others (Hakim, 2010). For instance, the activation of the mouse hemoglobin β-chain complex 
(Hbb) genes occurs with the cooperation of their distal enhancers located around 50 kb away 
from the promoters. Gene transcription is triggered by formation of a loop structure between 
the enhancer and the TSSs of the genes, thus composing a so-called hub (Chakalova, 2005) 
(Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A chromatin hub. The figure represents a hub formation between the Hbb gene 
cluster and enhancer. The Hbb complex shares a distal enhancer that leads to transcriptional 
activation (Adapted from Chakalova, 2005). 
 
A similar gene regulation was found for the Hox (Homeobox) genes. In higher vertebrates, 
Hox genes are clustered into four groups: HoxA, HoxB, HoxC and HoxD, where each cluster 
of genes is arranged in the same linear order. In mouse, the activated Hoxb gene cluster forms 
a loop with distal enhancers that may be located even at other chromosomes. Local 
decondensation of the chromatin, together with transcription activation might lead to 
chromatin mobility that facilitates formation of loops, thus enabling contacts between the 
genes and distal regulatory elements. In this way, genes located in the same chromatin loop 
may share a common regulation of their expression (Fraser, 2007).  
In addition, chromatin fiber may create a loop through interaction with the CCCTC-binding 
factor (CTCF), an insulator that contains eleven zinc finger DNA-binding domains that allow 
Active 
enhancer Inactive (Hbb) gene 
 
Intergenic promoter activity Active (Hbb) genes 
Insulators 
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binding to a variety of sequences and to specific co-regulators. CTCF is known to have many 
functions, including promoter activation/repression, enhancer blocking and barrier isolation 
(Cuddapah, 2009). Moreover, CTCF has ability to separate euchromatin from 
heterochromatin state (Felsenfeld, 2004). It can mediate chromatin loop formation via the 
contact of two CTCF insulators (Philips, 2009).   
Interestingly, Kim et al. observed that CTCF-depleted domains contain clusters of co-
regulated genes or gene families that share similar patterns of expression, suggesting that 
segregated clusters undergo intra-domain transcriptional regulation (Kim, 2007).  
 
Thus, the state of nucleosome positioning, histone modification, DNA methylation, chromatin 
organization, activity of DNA-binding proteins and co-regulator proteins are determining the 
transcriptional expression of a gene (Sproul, 2005). 
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1.2. The nuclear receptor superfamily 
 
Nuclear receptors (NRs) are proteins belonging to the transcription factors that mediate the 
transcriptional response to lipophilic hormones like vitamins D3 and A, thyroid and endocrine 
steroids as well as to metabolic molecules. These ligands are specifically regulating the 
transcriptional activity of NRs (Nagy, 2006). NRs can regulate a number of genes involved in 
many processes in the body, like reproduction, development, growth, mineral homeostasis and 
nutrition utilization, as well as in the immune response (Bookout, 2006).  
In the 1960s, steroid receptors were identified and analyzed, but only in the mid 1980s nuclear 
receptors were classified as a superfamily of transcription factors. In the beginning of the 
1990s, the regulation of most NRs by their ligands was identified as a general phenomenon 
(Tata, 2002). 
1.2.1 Classification  
Since NRs have the ability to bind directly to DNA and influence the expression of their 
target genes, they are assigned as TFs. In human the NR superfamily consists of 48 members, 
which share a common protein structure (Yang, 2006). The activity of a significant number 
among the 24 NRs is modulated by ligands, small lipophilic molecules (Gronemeyer, 2004). 
The presence of the ligand triggers conformational changes of the receptor that allows the NR 
to interact with many different proteins like co-regulators and chromatin modifiers, resulting 
in changes in the transcriptional expression of a targeted gene. However, some NRs can 
decrease the gene expression in a ligand-independent or dependent manner, by repressing it 
through its interaction with co-repressor complexes on the gene promoter (Germain, 2006). 
There are several ways for classifying the superfamily. One is to divide them into three 
categories according to their ligand-binding affinities: classic endocrine receptors bind with 
high affinity (e.g. vitamin D receptor (VDR), androgen receptor (AR), glucocorticoid receptor 
(GR)); adopted orphan receptors – have a low affinity to their ligands (e.g. retinoic X receptor 
(RXR), liver X receptor (LXR)); and orphan receptors, for which the kind of activation and 
ligands are still unknown (e.g. SHP) (Germain, 2006) (Table 1).  
Another way of classification refers to the DNA binding: NRs of type 1 bind to DNA as 
homodimer; after ligand activation in the cytoplasm is transported to the nucleus (e.g. 
estrogen receptor (ER), progesterone receptor (PR), AR); NRs of type 2 usually bind to DNA 
as heterodimers with RXR (e.g. VDR, retinoic acid receptor (RAR), thyroid receptor (TR)); 
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type 3 NRs include some “orphan” receptors which bind to DNA as monomers (see, 
www.nursa.org). 
The third and most recent way of division is due to shared physiology and function (Bookout, 
2006) (Fig. 3). That analysis points out relations of NRs in various processes. Besides the 
importance of single receptors this classification also revealed the interconnection of NRs that 
together regulate the expression of specific gene networks (McKenna, 2009). 
 
Table 1. Classification of the superfamily comprising 48 nuclear receptors in human. 
The natural ligands of the NRs are shown on the right (taken from Sonoda, 2008). 
 
 
1.2.2. Role of nuclear receptors 
Bookout and colleagues divided NRs according to their expression, function and physiology. 
They segregated two major classes into six subclasses: three for nutrient metabolism and three 
for reproduction. Cluster IA represents NRs involved in steroidogenesis. Cluster IB contains 
all steroid hormone receptors involved in reproduction (e.g. AR, ER, PR). It also contains 
retinoic acid receptors (RAR) participating in development. Custer IC comprises the largest 
number of NRs. They are expressed in the CNS (e.g. RORα, ERR ß) and are responsible for 
controlling the basal metabolism (e.g. LXRß, RXRα, RXRß). Cluster IIA represent NRs 
regulating nutrient intake (e.g. VDR, CAR, PXR). Cluster IIB and cluster IIC contain NRs 
that govern utilization of lipid nutrients as fuel and are thereby responsible for energy 
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homeostasis (e.g. peroxisome proliferator-activated receptors (PPARs), LXRα) (Bookout, 
2006) (Fig.3).  
Notably, as NRs have a big impact on a wide range of biological processes, the loss of control 
of NR signaling pathways provokes deregulation of their normal function and thus, contribute 
to many diseases such as chronic inflammation, metabolic (Lonard, 2007), cardiovascular 
diseases and cancer (Payne, 2011; Beer, 2007). For that reason, NRs can be used as drug 
targets to develop ligand-based therapies to treat and prevent important disorders. Since they 
were discovered, many NR ligands were evaluated in clinical trials and several have been 
approved for use in therapy. The endocrine receptors are cancer drug targets and their ligands, 
agonist or antagonist, are commonly used in pharmacology: anti-estrogens to treat breast 
(Veer, 2002) and ovarian cancer, androgens and anti-androgens for the treatment of prostate 
cancer (Sharifi, 2010). Vitamin D is used in fortified food to prevent inflammatory and bone 
diseases (Evans, 2003).  
Adopted orphans receptors are the most promising drug targets for the metabolic syndrome, 
because of their functions in the lipid – glucose homeostasis and inflammation. Synthetical 
ligands for PPAR, for instance, are commonly used drugs for treatment of for type II 
diabetes (Sonoda, 2008). 
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Figure 3. The nuclear receptor ring of physiology 
Classification of the NRs according to their expression, function and physiology (taken from 
Bookout, 2006). 
 
1.2.3. General structure of nuclear receptors 
All NRs contain specific domains in their protein structure. These are: the N-terminal 
activation function-1 domain (AF1), a central DNA-binding domain (DBD), a hinge region, a 
ligand-binding domain (LBD), and the C-terminal activation function-2 domain (AF2). 
 
 
 
Figure 4. Structure of the nuclear receptors  
NRs contain five domains: the N-terminal AF1 domain, the DNA-binding domain (DBD), the 
hinge region (Hinge), the ligand-binding domain (LBD), and the C-terminal AF2 domain 
(taken from Jonker, 2009). 
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The AF1 domain has a different length and sequences across different NRs and can be 
recognized by co-regulators. The DBD is the most conserved domain. It contains two zinc 
fingers motifs, that are responsible for the binding to a specific DNA sequence of a target 
gene, the so-called hormone response elements (HREs). The response elements (REs) of NR 
are described as two hexameric half-site motifs. The consensus sequences of these motifs is 
RGGTCA (R = A/G) and may be configured as direct, inverted or everted repeats with a 
different number of spacing nucleotides between the motifs. These modifications form REs 
selective for specific receptors (Gronemeyer, 2006). Ligand-induced steroid hormone 
receptors, like AR or ER, form homodimers and bind to DNA in the inverted repeat manner. 
Others form heterodimers with RXR in a direct repeat manner e.g. VDR, RAR, thyroid 
receptor (TR) and several orphan NRs. The last group binds as monomers; this class 
comprises of some orphan NRs (Mangelsdorf, 1995).  
 
 
 
 
 
Figure 5. Types of nuclear receptor binding sites 
There are three types of NRs binding to the response elements: in direct repeat (DR), in 
everted repeat (ER), or in inverted repeat (IR). (Transformed from Jonker, 2009). 
 
Between the DBD and the LBD lies a less conserved hinge region, which enables to separate 
those two domains. In addition it allows the DBD and the LBD to perform conformational 
changes (Germain, 2003). The LBD mediates ligand-binding, dimerization, the binding of co-
regulators and transactivation (Germain, 2006). The LBD is composed of twelve helices; 
eleven of those create a structure consisting of a specific ligand-binding pocket (differs 
between family members of the NRs). The twelfth helix (H12) that contains transactivation 
domain AF2 rests on the top of the pocket. It changes its conformations upon the LBD 
interaction with the ligands. Those specific, lipophilic molecules are able to pass through the 
lipid bilayer of the cell membrane and interact with the receptors. In most cases, binding of a 
ligand leads to allosteric effects that cause the H12 repositioning which promotes co-
repressors displacement and the recruitment of co-activators that interact with the LBD 
surface via specific short LxxLL-like motifs (L = leucine and x = any amino acid). As a result 
RGGTCA  (N) X  RGGTCA
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of ligand-mediated action the transactivation function of a NR is switched on (Germain, 
2006). 
This is the classical way of the LBD ligand-dependent function. Nevertheless, it has been 
shown that other mechanisms exist. Some co-factors like receptor-interacting protein-140 
(RIP-140) and ligand dependent co-repressor (LCoR) act as NR co-repressors in a ligand-
dependent manner and replace co-activators. Co-repressors can trigger the recruitment of 
transcriptional complexes with histone deacetylases, which leads to the deacetylation of 
histones that closes the local chromatin and may result in gene repression (Gurevich, 2007).  
1.2.4. Mechanism of action 
The specific regulation of transcriptional activation upon ligand binding to its NR, facilitates 
recruitment of the transcriptional machinery compounds, including RNA polymerase II, co-
regulators and histone modifiers, and induces the expression of the targeted gene (Germain, 
2006). 
The principle concerning the function of classical mechanism of the steroid receptors (e.g. 
GR, ER, AR) is that in the non-active state they are located in cytoplasm and are associated 
with HSPs. Upon hormone activation HSPs dissociate, thus allowing NRs to target their 
specific genes as homodimers, and recruits series of co-regulators. 
Another group of NRs binds, upon ligand activation, to the REs in the promoter or enhancer 
regions of targeted genes as heterodimers with RXR, and leads to transcriptional activity. 
Prominent example of those receptors is vitamin D receptor, which may generate biological 
response after interaction with hormonally active vitamin D (Fig. 6). 
 
 
 
 
 
 
 
 
Figure 6. Activation of nuclear receptors 
Classical example of NR heterodimerization with RXR. The LBD changes its conformation 
due to ligand action; the DBD recognizes a specific DNA sequence (Taken from Jonker, 
2009). 
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Two types of mechanisms for repression can be distinguished. The first one refers to the 
ligand-independent action by attracting a complex of co-repressors leading to the repression 
of the genes. The second kind, called transrepression, happens in a ligand-dependent manner. 
Transrepression applies to the process where a NR represses the activity of another TF by 
protein – protein interaction and therefore inhibits expression of specific genes. For instance, 
it was shown that ligand-activated GR has the capability to physically bind to NFkappaB and 
to block its activity (De Bosscher, 2003). Moreover, an example for repression in the ligand-
dependent manner is the negative regulation of the CYP27B1 gene by VDR upon vitamin D 
stimulation. This gene encodes an enzyme that plays a crucial role in vitamin D biosynthesis. 
Therefore, due to recruitment of specific co-repressors involved in chromatin remodeling and 
histone modification, the gene is negatively regulated, which results in suppressing the 
vitamin D synthesis. Details of that homeostatic regulation are described later (Germain, 
2006).  
1.2.5. Interaction with co-regulators 
Transcriptional regulation requires a number of co-regulators with different functions and 
enzymatic activities (Perissi, 2005). As mentioned before, liganded NRs interact with co-
activators/co-repressors and mediate target gene transactivation/transrepression. Co-activators 
(as well as co-repressors) form complexes that are recruited to NRs. The complexes mediating 
transactivation include proteins involved in histone modifications and chromatin remodeling 
(e.g. HATs, SWI/SNF complexes), initiation of the transcription (e.g. SRC-1), elongation of 
RNA chains, mRNA splicing, and proteolytic termination of the transcriptional response (E3 
ligases). To date, more than 300 co-regulators have been discovered (O’Maley, 2009). 
In contrast, unliganded NRs may interact with co-repressors leading to repression of targeted 
gene. These include nuclear receptor co-repressor (NCoR) and silencing mediator for retinoid 
and thyroid hormone receptors (SMRT), which are essential for binding smaller complexes 
containing HDAC activity. This complex increases the histones’ ability to bind to DNA, 
thereby tightening it up and repressing transcription. Interestingly, there are many other co-
repressors like LCoR that compete with co-activators and replace them in the presence of 
ligand (Perissi, 2005; Germain, 2006). 
Transcriptional regulation is a highly dynamic event. Many scientists argue whether 
regulating complexes are temporarily recruited to each active site or, on contrary, if DNA 
migrates to “ready” transcriptional factories (Perissi, 2005). Because of the complex, three-
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dimensional nuclear organization and limited molecular techniques for studying the kinetics 
of nuclear factors, the dilemma remains unsolved (Sutherland, 2009). 
Therefore, the gene expression is controlled by tightly regulated bulk of proteins and their 
small disruption, like under- or over-expression can lead to many diseases including cancer, 
possibly because of their pleiotropic capabilities (Lonard, 2007).  
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1.3. Vitamin D and the vitamin D receptor (VDR) 
 
1.3.1. The history of Vitamin D 
In mid 1920s, Windaus, Hess, Rosenheim and colleagues found that skin exposure to 
ultraviolet B (UV-B) light or sunlight results in vitamin D synthesis, thus restoring a positive 
calcium balance (Feldman, 2011). In the 1970s it was already well known that vitamin D has 
to be turned into its active form of the steroid hormone, 1α,25-dihydroxyvitamin D3 
(1α,25(OH)2D3), also known as calcitriol, to have biological function, and that its intake 
involves three organs: intestine, bone and kidney which are involved in calcium homeostasis 
(Norman, 2006). During the next 15 years scientists discovered that steroid hormones like 
1α,25(OH)2D3 serve as regulators of gene expression (Mangelsdorf, 1995) through interaction 
with their corresponding receptors. Together they form a high affinity ligand – receptor 
complex, such as VDR with its affiliated ligand 1α,25(OH)2D3.  
Today we know that 1α,25(OH)2D3 is not only essential for mineral homeostasis and bone 
integrity, but it has functions in many biological processes like regulation of growth, 
differentiation and apoptosis in a broad variety of normal and malignant tissues like prostate, 
breast, skin, adipose tissue, brain, bone marrow, colon, muscle, as well as in activated B and T 
lymphocytes. There are more than 30 target tissues where VDR is present (Norman, 2006; 
Reichrath, 2007). This suggests a global transcriptomic reaction upon stimulation with 
1α,25(OH)2D3 across may different types of cells. 
 
1.3.2. Vitamin D metabolism 
Vitamin D is mainly synthesized in the epidermal layers through exposure to UV-B or 
sunlight and less in intestine from food and supplements. Vitamin D synthesis is a multistep 
process. The first step is conversion of pro-Vitamin D3 (7-dehydrocholesterol) into pre-
Vitamin D3, which is isomerized into Vitamin D3 (cholecalcitriol). This form is transported 
with the bloodstream to the liver, by binding to vitamin D binding protein (DBP). There it is 
hydroxylated, by a group of 25- hydroxylases from the cytochrome P450 family (encoded by 
CYP27A1, CYP3A4 and CYP2R1) (Prosser, 2004) to 25-hydroxycholecalcitriol (25(OH)D3). 
In the kidney, that form is a substrate for 1α-hydroxylase (encoded by CYP27B1), which turns 
it into the biologically active form of vitamin D3 called 1α,25-dihydroxycholecalciferol - 
1α,25(OH)2D3 (calcitriol) (Deeb 2007). The major inducers of 1α-hydroxylase are parathyroid 
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hormone (PTH) as well as low body levels of phosphate and calcium (Prosser, 2004).  
Degradation of 1α,25(OH)2D3 is promoted by 24-hydroxylase, product of the CYP24A1 gene. 
This constitutes a negative feedback loop, since 1α,25(OH)2D3 strongly induces the 
expression of the CYP24A1 gene. The consequence is formation of the blood metabolites 
1α,24,25(OH)2D3 from 1α,25(OH)2D3 and 24,25(OH)2D3 from 25(OH)D3 (Deeb 2007) (Fig. 
7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The metabolism of Vitamin D 
Explanation of the figure in the text (Taken from Deeb, 2007). 
 
1.3.3. Discovery of the Vitamin D Receptor  
The VDR was identified in 1969 as a binding protein for an unknown vitamin D metabolite 
(Haussler, 1969). In 1975 Brumbaugh and Haussler discovered that VDR forms a complex 
with the active form of vitamin D - 1α,25(OH)2D3 with a high affinity. Eventually, 
experiments with VDR knock-out mice proved a crucial role of this receptor in the action of 
vitamin D, including growth and bone formation (Yoshizawa, 1997). 
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VDR is a member of the nuclear receptor superfamily; it belongs to the subgroup of endocrine 
receptors. Upon 1α,25(OH)2D3 stimulation VDR can trigger a variety of biological processes 
via genome-wide modification of the expression of a high number of genes within many 
different types of tissues. The major requirement for its effect on gene modulation is the 
binding of the VDR protein close to the transcription start site (TSS) of the respective gene.  
 
1.3.4. Principles of VDR action 
The structure of VDR resembles that of a typical NR (Fig. 4). Ligand occupancy leads to the 
formation of two specific protein interaction sites within the VDR. One of them allows it to 
associate with its heterodimer partner RXR in order to bind to DNA, and the second one is 
required to engage a large number of co-regulator proteins that are essential for regulation of 
genes, encoding proteins which mediate 1α,25(OH)2D3 response at transcriptional level (Fig 
8).  
VDR binds to DNA through specific regulatory sequences called “vitamin D response 
elements” (VDREs). These are 2 hexanucleotides repeats with RGKTCA motifs (R = A/G, K 
= G/T) to which VDR binds in a direct repeat (DR) orientation, usually with a spacing of 
three nucleotides. The two half-sites of VDREs are occupied by a single VDR and a single 
RXR protein.  
These specific response elements may be located at distant or proximal sites from the 
promoter of the gene regulated by VDR. Therefore, VDREs can act as cis or trans elements to 
interact with the basal transcriptional machinery, and mediate the transcription process. Cis-
elements are located close to the transcription start site (TSS) of the targeted genes.  Trans-
elements, on the other hand, are distant and therefore VDR may bind far away up- or down-
stream from the TSS of a targeted gene. Interestingly, there are genes that are regulated by 
both proximal and distant response elements, e.g. the best-known VDR target, the gene 
CYP24A1. Two VDREs are located proximal to its promoter, but its induction is additionally 
correlated with a cluster of distal enhancers that also show association with VDR after 
1α,25(OH)2D3 stimulation (Meyer, 2010). Likewise, several enhancers seem to regulate the 
gene of the Receptor Activator of Nuclear Factor-B Ligand (RANKL) required for accurate 
osteoclast maturation and function, and is involved in bone remodeling. It is induced by 
1α,25(OH)2D3, and its expression is controlled by multiple functional VDREs of which the 
most distal from the TSS was located -96 kb in human (Nerenz, 2008).  
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1.3.5. Protein-protein interactions that mediate VDR transactivation 
Local changes in chromatin structure are essential for proper transcriptional action. For 
instance, when chromatin is in a condensed state VDR-RXR heterodimers are not able to bind 
to their response elements. Only a local chromatin relaxation allows functional VDREs to 
associate with the liganded VDR. Therefore, changes in gene expression through VDR-RXR 
binding to the VDREs are accompanied by the involvement of a set of large complexes of co-
regulators mediating chromatin decondensation/condensation. These co-regulatory complexes 
seem to be gene-specific, conduct a serious of actions in specific environment manner and 
they also contain many proteins with enzymatic activities (Pike, 2010). These are mediator 
complexes called vitamin D receptor – interacting proteins (DRIPs), as well as complexes 
responsible for chromatin remodeling, histone modification, and the general transcription 
complex. Hence, gene regulation is a tightly regulated process that needs certain proteins to 
interact with each other to mediate the regulation (Fig. 8). The complexes are listed below: 
The chromatin remodeling complex  
Proteins involved in this process have the ability to effectively shift nucleosomes in an ATP-
dependent fashion. Thereby, they may assemble and reassemble the nucleosome core (Cairns, 
2009). 
The histone modifier complex  
A complex responsible for the chromatin state encompasses co-regulators that can trigger 
histone acetylation/deacetylation and methylation/demethylation, and it is related to an open 
or close state of chromatin structure.  
The Mediator complex  
While the chromatin is open and VDR is able to interact with VDREs freely, the Mediator 
complex also known as the Vitamin D Receptor Interacting Protein (DRIP) forms a bridge 
between the General Transcription complex on the TSS of a targeted gene through binding to 
the C-terminal domain (CTD) of the polymerase II RNA (RNA pol II) and the VDR. 
The General Transcriptional complex  
The RNA pol II is part of the General Transcriptional complex, which additionally 
encompasses transcription factor II D (TFIID), a subunit that contains the TATA-binding 
protein (TBP), which interacts with DNA close to the promoter. TBP is responsible for 
recruitment of RNA pol II, which is followed by joining the five remaining subunits of TFs to 
the whole complex.  
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VDR transactivation  
Taken together, 1α,25(OH)2D3 stimulation is a process that involves recruitment of co-
activators. The Mediator complex binds to VDR via DRIP205, the complex with HAT and 
HMT activities binds to VDR through SRC1, 2 or 3. SRC recruits CREB-binding protein 
(CBP) or p300 and other HATs and HMTs, which destabilize the DNA – histone connection 
and thereby enable transcription to take place. The Mediator with no HAT or HMT functions 
participates in RNA pol II transportation to the TSS of the gene (Bikle, 2010) (Fig.8). 
Interestingly, DRIP205 has the ability to bind directly to the VDR also at an enhancer 
position, which leads to recruitment of RNA pol II not only at TSS. This implies involvement 
of a series of co-regulators including SRC1, CBP (causing H4Ac), SMRT also to the 
regulatory regions (Meyer, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Effect of VDR on chromatin remodeling and transcription initiation 
The 1α,25(OH)2D3 mediated response regulates the action of several complexes of co-
regulatory proteins. There is a General Transcriptional Complex located at the TSS, a VDR-
RXR heterodimer at the VDRE, a Mediator complex that binds to the CTD thereby interacting 
with RNA pol II, a histone acetylation complex with HAT activity and a chromatin remodeling 
(SWI/SNF) complex with ATPase activity (Adapted from Pike, 2011). 
 
In contrast, VDR is able to repress gene transcription in a ligand-dependent (transrepression) 
or independent (derepression) manner. For example, CYP27B1, a gene encoding a critical 
enzyme in vitamin D synthesis, is induced by PTH via activation of protein kinase A and C 
DRIP 
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(PKA and PKC), but is suppressed by 1α,25(OH)2D3 (Fig. 9). In the absence of ligand, VDR 
interacting repressor (VDIR) binds to negative vitamin D response elements (nVDREs) of 
CYP27B1, interacts with HAT co-activators and leads to transactivation. Upon 1α,25(OH)2D3 
stimulation, the VDR-RXR complex blocks VDIR binding leading to the dissociation of 
HATs and recruitment of HDAC co-repressors which changes the chromatin structure. That, 
in turn, leads to transrepression of CYP27B1. Two DNA methyltransferases are involved in 
this process, i.e. DNMT1 and DNMT3B. They methylate cytosine residues at CpG sites close 
to the gene promoter, thereby turning it off. In the presence of PTH and the absence of 
1α,25(OH)2D3, VDR-RXR, DNMT and HDAC complexes are dismissed and the gene is 
activated (Kim, 2007; Kim 2009).  
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Mechanism of VDR-mediated gene repression 
Representation of ligand-induced transrepression of the CYP27B1 gene by VDR and 
derepression of the same gene via PTH action. Transrepression is a result of VDR-RXR 
heterodimer interaction with VDIR connected to VDREs. It leads to HDAC and DNMT 
recruitment and inhibition of gene expression. Derepression is an effect of PTH that 
stimulates PKC and PKA, which leads to DNA demethylation via methyl-CpG binding domain 
4 (MBD4) phosphorylation, and results in gene activation (Adapted from Kim, 2009). 
 
In the past few years, a series of genome-wide analyses uncovered great numbers of new 
VDR target genes as well as new binding sites located in distant and close proximity from the 
TSSs after stimulation with 1α,25(OH)2D3 in many different cell types. Moreover, a large 
number of recruitments of co-activator and co-repressors, occupancy of RNA pol II and 
modifications of histones across the genome were discovered. This enables researchers to 
analyze variable interactions within the nucleus. Interestingly, it has been shown that many 
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VDR target genes stimulated by 1α,25(OH)2D3 did not harbor VDREs close to the promoter, 
suggesting that rather distal regulatory regions, rich in VDR-RXR occupancy are involved in 
gene induction or repression. Furthermore, Meyer et al. have shown that MED1, a protein 
from the Mediator complex is present at many distal response elements, associated also with 
VDR (Meyer, 2010; Pike, 2011). The fact that distant response elements from promoters of 
1α,25(OH)2D3 target genes are functional and associate with VDR-RXR heterodimer and co-
regulators, suggested the formation of chromatin loops which facilitate the contact between 
enhancers and the TSSs, thus enabling transcription regulation (Hakim, 2010).   
 
1.3.6. 1α,25(OH)2D3 and its analogs 
Since 1α,25(OH)2D3 was shown to play an important role in many biological processes, 
including the prevention of disorders, its therapeutic use has gained considerable attention. 
Considering the fact that intake of the natural ligand for VDR may lead to some side effects 
like hypercalcemia as a result of excessive accumulation of calcium ions in the body, more 
than 3000 analogs of 1α,25(OH)2D3, with lower calcemic activity have been synthesized 
(Eduardo-Canosa, 2010). Many of the proposed analogs of 1α,25(OH)2D3 may also be used to 
prevent cancer development due to their enhanced anti-proliferative effect (Masuda, 2006).  
 
1.3.7. 1α,25(OH)2D3  effects in biological processes  
There are several areas in which 1α,25(OH)2D3 and its receptor elicit biological responses. 
These include calcium homeostasis, the immune system, glucose and fat metabolism, the 
cardiovascular, muscle and brain systems, and the control of the cell cycle, thus affecting also 
the process of cancer development. Responses to 1α,25(OH)2D3 are very broad since the VDR 
is present in more than 30 tissues in human (Norman, 2006; Norman, 2010). Insufficient 
sunlight exposure is a major factor for vitamin D deficiency. Since VDR plays an important 
role in cell growth and differentiation and has anti-proliferative activities (Bouillon, 2006), 
inadequate vitamin D levels may contribute to a series of abnormalities including bone 
diseases, multiple sclerosis (MS) (Holick, 2008), autoimmune diseases (van Etten, 2005), 
diabetes, cardiovascular diseases, hypertension, metabolic syndrome, infectious diseases and 
cancer (Norman, 2010; Liu, 2007; Tokar, 2005). According to M. Holick, A. Norman and R. 
Boullion the general recommendation of vitamin D intake, 200 International Unit (IU) per 
day, is much too low. It should be increased at least five times (Holick 2008, Holick 2011, 
Norman 2010) in order to prevent the development of above-mentioned disorders. Moreover, 
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Holick et al. propose that a high dosage of Vitamin D could have a beneficial impact on those 
diseases states. Three systems in which VDR and its ligands play a crucial are highlighted 
below. 
1.3.7.1 Functions of the VDR in calcium homeostasis 
Calcium (Ca
2+
) homeostasis is dependent on vitamin D. Ca
2+
 is one of the major components 
of the bone and is absorbed from the small intestine, passing through the epithelial transient 
receptor potential Ca
2+
 channel V6 (TRPV6) and the plasma membrane Ca
2+ 
ATPase PMCA 
pump (Bouillon, 2006; Fleet 2006) regulated by 1α,25(OH)2D3, thus enabling Ca
2+
 
transportation. Its absorption, reduced renal Ca
2+
 excretion and elevated bone resorption is 
related to elevated levels of circulating 1α,25(OH)2D3 (Xue, 2009). Low levels of vitamin D 
are related to rickets and low bone density. 1α,25(OH)2D3 together with parathyroid hormone 
has a crucial impact on proper bone mineralization, due to its genomic effects in regulation in 
osteoblasts and osteoclasts (Jones, 1998). These are the two types of cells in the bone 
remodeling process that control the bone formation and the bone resorption, respectively. The 
VDR regulates differentiation and function of osteoclasts and leads to bone resorption and 
release of the Ca
2+
 from the bone due to direct regulation of RANKL gene expression. RANKL 
is expressed in osteoblasts and is necessary for a proper osteoclast maturation and function 
(Nerenz, 2008).  
1.3.7.2. Functions of the VDR in the immune system  
It is well known that VDR regulates a number of genes implicated in the immune system and 
thus has a crucial role in the innate and adaptive immune system. Interestingly, the immune 
system participates in cancer prevention by protecting the host against viral infection (virus-
induced tumors), and by suppressing inflammation, by defeating pathogens that contribute to 
carcinogenesis (Fleet, 2012). VDR is expressed in several immune-related cells like 
monocytes, macrophages, activated T cells and dendritic cells (DCs). It has been found to 
stimulate phagocytosis and the synthesis of antimicrobial factors (Schauber, 2007). 
Macrophages infected with Mycobacterium tuberculosis (TB) when exposed to 1α,25(OH)2D3 
elicit signal events leading to the expression of toll-like receptors and expression of the 
cathelicidin (CAMP) gene, a defensive, antimicrobial protein, that removes TB from the cell 
(Liu, 2006).  
In addition, cytokines that have a pivotal role in T cell activation are regulated by VDR. 
Interleukin 12, crucial in T helper 1 (Th1) development, is repressed in the presence of 
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1α,25(OH)2D3 together with NF-B. Thus, VDR suppresses the Th1-response (D’Ambrosio, 
1998).  
In addition, the chronic bowel inflammatory disease called Crohn’s disease (CD) caused by 
chronic inflammation due to intestinal bacteria’s may be a result of vitamin D deficiency. 
Genes encoding nucleotide oligomerization domain 2 (NOD2) and human  defensin 2 
(HBD2), proteins involved in innate immune response to pathogens in CD, are up-regulated 
upon 1α,25(OH)2D3 stimulation (White, 2011).  
1.3.7.3. Functions of the VDR in cell cycle and cancer  
VDR exerts anti-proliferative and pro-differentiation effects on many cells, which suggests, 
together with its pro-apoptotic functions, that it could decrease cancer progression. Already in 
the 1990s it was discovered that the functions of vitamin D are not only confined to mineral 
homeostasis. Abe and colleagues showed that in murine myeloid leukemia cells activation of 
VDR stopped their proliferation and enhanced their differentiation into macrophages (Abe, 
1998). Since then a bulk of genes important for regulation of proliferation and differentiation 
were identified in the context of VDR action (Holick, 2008; Peehl, 2003; Feldman, 2000). 
Moreover, studies with model systems of cancers of prostate (Banach-Petrosky, 2006), ovary 
(Zhang, 2005) or lung (Nakagawa, 2005) demonstrated that vitamin D had anti-cancer effects.  
These VDR functions are related to cell cycle arrest, a process strictly regulated by number of 
events to prevent uncontrolled division and pre-maturation of a cell. Progression of cells from 
G1 to S phase directs the phosphorylation of retinoblastoma (Rb) protein through G1 cyclins in 
complex with their cyclin-dependent kinases (CDKs) (Feldman, 2000). C-myc, a transcription 
factor with an oncogene function, regulates the progression into the S phase of the cell cycle. 
In general, c-myc, among many targets, induces cyclin D expression thereby leading to 
increased CDK4 activity due to the formation of cyclin D-CDK4 complexes that can 
phosphorylate Rb. The active Rb dissociates from the transcription factor E2F and allows 
becoming active; this results in the transcription of various genes that enable the cell to enter 
S phase. VDR leads to dephosphorylation of Rb via the up-regulation of CDK inhibitors 
(CDKIs) including p21
 (waf1/cip1)
 and p27
 (kip1)
 (Liu, 1996; Thorne, 2010; Li, 2004). Studies 
have identified several VDREs close to the p21
 (waf1/cip1)
 promoter, indicating direct action of 
VDR on that gene (Liu, 1996; Saramaki, 2006). VDR also mediates G2/M-phase cell cycle 
arrest by the induction of the growth arrest and DNA damage-inducible  (GADD45) gene 
involved in growth arrest and DNA repair mechanism (Campbell, 2006).  
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Interestingly, 1α,25(OH)2D3 affects the activity of prostaglandins (PGs). In some cells, 
especially in prostate cancer (PCa) cells, PGs can trigger cell growth. Vitamin D suppresses 
this by inhibiting gene encoding PG synthesizing cyclooxygenase-2 (COX2), also known as 
prostaglandin-endoperoxide synthase 2 (PTGS2), and increasing the gene encoding the 
expression of the PG inactivating dehydrogenase (15-PGDH). Thus, calcitriol influences the 
proliferation of PCa cell growth (Moreno, 2005). 
Moreover, vitamin D seems to have indirect effects on cell cycle regulation via different 
pathways; e.g. studies revealed an interplay between 1α,25(OH)2D3 action and some of the 
growth factors. For instance, it stimulates expression of key components of the transforming 
growth factor 2 (TGF2)-SMAD3 signaling pathway, which is involved in cell growth and 
differentiation. 1α,25(OH)2D3  induce TGF, and by that mediates activation of the SMAD 
proteins that are co-activators for regulation of gene expression involved in growth inhibition 
like E-cadherin (Wu, 1999; Murthy, 2004). Also, members of the insulin-like growth factor 
(IGF) binding proteins (IGFBPs) family like IGFBP3 and IGFBP5 are gene targets for VDR 
(Matilainen, 2005). The function IGFBPs is to control the IGFs - mitogens that participate in 
cell division, differentiation and apoptosis. IGFBPs bind IGFs and thus reduce their 
interactions with cell surface receptors (Fleet, 2012). Moreover, IGFBPs mediate IGF-
independent effects like cell growth arrest by stimulation of the p21
 (waf1/cip1)
 gene (Peng, 
2007). 
Furthermore, VDR may decrease proliferation through the induction of differentiation of 
cancer cells. Larriba et al. have shown that in the presence of 1α,25(OH)2D3, VDR promotes 
cell differentiation due to inhibition of the Wnt/-catenin pathway. Active -catenin induces 
expression of a series of factors important for promoting proliferation (e.g. c-myc). Over-
expression of -catenin is related with skin tumors (Bikle, 2011) and is found in most colon 
cancers. VDR is able to control and block -catenin by the induction of E-cadherin, which 
has the function to transport nuclear -catenin to the plasma membrane, thus blocking its 
action (Larriba, 2011).  
Additional VDR has the ability to induce apoptosis. It was shown that 1α,25(OH)2D3 
represses the expression of the anti-apoptotic gene BCL2 in breast cancer cells and that it 
induces the expression of pro-apoptotic genes like BAK and BAX in prostate and colorectal 
cancer cells (Deeb, 2007). 
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1.4. Prostate cancer and vitamin D 
1.4.1. Phenomenon of cancer 
The nineteenth century discovery that all cells of the body derive from the fertilized egg, 
suggested that a cancer cell developed from a single cell that lost its ability for creation of 
tissues of a normal form and function. More than one hundred years of studies revealed that 
cancer involves dynamic changes in the genome as well as in “tumor environment”. The 
complexity of cell malformation and the consequent implications of metastasis have inspired 
Hanahan and Weinberg in 2000 to propose the six basic hallmarks that most, if not all, types 
of cancer demonstrate during their progression. This unique set of cancer cell features 
include: sustaining proliferative signaling, evading growth suppressors, activating invasion 
and metastasis, enabling replicative immortality, inducing angiogenesis and finally resisting 
cell death. All cancer types fulfill those steps to complete tumorigenesis, though they may do 
so at different times and via different mechanisms (Hanahan and Weinberg, 2000) (Fig. 11). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The hallmarks of cancer  
The core of the cancer hallmarks is presented within the boxes, along with the emerging 
hallmarks (the deregulating cellular energetics and avoiding immune destruction) and with 
enabling characteristics (genome instability and mutations with tumor promoting 
inflammation) (Adapted from Hanahan & Weinberg, 2011). 
 
Recently, Hanahan and Weinberg expand their circle of hallmarks with two additional once: 
avoiding immune destruction (especially for detection by T, B lymphocytes and 
macrophages) and modifying or deregulating of the energy metabolism to promote cell 
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growth and proliferation. Those new hallmarks are considered to be emerging, since their 
functions are not yet fully validated. The genome instability and mutation (marking genetic 
alternation) as well as tumor-promoting inflammation, are the “enabling characteristics” for 
achieving the core and emerging hallmarks (Hanahan and Weinberg, 2011). 
Additionally, the new insights into chromatin organization together with the complexity of 
gene regulation have given a new perspective into the development of cancer, which acquires 
the capabilities presented in the above-mentioned hallmarks.  
 
1.4.2. Prostate cancer (PCa) genesis 
PCa is one of the most common non-cutaneous malignancies in the Western world. In 2010 
more than 200,000 new cases were diagnosed and the disease causes around 32,000 deaths 
per year in the United States (Berger, 2011). Data from the National Cancer Institute show 
that there are differences in the PCa incidence among the races. Mostly it affects Afro-
American men. Thus, per each 100,000 men from diverse ethnicity there are  ~234 Black, 
~150 White and ~88 Asian men diagnosed with PCa (data taken from 2004-2008, see 
www.seer.cancer.gov). As seen above, the probability of getting PCa in Southeast and East 
Asian populations is much lower, but interestingly De Marzo et al. noticed that it increases 
when Chinese/Japanese men move to the west. This suggests that geographic variation 
associated with insufficient sun exposure is a potential risk factor, along with diet, older age, 
family history and race (De Marzo, 2007). 
 
1.4.3. PCa and inflammation  
Chronic inflammation is one of the risk factors for the development growth of many cancers. 
It is often related to environmental exposures. In PCa, inflammation is linked to infectious 
agents (viruses, bacteria), urine reflux and physical trauma, which might be caused by 
development of corpora amylacea (small nodules in the lumen and ducts), dietary habits 
(consumption of red meat with carcinogens, vitamin deficiency), and finally hormonal 
changes (De Marzo, 2007). The last phenomenon is particularly interesting, since the AR is 
one of the major gene regulators in prostate cells. In addition, the over-expression of 
estrogens in prostate cells is linked to the development of PCa  (Harkonen, 2004). The 
inflammation-related factors lead to malformations of the epithelial secretory cells in the 
peripheral prostate gland (Polek, 2003). They start to form proliferative inflammatory atrophy 
(PIA) lesions that are related to the emerging cancer hallmark, the avoidance of immune 
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destruction. Through the following proliferation prostate intraepithelial neoplasia (PIN) 
develop, which is genetically instable and often leads to invasive prostate carcinoma (De 
Marzo, 2007) (Fig. 12). 
 
 
 
 
 
 
 
 
Figure 12. Model of early prostate carcinogenesis 
Four stages of PCa progression are presented. The first stage is the formation of PIA with 
chronic inflammation being the crucial agent. Continuous cell growth and genetic changes 
lead to massive proliferation of genetically unstable intraepithelial cells (PIN) and 
accumulation of new genomic alternations that finalizes in the formation of an invasive 
carcinoma (Taken from De Marzo, 2007). 
 
1.4.4. The cancer hallmarks distinguished in PCa 
The AR, as a nuclear receptor activated by androgens, plays an important role in the 
development and maintenance of non-malignant prostate via specific gene regulation, but 
being deregulated, it also takes part in initiation and progression of prostate cancer. Tumor 
growth is initially androgen-dependent. Ablation of androgens (e.g. dihydrotestosterone 
(DHT)) causes regression of “androgen-dependent” tumor and is often used in cancer therapy 
(Pheel, 2004). However, the symptomatic relapse frequently occurs 2-3 years later with so-
called “androgen-independent” disease and the mechanism for this transition is not yet clear. 
The activation of the AR in androgen-independent states leads to the up-regulation of genes 
that are implicated in the M-phase of the cell cycle, and therefore cell growth is promoted 
(Wang, 2009). Additionally, two proteins of the kallikrein (KLK) family, KLK3 and KLK2, 
which are encoded by neighboring genes on chromosome 19, are up-regulated after androgen 
treatment in an advanced, androgen-dependent PCa cell line called LNCaP. AR seems to have 
a direct regulating effect on these genes as the proteins of AR, RNA pol II and a set of co-
factors were detected on the promoters of these genes (Kang, 2004). KLK3, also known as 
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prostate specific antigen (PSA), is a serine protease that is commonly used for the screening 
and monitoring of PCa (see also chapter 1.5).  
1.4.4.1. Evasion of growth suppressors  
Several genes have already been correlated with the development of PCa. In advanced PCa 
tumor suppressor genes are lost. For example, the single copy deletion of the NKX3.1 gene 
that encodes the prostate-restricted homeobox protein leads to increased cell growth and 
oxidative DNA damage (De Marzo, 2007). Moreover, in primary tumor cells including PCa, 
the phosphatase and tensin homologue encoded by the PTEN gene that suppresses 
proliferation and increases apoptosis, is frequently lost (Li, 1997). Also the cyclin-dependent 
kinase inhibitor p27 encoded by the CDKN1B (p27) gene, a cell cycle suppressor gene, is 
silent in PCa (Taylor, 2010).  
1.4.4.2. Sustained proliferative signals, death resistance and immortality  
C-myc as an oncogene and transcription factor, together with the pro-apoptotic BCL2 gene 
were shown to be over-expressed in many cancers including PCa. Thereby, their main 
functions of regulation of cell proliferation and apoptosis are deregulated in tumors (Sinha, 
1995). Similarly, the proper cell growth and apoptosis are affected in advanced PCa by 
inappropriate integrin expression, which additionally influences cell adhesion and migration 
(Altieri, 2010). Gene expression arrays identified novel target genes as well as variety of 
mutations, including gene fusions. The best-known gene fusion in PCa is the one of the 
androgen-regulated trans-membrane protease serine 2 (TMPRSS2) gene with the erythroblast-
transformation specific (ETS)-related gene (ERG) (Witte, 2009). Merged, they play a role of 
an oncogene. The TMPRSS2 gene under AR action mediates over-expression of the 
transcription factor ERG, which eventually contributes to deregulation of many genes and 
promotes cell growth and invasion in PCa (Tomlins, 2007; Yu, 2010). In addition, Berger and 
colleagues performed a ChIP-Seq analysis in seven prostate tumors. The genomes were 
divided according to the presence of the TMPRSS2-ERG fusion. The location of the fusion 
was correlated with an open state of the chromatin, thus with the presence of ERG, the AR, 
the co-regulators and the RNA pol II that mediates gene expression. In contrast, the lack of 
TMPRSS2-ERG fusion was associated with a closed chromatin state and therefore results in 
gene repression (Berger, 2011).  
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1.4.4.3. Induced angiogenesis  
A fast developing tumor needs a blood connection for nutrition and oxygen supply. The 
process of new blood vessel formation is called angiogenesis (Polek, 2002). Many pro-
inflammatory agents are able to activate that process, by controlling the vascular endothelial 
growth factor (VEGF), a stimulus of angiogenesis. As a growth factor, VEGF is critical in cell 
proliferation, migration and it is therefore crucial for vessel formation (Benjamin, 1999). 
Furthermore, PTGS2 was shown to increase angiogenesis, whereas its inhibitors block that 
process. It is a gene responding fast to stress-related factors like mitogens, growth factors, 
cytokines and tumor promoters. Moreover, PTGS2 is over-expressed in PCa (Hussain, 2003). 
A further study revealed connection between PTGS2 and VEGF. A selective PTGS2 inhibitor 
reduces the growth of advanced, metastatic prostate cancer cell line (PC-3) implanted into 
mice, through apoptosis and down-regulation of VEGF. As a consequence, microvessel 
density decreases and angiogenesis is inhibited. PTGS2 therefore facilitates tumor progression 
via angiogenesis, tumor invasion and resistance to apoptosis (Liu, 2007). 
Interestingly, the transforming growth factor (TGF)- pathway that is involved in cell growth 
and differentiation, mediates the inhibition of an immune response and promotes angiogenesis 
in cancer. Lu et al. have shown that over-expressed TGF1 in PCa up-regulate the expression 
of potent pro-angiogenic interleukin 8 (IL8) (Lu, 2006).  
 
1.4.4.4. Metastasis  
Metastasis is a process of cell invasion leading to the growth of tumors that might be detected 
far away from the original location. The epithelial-mesenchymal transition (EMT) mediates 
the process of metastasis. The initial steps of invasion include the degradation of extracellular 
matrix, adhesion and degradation of the basement membrane, with invasion into vessels often 
termed as intravasation and angiogenesis essential for tumor cells translocation to distinct 
organs where they proliferate (Sung, 2000). The EMT involves fundamental alternations in 
the gene expression profiles. This includes repression of E-cadherin, encoded by the CDH1 
gene, that enables epithelial cells to adhere to one another as well as the repression of the -
catenins that allow binding to actin fibers. Moreover, as mentioned above, the TGF signaling 
besides the role in angiogenesis is also able to induce EMT in cancer cells together with 
effects mediated by mutations in the RAS oncogene. Reduced expression of E-cadherin, -
catenins and most ,  integrins (with exception of 6 and 4 that are over-expressed in 
androgen independent tumor (Baust, 2010)) responsible for cell-cell and cell-matrix adhesion 
1.Introduction 
 
 30 
and participation in control of cell proliferation and apoptosis, was also observed in PCa. 
Additionally, matrix metalloproteinases (MMPs), the most important effectors of EMT 
formation that degrade the extracellular matrix, are secreted in cancer including PCa 
(Weinberg, 2007). 
 
1.4.5. Vitamin D and its function in non-malignant prostate cells  
The VDR is expressed in both, non-malignant and tumor prostate cells. Studies with 
immortalized non-malignant human prostate epithelial cell line (RWPE1), revealed after 
1α,25(OH)2D3 treatment an up-regulation of the infection/inflammation gene CD14 and 
inhibition of the pro-angiogenic VEGF gene. Moreover, several transcripts related to control 
of the cell cycle were repressed in the long-term treatment. These results indicate that vitamin 
D may inhibit cell growth and has anti-angiogenic and anti-inflammatory actions (Kovalenko, 
2010).  
Furthermore, the enzyme CYP27B1 catalyzing the conversion of 25(OH)D3 into its active 
hormone, is present in non-malignant human prostatic epithelial cells, indicating the local 
production of 1α,25(OH)2D3 derived from 25(OH)D3. Interestingly, CYP27B1 activity is 
reduced in PCa cells compared with non-malignant cells, leading to a local reduction of the 
1α,25(OH)2D3 production and the excessive, intrinsic growth of cancer cells. As the prostatic 
CYP27B1 gene is not regulated by PTH or calcium, the treatment with vitamin D might be a 
useful chemoprevention, without undesirable side effects of increased circulating hormone 
levels (Chen, 2003; Swami, 2011). Intriguingly, the anti-proliferative and differentiating 
cytostatic rather than a cytolytic one, action of vitamin D, can be more effective in prevention 
therapy or in the treatment of early disease, with doses not exceeding toxicity level (Krishnan, 
2010). 
 
1.4.6. VDR and PCa epidemiology 
A variety of modified genes involved in PCa, including the deficiency of tumor suppressors 
and the up-regulation of oncogenes, are closely related to inflammation, proliferation and 
differentiation, the processes in which vitamin D signaling plays a crucial role. Thus, it is 
crucial to investigate the relationship between PCa and VDR function. 
Another connection between prostate cancer development and vitamin D intake may be, as 
above-mentioned, ethnicity. The disease affects mainly Afro-American men; white men have 
a nearly twice lower risk and Asian men, the lowest. Epidemiological studies implied that the 
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chance of suffering from PCa is also associated with residence in northern countries. Thereby, 
a strong correlation between sunlight exposure and cancer growth was monitored (Polek, 
2002; John, 2007). Since vitamin D synthesis occurs via the action of UV-B light in the skin, 
a low level of 1α,25(OH)2D3 was correlated with an increased probability of getting PCa 
(Moreno, 2005).   
 
1.4.7. Role of VDR in prostate cancer development 
 
1.4.7.1. The anti-proliferative function of the VDR  
It is well known that 1α,25(OH)2D3 controls the cell cycle through regulation of expression of 
genes involved in that process (Norman, 2010). It was reported that VDR action arrests the 
cell cycle in the G0/G1 phase in LNCaP advanced prostate cancer cell line due to up-
regulation of p21 and p27 gene expression (Zhuang, 1998; Lou, 2004). Interestingly, the 
transgenic over-expression of human c-myc in the murine prostate has been shown to lead to 
the development of neoplasia, which transformed into invasive adenocarcinomas (Ellwood-
Yen, 2005). JoyAnn et al. reported that stimulation of androgen-independent prostate cancer 
cells (C4-2) with 1α,25(OH)2D3 reduces MYC expression on the mRNA level and decreases 
protein stability. Moreover, after MYC gene silencing, cell growth inhibition and G1 phase 
accumulation was observed. These findings suggest importance of 1α,25(OH)2D3 in cell cycle 
arrest in PCa studies. Nevertheless, the exact mechanism by which VDR controls cell growth 
in PCa is still not fully understood (JoyAnn, 2009; Stewart, 2005). 
One of known targets of VDR, IGFBP3 encoding a protein that binds to the IGF, as 
mentioned above, interestingly is reduced in PCa (Jerome, 2003). IGFs are essential for 
proper cell proliferation and development (Kriebitzsch, 2009). Microarray analysis has shown 
that IGFBP3 is the highest induced gene in LNCaP cells after stimulation with 1α,25(OH)2D3 
(Krishnan, 2004). Moreover, in the same cell line it was noticed that IGFBP3 expression is 
directly regulated by VDR through binding to the VDRE located close to the promoter of that 
gene. IGFBP3 activates pathways including the activation of p21 that participates in cell cycle 
arrest. Thus, IGFBP3 contributes to the growth inhibitory action of 1α,25(OH)2D3 and is 
associated with the induction of apoptosis (Peng, 2004). 
A pro-apoptotic function of 1α,25(OH)2D3 was confirmed by many studies on different cancer 
cells including prostate (Blutt, 2000). For example, the activation of VDR is lowering the 
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expression level of the anti-apoptotic gene BCL2 (Samuel, 2008) that is normally highly 
expressed in PCa (Moreno, 2005), and thus enhances apoptosis.  
Moreover, genes involved in PG metabolism and action were shown to be regulated by VDR 
in primary prostatic cells and in PCa cell lines. Interestingly PGs, along with having effect on 
growth promotion and PCa progression, are involved in the inhibition of apoptosis. The 
effects of 1α,25(OH)2D3 may reduce the levels of biologically active PGs and therefore 
decrease a PG-related cell proliferation in PCa. Microarray data from an advanced prostate 
cancer cell line (LNCaP and PC3) stimulated with 1α,25(OH)2D3 confirmed this hypothesis 
(Moreno, 2005). The analysis revealed significant induction of the NAD-dependent 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) gene, a putative tumor suppressor gene, 
product of which is important in inactivation of PGs synthesis. In addition, the expression of 
PTGS2 gene, which catalyzes PG synthesis and is induced in many cancer cells (Greenhough, 
2009), is down-regulated after 1α,25(OH)2D3 treatment. (Moreno, 2006; Kriebitzsch, 2009). 
In addition, relations between androgens and vitamin D action were reported in association 
with the control of cell growth. A recent genomic study on the LNCaP cell line revealed over 
250 genes that were synergistically regulated by both, the AR and the VDR, in a co-treatment 
experiment. Interestingly, neither hormone alone did not significantly enrich those genes 
(Wang, 2011). This study indicates a relation between VDR signaling and AR signaling.  
The co-operation between VDR and AR was also investigated in vivo. A mouse model for 
PCa with and without Vdr was compared, indicating that Vdr ablation is correlated with PCa 
progression. Vdr knockout mice showed increased cell proliferation and faster prostate tumor 
progression than the control wild-type Vdr (VDRWT). Moreover, supplementation of both 
types of mice with testosterone abrogated the protective role of vitamin D, suggesting a cross 
talk between VDR and AR (Mordan-McCombs, 2010). 
Furthermore, other animal models validated the postulated function of vitamin D in growth 
regulation of PCa (Thorne, 2008; Chen, 2003). For instance, Banach-Petrosky et al. have used 
a mouse model with a loss of function of Nkx3.1 and Pten tumor suppressor genes; these 
mutations are known to be relevant in PCa development. They reported that, upon 
1α,25(OH)2D3 stimulation, the progression of PIN formation from low to high level was 
significantly reduced, especially when administrated before, rather than subsequent to, the 
initial occurrence of PIN (Banach-Petrosky, 2006). These findings support the role of vitamin 
D in chemoprevention of PCa, and suggest that clinical trials for patients with PIN or earlier 
stage of disease may show a slowdown of PCa development (Swami, 2011; De Marzo, 2007). 
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1.4.7.2. Anti-angiogenic functions of VDR  
It is already known, that vitamin D may inhibit angiogenesis. 1α,25(OH)2D3  does not only 
reduces proliferation, but also moderates the formation of endothelial cell tube-like structures 
induced by the VEGF. 1α,25(OH)2D3 decreases expression of VEGF gene in several 
malignant cells including PCa. Moreover, suppression of PTGS2 sustains vitamin D’s anti-
angiogenic action (Krishnan, 2010; Kundu, 2008). Mantell et al. have performed an in vivo 
study in mice implanted with transfected breast cancer cells with VEGF over-expression. The 
tumor was less vascularized in the presence of 1α,25(OH)2D3 compared to the vehicle control, 
due to VDR-dependent reduction of VEGF gene expression (Mantell, 2000).  
 
1.4.7.3. Anti-metastatic function of the VDR  
1α,25(OH)2D3 inhibits the angiogenesis and controls expression of genes involved in the 
progression to invasion and metastasis (Krishnan, 2004). For instance, through stimulation of 
an up-regulation of 6 and 4 integrins, the receptors for the basement membrane matrix 
protein laminin involved in cell migration and adhesion in metastatic PC-3 and DU145 
prostate cancer cell lines, 1α,25(OH)2D3 shows association with PCa metastasis suppression 
(Sung, 2000). Moreover, in PCa vitamin D increases the level of the tumor suppressor E-
cadherin, which down-regulation is correlated with cell proliferation, progression to invasion 
and metastasis (Krishnan, 2010). 
 
1.4.8. Clinical studies of vitamin D in PCa  
In general, the care of common prostate cancer patients is based on prostatectomy combined 
with radiation and hormonal therapy. Clinically two basic stages of PCa are distinguished: 
early (androgen-dependent) and late (androgen-independent) (Krishnan, 2007). Since the 
growth of prostate cells depends on androgen, its deprivation is used for treatment of an early-
detected PCa. This therapy is effective as palliation. However during PCa progression, the 
tumor is no longer androgen-dependent and stops therefore responding to a hormonal therapy 
(Schwartz, 2009; Vijjan, 2007). Considering the relation between PCa and vitamin D 
deficiency, 1α,25(OH)2D3  appeared to be beneficial in slowing down the tumor progression 
in clinical trials. Nevertheless, the promising long time-scale administration of high dosage of 
1α,25(OH)2D3 to the patients with advanced cancer, brought side effects, like hypercalcemia 
(Schwartz, 2009). Thus, the question arose how to get a response without inducing 
hypercalcemia. Some clinical studies in androgen-independent PCa showed that intermittent 
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application of very high doses of 1α,25(OH)2D3 alone or in combination with dexamethasone, 
an immunosuppressant and an agonist of GR, enhanced the anti-proliferative effects of 
1α,25(OH)2D3 and caused only a transient hypercalcemia. In 28% of those patients the PSA 
serum level was halved (Trump, 2006). 
Another study on androgen-independent PCa reported the relation between high dosage of 
1α,25(OH)2D3 in combination with the chemotherapy drug docetaxel and tumor progression. 
The PSA doubling time was prolonged in 63% of the patient treated with 1α,25(OH)2D3 and 
docetaxel (Beer, 2007). 
Also, analogs of 1α,25(OH)2D3 with enhanced anti-proliferative function and reduced 
calcemic action have been created and administrated to patients (Masuda, 2006). Further, 
using low doses of vitamin D or its analogs in combination with low doses of other drugs, 
could minimize the side effect of the latter ones and augment their response on cancer. For 
instance, long intake of the Non-Steroidal Anti-inflammatory Drugs (NSAIDs) like aspirin, 
ibuprofen or naproxen may block tumor progression (Hussain, 2003), by inhibiting PTGS2 
activity and thereby leading to a reduction of PG synthesis. However, it also lead to the 
development of cardiovascular complications. Cocktails containing lower concentrations of 
1α,25(OH)2D3 and NSAIDs induced equally strong inhibition of PCa growth when compared 
to NSAID alone, but without the side effects (Moreno, 2006). In early recurrent PCa the 
administration of 1α,25(OH)2D3 in combination with naproxen slowed down the PCa 
progression and prolonged the PSA doubling time in 75% of the patients (Srinivas and 
Feldman, 2009). 
Interestingly, there is a controversy whether PSA is a good biomarker for PCa. On the one 
hand it is the best-known indicator of risk for PCa, its initial diagnosis and in monitoring the 
cancer progression, but it is also elevated in benign prostate diseases. Therefore, many cases 
of over-diagnosis and over-treatment have occurred due to PSA screening (Lilja, 2008; 
Croswell, 2011).  
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1.5. The Kallikrein gene family 
 
1.5.1. General overview on the Kallikrein gene family  
PSA, being used as a biomarker for routine screening of PCa, is a member of the largest, 
contiguous gene cluster family in the human genome, encoding so called kallikrein-related 
peptidases (KLKs). It is a family of highly conserved, trypsin- or chymotrypsin-like serine 
protease enzyme that consists of 15 members (KLK1-15) (Sardana, 2009). First KLK1 was 
discovered, which was followed by the detection of elevated levels of KLK3 in PCa in the 
1970s. A few years later the localization of KLK1, KLK2 and KLK3 was assigned to 
chromosome 19q13.4. The other family members were detected in the 1990s because of 
similarities in their gene structure (Borgono, 2004). The KLKs encode pre-pro-enzymes that 
are up to 40% identical in all family members. The KLK genes are often co-expressed in 
normal tissues (prostate, breast, ovarian, skin, central nervous system (CNS), pancreas) and 
biological fluids, which suggest that these secreted proteins may have a common mechanism 
of action (Paliouras, 2007). The activation of KLK pro-enzymes, produced as zymogens, is a 
consequence of a complex proteolytic cascade resulting in the activation of multiple KLKs. 
Together they are involved in various processes like skin desquamation, degradation and 
remodeling of ECM, semen liquefaction, innate immunity, among others (Sotiropoulou, 
2009). Intriguingly, KLKs can act individually or in a complex that promotes the proteolytic 
cascade. However, the diversity of KLKs functions and altered expression in various types of 
cancer/diseases is broad and still not well understood (Emami, 2007).   
 
1.5.2. Organization and structure of the KLKs and their genes 
The KLK family is located on chromosome 19q13.3-13.4 and forms a cluster, with the length 
of 265 kb. Except KLK2 and KLK3 all genes are transcribed from telomere to centromere.    
34 - 52% of the locus consists repetitive elements mainly located outside the protein coding 
regions (only 4.3% were found inside) (Yousef, 2001). Moreover, the “classical kallikreins” – 
KLK1, KLK2 and KLK3 are highly similar in the amino acid sequence. KLK2 and KLK3 show 
62-67% of identity with the KLK1, whereas the other KLKs (4-15) are less conserved and 
show only about 27-39% homology.  
All genes contain five exons, conserved in size and arrangement. In addition, each KLK shows 
several transcript variants, as a result of alternative transcription start sites (TSS) derived from 
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additional upstream exons, usually between one and three (Clements, 2004). Tandem genomic 
organization of the 15 KLK genes is shown in the figure bellow (Fig. 13).  
Interestingly, KLK1 and KLK4-15 are present in all placental mammals, whereas KLK2 and 
KLK3 are not, suggesting a different evolutionary background. KLK2 and KLK3 show high 
similarities to KLK1. Probably, KLK1 duplicated to give rise to KLK2 from which in primate 
evolution KLK3 has arisen (Yousef, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The kallikrein gene locus organization 
A. KLKs are located on chromosome 19q13.4 in a cluster of 265 kb length. The “classical 
kallikreins” (KLK1, KLK2 and KLK3) are marked by red arrows, the pseudogene KLK1 in 
yellow and the KLK4-KLK15 in purple B. All KLK genes are similar and have usually five 
exons and three introns C. The human KLK proteins contain an amino-terminal signal 
sequence (Pre), a pro-peptide (Pro), and a serine-protease domain responsible for catalytic 
activity (Taken from Borgono, 2004). 
 
All human KLKs (hK) are synthesized as inactive or minimally active pre-pro-enzymes. The 
pre-domain (Pre) enables insertion of the KLKs into the endoplasmatic reticulum for later 
secretion. The emerged pro-enzymes (Pro), called zymogens, stay in latency until the pro-
domain is discarded, which lead to conformational changes in the enzyme and activation of 
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the catalytic activity of the serine-protease domain. Thus, they are able to cleave bonds in 
targeted polypeptide chains and to start protein catabolism (Lawrence, 2010). 
Studies have shown that some hKs undergo self-activation, which means that they are 
activated by other hKs, e.g. pro-hK3 is activated by hK2, hK4, hK5 and hK15 (Borgono, 
2004). Moreover, they may lose their activity via internal cleavage by the same or different, 
mature hKs (Sotiropoulou, 2009). For instance, hK6 maintains an autoactivation / 
autoinactivation process of its own (Magklara, 2003), whereas pro-hK2 and pro-hK3 activated 
by hK5 are inhibited by the same enzyme, after longer incubation (Michael, 2006). Moreover, 
as other serine proteases, hKs interact with endogenous inhibitors like the serpins in two 
ways. One, known as the “inhibitory pathway”, results in the irreversible inactivation of the 
kallikrein when the inhibitory covalent hK-serpin complex is formed, and triggers permanent 
hK deformation. In the second way, the so called “substrate pathway”, the hK cleaves and 
inactivates the serpin, whereas the hK remains active (Sotiropoulou, 2009). 
The regulation of the enzymatic activity of KLKs requires a series of feedback loops and 
inhibitors. Therefore, it involves a complex network of events that occurs at multiple levels.  
 
1.5.3. Regulation of kallikrein genes 
Kallikreins are present in most of the tissues and body fluids in human (Yousef, 2001). 
Intriguingly, many of the KLKs and their different transcript variants, are simultaneously 
expressed in a cell-specific manner. For instance, sets of KLKs are found in breast (KLK3, 
KLK4, KLK5, KLK6, KLK8, KLK10, KLK13, KLK14), in the skin (KLK5, KLK7, KLK8, 
KLK9, KLK11, KLK13, and KLK14), in the CNS (KLK5-KLK9, KLK11, KLK14) and in 
prostate (KLK2-KLK6, KLK11-KLK13, and KLK15) (Lose, 2011; Paliouras, 2007). This way 
of expression suggests a complex mechanism of regulation that may be common for a cluster 
of genes.  
The majority of the KLK genes are regulated by steroid hormones, like androgens, estrogens, 
glucocorticoids and mineralocorticoids (Lawrence, 2010). The most studied, in terms of 
hormonal regulation of gene expression, are KLK3 and lately KLK2. They are related to PCa 
and regulated by androgens through several AR response elements (ARE) located proximal 
and distant from the TSSs of the genes. This suggests a possible formation of a chromatin 
loop in order to bring the ARE enhancer and the promoter together (Jia, 2006). Interestingly, 
anti-androgen treatment resulted in AR occupancy in the promoter but not at the enhancer of 
KLK3, which was correlated with the recruitment of co-repressors, e.g. NCoR and SMRT, 
1.Introduction 
 
 38 
instead of RNA pol II and co-activators (Kang, 2002; Kang, 2004). Moreover, several 
polymorphisms that occur within the KLK3 promoter and its enhancer were associated with a 
different response to androgen stimulation. They could either increase or decrease the AR 
affinity to its AREs (Lawrence, 2010). 
It was also reported that KLKs might be additionally regulated by a series of other factors, 
including progestin, thyroid hormone, retinoic acid, and vitamin D. Yet, the exact mechanism 
of the transcriptional regulation by these ligands for specific nuclear receptors of the whole 
KLK cluster is not yet known (Lawrence, 2010).  
 
1.5.4. The role of KLKs in cancer 
The expression of many KLKs is altered in hormonally regulated cancers. In general, the 
expression of these extracellular proteases was thought to be correlating with cancer 
progression, as they are capable of the degradation of the extracellular matrix (ECM), which 
is necessary for tumor metastasis and invasion. However, recent studies have shown that 
specific proteases might have anti-tumor properties. The over-expression of KLKs in cancer is 
linked with poor clinical prognosis. Nevertheless the increased level of some of the KLKs is 
associated with their role in cancer prevention (Lopez-Otin, 2007).  
For instance, KLK6 is silenced in metastatic breast cancer. Pampalakis et al. analyzed non-
malignant vs. tumor breast cells and found that loss of KLK6 is correlated with the presence of 
hypermethylation of specific CpGs located near the KLK6 promoter, and with the 
deacetylation of histones that led to formation of condensed chromatin in cancer but not in 
non-malignant breast cells. Moreover, treatment with inhibitors of DNA methyltransferase 
and histone deacetylase, re-activated expression of the KLK6 gene. This caused a recruitment 
of histone acetyltransferase CBP co-activator together with RNA pol II and TATA-binding 
protein (Pampalakis, 2009). Interestingly, re-expression of the KLK6 protein results in 
reduced proliferation and motility, and thus inhibits tumorigenicity in breast tumor cells. The 
potential substrates for KLK6 found after its reactivation include vimentin, a major 
mesenchymal marker of cancer aggressiveness, that was down-regulated in parallel with the 
up-regulation of the epithelial markers that are associated with tumor reversion, e.g. anti-
angiogenic activity. In this way the KLK6 action shows a protective role against cancer 
development by inhibition of EMT (Pampalakis, 2009).  
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Additionally, a similar pattern of promoter hypermethylation and, as follows gene inhibition 
was observed for KLK10. This gene was also characterized by its anti-proliferative action, and 
was proposed to have a role as tumor suppressor in breast cancer (Borgono, 2004).  
Furthermore, in breast cancer cells, hormonal steroids may induce the expression of multiple 
KLKs including KLK2, -3, -8, -10, -11, 13-15. The promoters of KLK3, KLK10 and KLK11 
recruit AR upon androgen stimulation. KLK5, -6, -10, -14 are up-regulated upon estrogen 
stimulation, though it is not clear whether these genes are ER-dependent since they are also 
expressed in ER-negative tumors (Lawrence, 2010; Luo, 2002). In addition, loss of KLK10 in 
breast cancer is linked with poor prognosis and does not respond on the ER action (Paliouras, 
2007). 
Interestingly, the lack of KLK8 is correlated with the poor prognosis in patients with non-
small cell lung cancer. KLK8 is able to repress cell invasiveness and motility through 
targeting and cleaving the fibronectin, a protein of the ECM responsible for integrin signaling. 
By that KLK8 may suppress tumor progression (Fortier, 2003).  
Moreover, PSA (KLK3) known from its role as biomarker for screening, diagnosis and 
monitoring of prostate cancer, can promote metastasis from the prostate to the bone and may 
have immunosuppressive function that can result in inhibition of T cell proliferation. 
However, its putative functions are widely heterogeneous. KLK3 may regulate oxygen 
stability in cancer; enhance expression of androgen target genes in castrate resistant prostate 
cancer cells by binding to a specific co-activator. It can also cleave semenogelins that forms 
seminal clots and encases spermatozoa (Lawrence, 2010). Moreover, KLK3 together with 
KLK2, KLK4, KLK5, KLK11 and KLK14 are able to target the IGFBPs. The cleavage of 
those proteins through the protease activity of KLK proteases results in a reduced affinity for 
IGF leading to abnormal cell growth stimulation in malignant prostate cells (Borgono, 2004). 
Additional data shows that KLK3 and KLK4 participate in the EMT of the prostate cancer, 
i.e. the transformation of stable epithelial cells into migratory mesenchymal cells (Lawrence, 
2007). Moreover, some KLKs can promote angiogenesis, by cleavage of ECM components or 
through the pathways, in which they are involved i.e. the kallikrein-kinin, urokinase 
plasminogen activator (uPA) and/or PARs pathways that facilitate tumor invasion and 
migration (Emami, 2007).  
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1.5.5. Signaling pathways and other functions 
Since KLKs are characterized by various expression and activation profiles, they are believed 
to be involved in a variety of signaling pathways, as well as biological and physiological 
processes.  
1.5.5.1. The kallikrein-kinin pathway 
The best understood signaling cascade involving KLKs is the kallikrein-kinin pathway. Here, 
KLK1 and KLK2 can cleave the precursor called kininogen to release kinins, like bradykinin, 
via a specific KLK protein loop that contains kininogenase activity. Active kinin peptides 
mediate a series of actions by binding to their receptors. These G protein-coupled, 
transmembrane receptors induce the production of prostaglandins, nitric acids and other 
mediators that are involved in a wide range of processes including the regulation of blood 
pressure, inflammation, the stimulation of angiogenesis and the development of 
cardiovascular diseases (Costa-Neto, 2008). 
1.5.5.2. The urokinase plasminogen activator (uPA) 
Moreover, some KLKs like KLK2, KLK4, and KLK12 are able to activate uPA. This enzyme 
cleaves a variety of extracellular substrates like plasminogen into active plasmin. Later on, the 
plasmin proceeds to cleave and activate other pro-enzymes, like the pro-MMPs that are 
involved in ECM degradation and in the release and/or activation of tumor growth factors. 
Alternatively, uPA may activate some pro-MMPs directly (Borgono, 2004). 
1.5.5.3. The PARs 
KLKs are also activators of PARs that belong to the G protein-coupled receptor family and 
are activated by cleavage of part of their extracellular domain. Upon KLK1, KLK2, KLK4 – 
KLK6 and KLK14 cleavage, PARs initiates downstream signaling taking part in the 
inflammatory response as well as in cellular migration (Lawrence, 2010; Hollenberg, 2007).  
1.5.5.4. Additional functional roles of KLK6  
Besides its tumor suppressor function, KLK6 is also associated with the inflammation of the 
CNS and in MS. For instance, KLK6 is abundantly expressed in the normal CNS and altered 
levels of the KLK6 in the brain are correlated with neurological disorders including 
Alzheimer’s and Parkinson’s disease. Importantly, this protein is widely induced by 
inflammatory cells (T cells) in human brain at damaged myelin sheaths suggesting that KLK6 
participate in the demyelination by the cleavage of myelin. Nevertheless, the physiological 
role of KLK6 in the brain is poorly understood (Blaber, 2004). Alzheimer’s disease brain cells 
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reveal a low level of KLK6 compared to healthy control cells (Ashby, 2010). Moreover, 
KLK6 might have a role in the pathogenesis of Parkinson’s disease, since it degrades -
synuclein, the major component of the so-called Lewy bodies, abnormal aggregates of 
proteins. Upon a stress signal KLK6 translocates from the mitochondria to the cytoplasm, 
where it cleaves -synuclein, thereby preventing the accumulation of aggregates (Iwata, 
2003; Sotiropoulou, 2009). 
Intriguingly, KLK6 expression may be modulated by vitamin D action. Up-regulation was 
seen in normal skin keratinocytes (Lu, 2005) as well as in colon cancer (Palmer, 2003). Also 
one VDRE located up-stream from the KLK6 TSS was found in colon cancer (Wang, 2005). 
Yet, the exact function of its hormonal regulation is not well defined and need to be further 
explored. 
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2. OBJECTIVES 
 
The main objective of my thesis was to explore in a broad approach the action of 
VDR in human prostate cells. Many studies have shown that VDR affects pathways 
crucial for proper cell and tissue function by regulating the expression levels of its 
target genes. It has been documented that many of these genes are fundamental to the 
immune system and to the regulation of proliferation and differentiation. As they 
were found to be deregulated across various tumor cells (reviewed by Deeb, 2007), an 
important role of the VDR in cancer prevention can be assumed. Therefore, additional 
investigations are required to fully understand the mechanisms underlying the effects 
elicited by 1α,25(OH)2D3. For that reason, the aims of my study were the following: 
 
1. To identify primary and secondary VDR target genes on a transcriptome-
wide level in human non-malignant prostate cells. 
 
2. To compare the inducibility of a selected group of genes (Kallikreins) 
between human non-malignant and malignant cell lines. 
 
3. To examine the effect of VDR suppression on the mRNA expression of 
KLKs in non-malignant prostate cells. 
 
4. To correlate the results of in silico screening for putative VDR binding 
sites with the mRNA regulation of identified KLK genes. 
 
5. To investigate the functionality of identified VDR binding sites within the 
genomic region of VDR-regulated KLK genes.
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3. MATERIALS AND METHODS 
 
3.1. Cell culture 
 
Human immortalized non-malignant adherent epithelial prostate RWPE1 cells were 
derived from the peripheral zone of a histologically healthy 54-year old male’s 
prostate and malignant RWPE2 cells were derived from RWPE1 cells via 
transformation with Ki-ras by the Kirsten murine sarcoma virus (Bello, 1997). Both 
cells were obtained from American Type Culture Collection (ATCC). Cells were 
cultured in Keratinocyte serum free medium (SFM) containing L-glutamine, 25 mg 
bovine pituitary extract, 2.5 g human recombinant epidermal growth factor, and 100 
U/ml of penicillin-streptomycin mixture. For mRNA and chromatin extractions cells 
were seeded in the culture medium except short-interfering RNA (siRNA) 
transfection experiments medium did not contain the antibiotics. PC3 human adherent 
from a bone metastasis prostatic adenocarcinoma cells from 62-year old male were 
cultured in RPMI medium containing 10% fetal bovine serum (FBS), 2 mM 
glutamine and 100 U/ml penicillin-streptomycin mixture. DU145 human adherent 
brain-derived prostatic carcinoma cells were cultured in DMEM medium containing 
10% fetal bovine serum (FBS), 2 mM glutamine and 100 U/ml of penicillin-
streptomycin mixture. Around 24h prior to treatment PC3 and DU145 cells were 
seeded into medium with lower (5%) charcoal-treated fetal bovine serum (FBS). All 
cells were maintained in a humidified 95% air / 5% CO2 incubator. Cells were 
maintained according to recommendations from ATCC. 
For all experiments cells were treated either with solvent (ethanol, with final 
concentration of 0.1%) or 100 nM 1α,25(OH)2D3. 
 
3.2. Total RNA extraction and cDNA synthesis 
 
Total RNA was extracted using the Invisorb Spin Cell RNA Mini Kit (Invitek GmbH, 
Berlin, Germany) according to the manufacturer’s instructions. cDNA was 
synthesized for 1h at 37 
O
C using 1 g of total RNA as a template, 100 pmol 
oligodT15 primer  and 40U of M-MuLV reverse transcriptase (Fermentas). The 
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reverse transcription was terminated by 10 min incubation at 70 
O
C. The cDNA was 
diluted 1:10 and served as a template for real-time quantitative PCR. 
 
3.3. Microarray analysis 
 
RNA samples quality was checked with BioRad Experion Automated Electrophoresis 
Systems (Biorad). Samples were analyzed with Human HT-12 Expression Beadchip 
Arrays from Illumina (San Diego, USA). The microarray data pre-processing and 
differential expression analysis were performed using the R statistical software, 
version 2.11 (R Development Core Team, 2011). Lumi package (Du, 2008) was used 
for processing raw data normalization. Data was normalized using VST 
transformation function, which was followed by RSN normalization used as a 
standard approach for Illumina arrays. In order to eliminate probes without detected 
signal normalized data was filtered. Probes that had a detection p-value < 0.05 were 
used in the statistical analysis using linear Models for Microarray Data (limma) 
package (Smyth, 2004) for detection of differentially expressed genes. The adjusted 
p-value corrected for multiple testing by the Benjamini–Hochberg method 
(Benjamini, 1995) was set to 0.01.  Significantly differentially expressed genes for a 
selected time-point in response to 1α,25(OH)2D3-treatment were detected using the 
cut-off that was set for log2 fold change > 0.5 or less than < -0.5. 
 
3.4. Real-time quantitative PCR 
 
Real-time quantitative PCR was performed using iCycler (BioRad) with Absolute 
SYBR Green Fluorescein (Thermo Scientific) and in Applied Biosystems 7500 Fast 
Real-Time PCR System using Absolute Blue qPCR SYBR Green Low ROX Mix 
(Thermo Fisher Scientific, Surrey UK). The PCR cycling conditions were as follows: 
polymerase activation time of 15 min at 95
O
C, followed by 40 cycles performed with 
30s at 95
O
C, 30 s at primer specific temperatures, 30s at 72
 O
C and final elongation 
for 5 min at 72
 O
C. We performed 2 technical replicates per sample on a PCR plate. 
Fold inductions were calculated using the formula 2
-(ΔΔCt), where ΔΔCt is the 
ΔCt(ligand)-ΔCt (vehicle), ΔCt is the Ct(target gene)-Ct(house keeping gene) and Ct is the cycle at 
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which the threshold is crossed. Quality of the PCR product was monitored using post-
PCR melt curve analysis. The values were normalized to acidic riboprotein PO 
(RPLPO) gene. The sequences of the primers are shown in Appendix I. 
 
3.5. siRNA silencing 
 
RWPE1 cells were transfected with non-specific control siRNA oligonucleotides or 
with specific for human siRNAs targeting the VDR or CTCF, by using Lipofectamine 
RNAiMAX (Invitrogen) according to the manufacturer’s instructions. The sequences 
of double-stranded siRNAs were obtained from Eurogentec. RWPE1 cells were 
seeded in 6-well plates in Keratinocyte serum free medium (SFM) containing L-
glutamine, 25 mg bovine pituitary extract, 2.5 g human recombinant epidermal 
growth factor, and 100 U/ml of penicillin-streptomycin mixture for 24 h. The specific 
siRNAs and control siRNAs were incubated with RNAiMAX in a total volume of 500 
l of antibiotic-free medium. The mixture was added to the cells and the transfection 
was continued for 48 h, and then cells were treated with 100 nM 1α,25(OH)2D3 or 
ethanol for 4 h and 24 h for cells transfected with siRNA against VDR and 4 h for 
cells transfected with siRNA against CTCF. 
 
3.6. Chromatin immunoprecipitation (ChIP) assays 
 
Cells were grown in 60 mm dish at confluence for 24 h. Next they were treated for 60 
min with 100 nM 1α,25(OH)2D3. The nuclear proteins were cross-linked to genomic 
DNA by adding formaldehyde directly to the medium to a final concentration of 1% 
for 5 min at room temperature. Cross-linking reaction was stopped by adding glycine 
to a final concentration of 125 mM and incubation for 5 min at room temperature. 
Next, medium was aspirated; cells were rinsed twice with ice-cold phosphate-
buffered saline (PBS) and collected by scraping. After centrifugation pellet was 
resuspended in 600l of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 
8.0, protease inhibitors) and incubated on ice for 10 min. Next, chromatin was 
sonicated by a Bioruptor (Diagenode, Liege, Belgium) with 30 pulses of 30 s on and 
30 s off to obtain DNA fragments of 300-700bp in length. Cellular debris was 
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removed by centrifugation and the lysates were diluted 1:10 in ChIP dilution buffer 
(20 mM Tris-HCl pH 8, 2 mM EDTA, 1% Triton X-100, 150 mM NaCl). Chromatin 
mixture was incubated overnight at 4
O
C with rotation with 1 g of antibodies against 
VDR (sc-1008X) or control IgG (sc-2027) and 5 l H4Ac (06-866), CTCF (07-729). 
The immuno-complexes were collected with 60 l of protein A agarose slurry 
(Millipore) for 2h at 4
O
C with rotation. The beads were washed consecutively for 3 
min on rotating platform with 1 ml of each solution: ChIP wash 1 (20 mM Tris-HCl 
pH 8, 2 mM EDTA, 1% Triton X-100, 150 mM NaCl), ChIP wash 2 (20 mM Tris-
HCl pH 8, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, 500 mM NaCl), ChIP wash 3 
(0.25 M LiCl, 1%NP-40, 1% Na-deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8) 
and finally twice with TE buffer (10 mM Tris-HCl, 1 mM EDTA pH8). For each 
wash, samples were incubated 3 min and then centrifuged for 1 min at room 
temperature with 400x g. The immuno-complexes were next eluted twice using 250 
l of elution buffer (1% SDS, 0.1 M NaHCO3) for 15 min at room temperature with 
rotation. Proteins from the obtained supernatant were digested overnight at 65 
O
C 
using proteinase K (Fermentas, final concentration = 40 g/ml). Genomic DNA 
fragments were extracted using the ChIP DNA Clean & Concentrator
TM
 isolation kit 
(Zymo Research Cooperation, HiSS Diagnostics, Freiburg, Germany) according to 
manufacturer’s instructions. For anti-VDR and anti-IgG antibodies collections of 
more than 50 immunoprecipitations were pooled in 40 l nuclease-free water. 
 
3.7. PCR of chromatin templates 
 
Genomic primers for the KLKs TSSs and regions containing putative VDRE were 
designed and real-time PCR was performed with Absolute Blue qPCR SYBR low 
Rox Mix (Thermo Scientific) using 7500 Fast Real-Time PCR System (Applied 
Biosystems). The cycling conditions were: pre-incubation for 15 min at 95
O
C, 
followed by amplification steps: 40 cycles of 30 s at 95
O
C, 30 s at 60
 O
C, 30 s at 72
 
O
C and final elongation for 10 min at 72
 O
C. Relative association of chromatin bound 
proteins or histone modifications were calculated using the formula 2
-(ΔCt), where ΔCt 
is the Ct (output)-Ct (input). Output is the immuno-precipitated DNA and input is the 
purified DNA from the starting material of the ChIP assay. Relative fold changes 
were calculated against the control IgG. 
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3.8. RNA degradation rate experiment 
 
RWPE1 cells were seeded in 6-well plates in Keratinocyte serum free medium (SFM) 
containing L-glutamine, 25 mg bovine pituitary extract, 2.5 g human recombinant 
epidermal growth factor, and 100 U/ml of penicillin-streptomycin mixture for 24 h. 
Next, cells were treated with 100 nM 1α,25(OH)2D3 for 2h and then new RNA 
synthesis was blocked by treating the cells with Actinomycin D (final concentration: 
10 µg/ml).  
 
3.9. Gene annotation analysis 
 
Genes were annotated according to Gene Ontology (GO) biological processes and 
enriched pathways analysis were determined by publicly available Database for 
Annotation, Visualization and Integrated Discovery (DAVID) software 
(http://david.abcc.ncifcrf.gov/), using default parameters with selected background as 
a reference (Huang, 2009). The performed statistics for GO was generated as 
expression analysis systematic explorer (EASE) score. Significant p-values and the 
false discovery rate (FDR) were less than 0.05 and 25%, respectively. 
 
3.10. The in silico screening analysis 
 
The identification of putative VDR binding sites was performed using publicly 
available JASPAR database, using default parameters (Sandelin, 2004). By 
employing the positional weight matrix (PWM) with cut-off of 80%, 30 putative 
binding sites were selected within KLK locus. Datasets from the ENCODE (The 
ENCODE Project Consortium, 2007) regulation tracks in the UCSC Genome Browser 
version hg18, were applied to detection of putative active regions within genomic 
KLK region.  TSS marked by H3K4me3 and enhancers marked by H3K4me1 
together with H3K27Ac were displayed from the Regulation Super-track. Chromatin 
boundary elements i.e. CTCF were displayed from Open Chromatin Track using 
HeLA cells. The sequence conservation profile across species was obtained from the 
UCSC Human Genome Browser, version hg18 (Kent, 2002). 
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4. RESULTS 
 
 
4.1. Profiling of VDR target genes in non-malignant prostate 
cells 
 
VDR is essential for the control of growth and differentiation in non-malignant and 
cancer cells from tissues such as skin, bone, prostate, breast, and more (Norman, 
2010). However, the exact mechanism underlying the function of this nuclear 
receptor is continuously under investigations. VDR stimulation with 1α,25(OH)2D3  
ligand increases cell differentiation, apoptosis and exhibits anti-angiogenic and anti-
metastatic effects in a mouse model, whereas 1α,25(OH)2D3 deficiency may increase 
the risk of certain cancers (Deeb, 2007). After activation, VDR gains the abilities to 
mediate the inhibition of cell proliferation and promote cell cycle arrest. Hence, since 
VDR is expressed in non-malignant and malignant prostatic cells, it is considered to 
be an anti-proliferative agent and can be tested as a preventive factor against cancer 
development. 
In order to identify potential target genes of VDR in human non-malignant epithelial 
prostate cells (RWPE1), a transcriptome-wide expression analysis using Illumina 
Human Expression BeadChips array version 3 was performed, following stimulation 
with 100 nM 1α,25(OH)2D3 and its solvent (EtOH) for 4 and 24 h (Fig. 14).  
 
 
 
 
        
 
 
 
Figure 14. Experimental setup for microarray analysis 
Human non-malignant epithelial prostate RWPE1 cells were treated with either 
solvent (EtOH) or 100 nM 1α,25(OH)2D3 for 4 and 24 h. Technical triplicates were 
performed for each time point. After incubation RNA was extracted and analyzed on 
the Illumina human Expression BeadChips arrays. 
 
1α,25(OH)2D3 
h 
EtOH  1α,25(OH)2D3
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Based on the applied cut-offs set for logarithmic2 fold change (FC) > 0.5 or <-0.5 
(equivalent to FC >1.4 or <0.7), statistical analysis revealed 87 regulated genes (p 
value (p) < 0.01) after 4 h of treatment, 76 of which were up-regulated and 11 were 
down-regulated (see Appendix II for the list of 87 early regulated genes). 
Interestingly, VDR activation significantly altered the expression of 663 target genes 
after 24 h of stimulation, with 467 induced and 196 repressed genes (see Appendix II 
for top 100 up- and down-regulated genes after 24 h of 1α,25(OH)2D3 stimulation). 
 
 
 
 
 
 
The top 15 genes that were most induced by 1α,25(OH)2D3 treatment compared to the 
solvent control are listed in table 3 and table 4.  
TIME 
UP 
(P VAL < 0.01) 
DOWN 
(P VAL< 0.01) 
TOTAL 
4 h 76 11 87 
24 h 467 196 663 
GENE 
SYMBOL 
GENE NAME 
FOLD 
CHANGE 
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 32.35 
HAS3 hyaluronan synthase 3 5.27 
CD14 CD14 molecule 4.35 
IGFBP3 insulin-like growth factor binding protein 3 3.48 
KLK6 kallikrein-related peptidase 6 3.34 
PADI3 peptidyl arginine deiminase 3 3.25 
C9ORF169 chromosome 9 open reading frame 169 3.11 
FAM83A family with sequence similarity 83 A 2.85 
ANGPTL4 angiopoietin-like 4 2.83 
PTGES prostaglandin E synthase 2.77 
SERPINB1 serpin peptidase inhibitor clade B (ovalbumin) 1 2.75 
DHRS3 dehydrogenase/reductase (SDR family) 3 2.71 
DUSP1 dual specificity phosphatase 1 2.45 
ABCA1 ATP-binding cassette, sub-family A, 1 2.43 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 2.42 
Table 2. Number of genes significantly altered after 4 and 24 
h of stimulation with 1α,25(OH)2D3 in RWPE1 cells 
 
Table 3. Top 15 genes significantly up-regulated after 4 h of stimulation with 
1α,25(OH)2D3  in RWPE1 cells 
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GENE 
SYMBOL 
GENE NAME 
FOLD 
CHANGE 
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 60.21 
KLK6 kallikrein-related peptidase 6 38.28 
PADI3 peptidyl arginine deiminase 3 31.99 
CD14 CD14 molecule 28.18 
CA9 carbonic anhydrase 9 15.63 
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin) 1 15.44 
DHRS9 dehydrogenase/reductase (SDR family) 9 10.74 
BAIAP2L2 BAI1-associated protein 2-like 2 9.09 
TMEM91 transmembrane protein 91 7.51 
TCEA2 transcription elongation factor A 7.00 
IGFBP3 insulin-like growth factor binding protein 3 6.18 
MGC102966 keratin 16 pseudogene 3 5.18 
DUSP10 dual specificity phosphatase 10 5.18 
CALB2 calbindin 2 5.13 
KLK5 kallikrein-related peptidase 5 5.07 
 
Comparing the top 15 genes up-regulated at the two time points of 1α,25(OH)2D3 
stimulation we observed five genes that overlapped. The gene expression of CYP24, a 
well-known VDR target (Deeb, 2007), was the most elevated one at both time points. 
Moreover, the previously reported 1α,25(OH)2D3-dependent regulation of the 
expression of the VDR targets IGFBP3, CD14, DUSP10 (Kovalenko, 2010) and 
KLK6 (Lu, 2005) was also observed in our analysis.  
Microarray data from non-malignant prostate cells stimulated with 1α,25(OH)2D3 
demonstrated numbers of differentially regulated genes that can be considered as 
primary (4 h stimulation) or secondary (24 h stimulation) targets of VDR. In order to 
get an overview on the short- and long-term 1α,25(OH)2D3-dependent genes 
regulation, the VDR targets were segregated accordingly to the implemented fold 
change and statistical limits (p<0.01, log2FC>0.5 or <-0.5).  The expression levels of 
early responding (4 h) genes were sorted according to their regulation by 
1α,25(OH)2D3 treatment after 24 h, as they are displayed on the heat maps, in Figure 
15. This manner of sorting genes revealed different patterns regarding the VDR-
dependent regulation. 
 
 
Table 4. Top 15 genes significantly up-regulated after 24 h of stimulation 
with 1α,25(OH)2D3  in RWPE1 cells 
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Figure 15. Microarray analysis revealed primary VDR target genes in RWPE1 
cells. (A) Heat maps displaying the gene expression profile of differentially 
expressed genes according to applied cut offs (p<0.01, log2FC>0.5 or <-0.5). (A) 
Common up-regulated genes: 56 genes significantly up-regulated upon 4 h of 
1α,25(OH)2D3 stimulation. Genes were sorted according to their induction after 24 h 
of treatment. (B) Oppositely regulated genes: depicted are 20 genes, that were 
significantly up-regulated after 4 h but down-regulated after 24 h of 1α,25(OH)2D3 
treatment. (C) Common down-regulated genes:  depicted are 11 significantly down-
regulated genes upon 4 and 24 h of 1α,25(OH)2D3 stimulation. Red indicates up-
regulation and blue down-regulation. KLK5 and KLK6 are highlighted as their 
regulation was later investigated in greater detail. 
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FOS 
KRT13 
DUSP1 
KLK5 
DUSP10 
IGFBP3 
TMEM91 
BAIAP2L2 
DHRS9 
SERPINB1 
CD14 
PADI3 
KLK6 
CYP24A1 
B 
IL1B 
FAM83A 
DHRS3 
MBP 
FOXA1 
C9ORF169 
FAM84B 
NAV2 
UPP1 
SMAD3 
FOXO1 
CRABP2 
TFCP2L1 
HOXA5 
ARS1 
FHL2 
C20ORF100 
ANGLPTL4 
HAS3 
FBXO32 
 
IER3 
FST 
PTHLH 
BIRC3 
THBS1 
SERPINB2 
PHACTR3 
VEGFC 
LOC652235 
ZBED2 
FOXA2 
7 15 
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The microarray results showed that 56 genes were significantly up-regulated after 4 h 
of stimulation and remained induced after 24 h of treatment with VDR ligand (Fig. 
15A). Interestingly, we found a set of 20 genes that was enhanced after 4 h but 
repressed after 24 h of stimulation. Among these genes were the IL1B and SMAD3 
genes (Fig. 15B). Moreover, 11 significantly down-regulated genes were identified 
after 4 and 24 h of treatment (Fig. 15C).  
Interestingly, among top list of significantly early induced VDR targets there were 
genes involved in fast immune response (CD14, FOS, IL8) and members of two gene 
families i.e. DUSP1 and DUSP10 that are part of the dual specificity phosphatase 
(DUSP) family and members of the KLK family of genes, with KLK6 being the 
second highest induced gene after 24 h of 1α,25(OH)2D3 stimulation (Figure 16A, B). 
Genes down-regulated at both time points were e.g. involved in angiogenesis 
(THBS1, VEGFC), with anti-apoptotic (IER3, BIRC3) or proliferative (FST) 
functions. Moreover, the PTHLH gene that encodes parathyroid hormone-like 
hormone protein, which increases activity of CYP27B1 that converts vitamin D into 
its active form, was decreased after 1α,25(OH)2D3 treatment (Fig. 16C, D).  
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Figure 16. Representation of VDR-regulated genes in RWPE1 cells. The fold 
changes of significantly (p<0.01) regulated VDR target genes were obtained from the 
microarray study. The inducibility of selected genes after 4 (A) and 24 h (B) of 
stimulation with 1α,25(OH2D3 are shown in upper panel, whereas genes down-
regulated after 4 (C) and 24 h (D) treatment with 1α,25(OH2D3 are shown in lower 
panel. A column represents the average of triplicates and a bars represents SD. 
 
Several of the significantly up-regulated genes were linked to the function of immune 
response, which would correlate with the identification of prostate cells as early 
sensors of infections (De Marzo, 2007). Significantly down-regulated genes after 4 h 
of stimulation indicated pro-apoptotic, anti-angiogenic and anti-proliferative VDR 
functions crucial in cancer prevention. 
 
UP-REGULATED GENES 
DOWN-REGULATED GENES 
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4.2. Physiological role of VDR in non-malignant prostate cells 
 
In order to understand the potential function of genes induced by VDR activation in 
non-malignant prostate cells, we identified overrepresented groups of genes that share 
common biological processes using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) (Huang, 2009). For the analysis we selected 
significantly regulated (p <0.01) genes both induced and repressed, from the array 
corresponding to 4 and 24 h of 1α,25(OH)2D3 treatment. Of the identified gene 
ontology (GO) terms some were matching to known VDR functions like “regulation 
of cell cycle”, “defense response”, “positive regulation of cell differentiation”, and 
“regulation of apoptosis”. The list of canonical biological processes in which VDR 
plays an important role is presented in the Table 5. The genes from each GO term 
were divided into two groups corresponding to the ones up- and down-regulated by 
1α,25(OH)2D3 in prostate cells. In addition, using the DAVID database we selected 
the pathways defined from Kyoto Encyclopedia of Genes and Genomes (KEGG) in 
which VDR target genes may be also involved. One of the most enriched groups was 
the “p53 signaling pathway” known from its role in cell cycle arrest and apoptosis. 
Also, the “arachidonic acid metabolism” pathway taking part in prostaglandin 
production, which may affects processes like cellular proliferation and inflammation 
was enriched. Interestingly, we could also assign significantly VDR-regulated genes 
to the “cancer pathway” where 22 genes were up-regulated and 9 gene were down-
regulated after 4 or 24 h of 1α,25(OH)2D3 stimulation. Among the significantly 
induced genes we distinguished tumor suppressors (RASSF5, RAC2 and CDH1) and 
transcription factors that control proliferation (JUN, FOS) or respond to hypoxia like 
HIF1A. The list of down-regulated genes contained the ones encoding angiogenic 
factor VEGFC and HSP90AA2, which is required for its activation. Moreover, we 
detected inhibitors of apoptosis (BIRC3, BIRC5) as well as transcription factors 
which, when over-expressed, have been associated with tumorigenesis (ETS1, MYC) 
(Table 6). 
These results indicate an important role of VDR in controlling the expression of 
genes involved in “cancer pathways”.  
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ID GO TERM 
No. of 
genes 
regula-
ted by  
VDR 
GENES 
P 
Value 
FDR 
Up-regulated Down-regulated 
GO:0051726 
regulation of 
cell cycle 
42 
BCL6, SERTAD1, 
SMAD3, BMP2, 
c13orf15, CCNB1, 
CCND2, CDKN1A, 
GADD45A, ID3, IL1A, 
IL1B, JUNB, JUN, 
NGF, PTGS2, PRKCQ, 
SPHK1 
BCCIP, CKS1B, CKS2, 
MAD2L1, NEK2, 
SMAD3, TTK, ASNS, 
BIRC5, BUB1, 
CAV2, CDK1, 
CDC25C, CENPE, 
CENPF, CCNA2, 
CCNB1, CCND2, 
CDKN3, DLGAP5, 
HERC5, IL1A, 
IL1B, KIF20B, 
PLK4, PTPRK, 
UBE2C, ETS1, MYC 
1.12E-07 2.00E-04 
GO:0006952 
defense 
response 
32 
BNIP3, BNIP3L, 
CEBPB, CD14, 
CD24L4, CD97, 
ELF3, ALOX5, BMP2, 
BMP6, CAMP, HIF1A, 
IL1RL1, IL1A, IL1B, IL8, 
MGLL, NGF, PRDX5, 
PTAFR, PDPN, 
TPST1, FOS 
CD83, ELF3, CCL20, 
CCL5, F2R, F3, 
CYP27B1, GAL, 
LOC100131909, 
IL1A, IL1B, THBS1 
3.05E-04 5.44E-01 
GO:0045597 
positive 
regulation of 
cell 
differentiation 
20 
SH3PXD2B, SMAD3, 
BMP2, BMP6, CA2, 
CCNE1, FOXA1, HIF1A, 
IGFBP3, JUNB, JUN, 
NGF, PLA2G10 
CD83, SMAD3, 
CCL5, CYP27B1, 
FOXA1, FOXA2, 
IL7R, ETS1, VEGFC 
5.02E-04 8.94E-01 
GO:0042981 
regulation of 
apoptosis 
52 
BCL6, BOK, BNIP3, 
BNIP3L, BTG2, CEBPB, 
CD24L4, FGD3, PERP, 
PYCARD, ARHGEF16, 
SMAD3, ACTN4, ABR, 
ALDH1A3, ANGPTL4, 
CDH1, CLCF1, 
CIDEA, CDKN1A, 
DUSP1, FOXO1, ID3, 
IGFBP3, IL1A, IL1B, 
JUN, NGF, NET1, 
NFKBIA, PRDX5, 
PHLDA3, PTGS2, 
SPHK1, TP53I3 
SMAD3, ANGPTL4, 
ASNS, BIRC3, 
BIRC5, CDK1, 
F2R, F3, GAL, 
IER3, IL1A, IL1B, 
JAG2, PMAIP1, 
PHLDA1, SERPINB2, 
SOCS2, THBS1, 
TNFRSF6B, MYC 
8.46E-03 1.41E+01 
 
Table 5. Enrichment analysis of the transcriptome profile of VDR-dependent 
genes in its canonical biological processes. 
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P value 
GENES 
FDR Up-regulated Down-regulated 
ID Name ID Name 
4.33E-03 
JUN jun oncogene BIRC5 
baculoviral IAP repeat-
containing 5 
 
5.05E+00 
 
CSF1R 
colony stimulating factor 1 
receptor 
BIRC3 
baculoviral IAP repeat-
containing 3 
EPAS1 
endothelial PAS domain protein 
1 
HSP90AA2 
heat shock protein 
90kDa alpha (cytosolic), 
class A 2 
CDKN1A 
cyclin-dependent kinase inhibitor 
1A 
VEGFC 
vascular endothelial 
growth factor C 
RASSF5 
Ras association (RalGDS/AF-6) 
domain family member 5 
PLCG2 
phospholipase C, 
gamma 2 
SLC2A1 
solute carrier family 2 (facilitated 
glucose transporter) 1 
SMAD3 SMAD family member 3 
IL8 interleukin 8 ETS1 
v-ets erythroblastosis 
virus E26 oncogene 
homolog 1 (avian) 
RAC2 
ras-related C3 botulinum toxin 
substrate 2 
CKS1B 
CDC28 protein kinase 
regulatory subunit 1B 
PDGFA 
platelet-derived growth factor 
alpha polypeptide 
MYC 
v-myc 
myelocytomatosis viral 
oncogene homolog 
(avian) 
FOXO1 forkhead box O1   
PTGS2 
prostaglandin-endoperoxide 
synthase 2 
  
HIF1A hypoxia inducible factor 1, alpha   
BMP2 bone morphogenetic protein 2   
FGFR3 
fibroblast growth factor receptor 
3 
  
FGF11 fibroblast growth factor 11   
LAMB3 laminin, beta 3   
SMAD3 SMAD family member 3   
MAPK3 
mitogen-activated protein kinase 
3 
  
FOS 
v-fos FBJ murine osteosarcoma 
viral oncogene homolog 
  
NFKBIA 
nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, alpha 
  
CCNE1 cyclin E1   
CDH1 
cadherin 1, type 1, E-cadherin 
(epithelial) 
  
 
Taken together, we found that the significantly regulated genes after 4 or 24 h of 
VDR ligand stimulation are enriched in various biological processes that indicate pro-
differentiative, pro-apoptotic, and anti-proliferative function of VDR in non-
malignant prostate cells.  
 
Table 6. Enrichment analysis of VDR-dependent genes involved in the cancer 
pathway. 
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4.3. Regulation of the KLK genes in non-malignant and 
malignant prostate epithelial cells by VDR 
 
The microarray analysis revealed that upon 1α,25(OH)2D3 treatment, the second most 
responsive and up-regulated gene after CYP24A1, was KLK6. Interestingly, eight 
members of the KLK gene family (KLK3, KLK5, KLK6 and KLK7-11) were found to 
be expressed in RWPE1 cells (Fig.17). The most prominent ones were KLK5 and 
KLK6, while other KLKs showed a similar modest inducibility profile. Stimulation 
with 1α,25(OH)2D3 for 4 h led to up-regulation of KLK5 with more than 1.5-fold 
induction and of KLK6 with more than 3-fold induction. After 24 h of 1α,25(OH)2D3 
treatment we noticed that KLK5 and KLK6 were induced over 5-fold and more than 
38-fold, respectively. In addition, the KLK7 gene was ~1.4-fold up-regulated, the 
KLK8 gene ~1.4-fold, and the KLK9 gene ~1.4-fold. A similar observation was 
previously published for keratinocyte cells where it was shown that KLK5-8, -10 and 
-13 were up-regulated by 1α,25(OH)2D3 stimulation (Lu, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Microarray analysis identified several 1α,25(OH)2D3-responsive 
genes from the kallikrein family. The relative expression of the KLK family genes 
after 4 and 24 h of 1α,25(OH)2D3 stimulation detected in the microarray study shows 
their inducibility by VDR activity. Each bar represents the averages and indicates SD 
of triplicates. 
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The fact that several members from the kallikrein family were strongly up-regulated 
and that these genes are located next to each other within the central region of the 
cluster on chromosome 19, can indicate a common transcriptional gene regulation.   
In order to validate the VDR-dependent up-regulation of the KLK genes that were 
identified as VDR targets by the microarray data, a series of real-time quantitative 
PCR (qPCR) experiments was performed for different prostate cell lines.  
First, we tested the responsiveness of KLK genes to VDR ligand stimulation in the 
non-malignant prostate cell line RWPE1 that was also used for the microarray 
experiment. The cells were treated for 2, 4, 6, or 24 h with 1α,25(OH)2D3 or with its 
solvent control (EtOH). Expression of the KLK genes was measured in relation to the 
control gene acidic riboprotein PO (RPLPO). The bona fide VDR target gene CYP24 
served as a positive control and showed that VDR was activated at each time point. 
We observed significant up-regulation of five KLKs, KLK5, -6, -7, -8 and -9 (Fig. 
18A). The most prominent induction was observed for the expression of KLK6 with a 
more than 5-fold change already after 2 h, which was followed by an increasing 
expression, up to 160-fold after 24 h of treatment. KLK5 and KLK7 were induced 
over 2-fold after 4 h and more than 7-fold after 24 h, whereas KLK8 and KLK9 were 
modestly up-regulated at 6 h and more than 3-fold induced after 24 h (Fig. 18A). 
Next, we tested whether the central region of the KLK locus would also be a VDR 
target in human malignant prostate cell lines such as RWPE2, PC3, and DU145. 
Therefore, we treated these cancer cell lines for 2, 4, 6, or 24 h with 1α,25(OH)2D3 or 
solvent. We observed that the effect of VDR ligand on the KLK locus in malignant 
cell lines was only slight and not significant in the PC3 cells and was even absent in 
DU145 cells (Fig. 18C and D). In contrast, in RWPE2 cells a significant, but delayed 
induction of the KLK genes could be observed (Fig. 18B).  
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Figure 18. Several members of the KLK gene family are responsive to 
1α,25(OH)2D3 stimulation in prostate cells and exhibit a distinct profile in 
cancer cell lines. The mRNA expression profiles of the KLK genes in the non-
malignant RWPE1 cell line (A) and in malignant cell lines RWPE2 (B), PC3 (C) and 
DU145 (D) were determined by qPCR. The KLKs that showed a significant response 
in at least one cell line are shown. All cells were stimulated with 1α,25(OH)2D3 or with 
solvent control (EtOH).. Values were normalized to the RPLPO control gene. The 
fold inductions of 1α,25(OH)2D3 treatment relative to solvent control (EtOH) over a 4-
time point series are displayed with significance, as calculated using a paired 
student’s t-test from three independent experiments, each performed in triplicates (* 
p < 0.05, ** p < 0.01, *** p < 0.001) and the error bars indicate SEM. The known 
VDR target gene CYP24 served as a positive control. 
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Comparing the different cell lines, the non-malignant RWPE1 cell line was clearly 
most responsive to 1α,25(OH)2D3. It is possible that an already high basal expression 
of the KLKs could explain the low inducibility by VDR in the cancerous prostate cell 
lines. Surprisingly, the basal expression was reduced for most of the KLK genes in the 
cancer cell lines compared to the non-malignant prostate cell line. In the non-
malignant RWPE1 cells KLK8 was the highest, while KLK7 was the lowest expressed 
KLK gene. The relative expression of KLK6 was comparable in all types of prostate 
cells (Fig. 19). Therefore the capacity of VDR activation to induce the KLK genes is 
not correlating to the basal expression of these genes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. The relative mRNA expression level of KLKs across four cell lines. 
The relative mRNA expression of the KLKs (shown as separate panels) was 
quantified by qPCR in relation to RPLP0 from the non-malignant RWPE1 cell line 
and from the malignant prostate cell lines RWPE2, PC3 and DU145. Data points 
show the means of three independent experiments, each performed in triplicate and 
the error bars indicate SEM. 
 
In order to investigate whether the reduced inducibility of VDR target genes in cancer 
cell lines relative to non-malignant prostate cells is confined to KLKs, we analyzed 
the expression of another bona fide VDR target, IGFBP3, in these cell lines. IGFBP3 
was highly induced in non-malignant prostate RWPE1 cells, whereas in the malignant 
RWEP2 cells its up-regulation was delayed and less pronounced (Fig. 20). 
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Figure 20. IGFBP3 expression in both non-malignant and cancer prostate cells 
after treatment with 1α,25(OH)2D3. Real-time quantitative PCR was performed to 
analyze the mRNA expression of IGFBP3 relative to the housekeeping RPLPO gene 
in RWPE1 cells after treatment with 1α,25(OH)2D3; the fold inductions were 
determined in relation to solvent control (EtOH). Data points show the means of 
three independent experiments, each performed in triplicate and the error bars 
indicate SEM. Paired student’s t-test was performed to specify the significance of 
ligand-dependent regulation of IGFBP3 gene (* p < 0.05, ** p < 0.01, *** p < 0.001). 
 
In summary, the mRNAs of five KLKs genes were higher expressed and regulated by 
VDR in non-malignant cells, whereas the prostate cancer cells showed only minor 
VDR-mediated effects. Moreover, the mRNA level of KLK6 was the highest induced 
one compared to the other KLKs in RWPE1 cells. The early induction profile 
observed suggests a direct regulation of KLK genes by ligand-bound VDR. 
 
4.4. Effect of VDR silencing on the central region of the KLK gene 
family 
 
In order to exclude that the regulation of the KLK gene family expression is due to an 
unspecific ligand effect and to verify that the up-regulation of the genes is dependent 
on the presence of VDR, we performed RNA interference experiments in RWPE1 
cells. Cells were transfected with siRNAs against VDR or control siRNA for 48 h, 
which was followed by 4 or 24 h treatment with 1α,25(OH)2D3 or solvent. The 
successful significant knockdown of around 80 % of VDR mRNA, compared to 
unspecific control siRNAs as determined by qPCR (Fig. 21A), was confirmed by the 
reduced induction of mRNA expression of the best-known VDR target gene CYP24. 
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We noticed that the effective silencing of VDR led to a ~90% reduced induction of 
CYP24 after 4 and ~70% after 24 h with 1α,25(OH)2D3 stimulation (Fig. 21B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. VDR silencing reduces the inducibility of CYP24. RWPE1 cells 
transfected for 48 h with specific siRNA oligonucleotides against VDR or unspecific 
siRNA were stimulated with 1α,25(OH)2D3 for 4 and 24 h to determine (A) the effect 
of VDR silencing. The known VDR target gene (B) CYP24 serves as a positive 
control for the effectiveness of VDR depletion. The mRNA expression of both genes 
relative to the control gene RPLPO was determined by qPCR. The CYP24 fold 
induction was determined in relation to solvent control (EtOH). Data points show the 
means of three independent experiments, each performed in triplicate and the error 
bars indicate SEM. Paired student’s t-test was performed to specify the significance 
of ligand-dependent regulation of CYP24 gene (* p < 0.05, ** p < 0.01, *** p < 0.001). 
 
Next, we tested whether the VDR knockdown has an effect on induction of KLK 
genes by VDR ligand treatment. After 4 h of stimulation with 1α,25(OH)2D3  
approximately 90% of the most responsive KLK6 gene expression was abolished and 
subsequently after 24 h of stimulation it was reduced about 74%. The decreased 
expression affected the induction of genes, which is presented on Figure 22. 
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Furthermore, the VDR silencing diminished the KLK5 gene inducibility after 4 h of 
1α,25(OH)2D3 stimulation and decreased the mRNA expression by 45%, and the ones 
of KLK7 by ~72%, of KLK8 gene by ~49% and of KLK9 by ~60%, respectively (Fig. 
22A). This effect was maintained or even increased after 24 h of VDR ligand 
incubation (Fig. 22B).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Effect of VDR depletion on the induction of the 1α,25(OH)2D3-
responsive KLKs. To determine the impact of VDR knockdown on the KLK genes 
expression in RWPE1 cells, qPCR was performed and the data were analyzed in 
relation to the control RPLPO gene. The induction profiles of the responsive KLK 
genes after (A) 4 h and (B) 24 h of 1α,25(OH)2D3 treatment are shown. The fold 
change of KLK genes was determined in relation to solvent control (EtOH). Data 
points show the means of three independent experiments, each performed in 
triplicate and the error bars represent SEM. Paired student’s t-test was performed to 
determine the significance for the siVDR silencing effect on the ligand-inducibility in 
relation to unspecific control siRNA (ctrl) or not transfected (no) samples (* p < 0.05, 
** p < 0.01, *** p < 0.001). The % represents the reduced gene expression level after 
VDR knockdown and it was calculated in relation to the ctrl siRNA.  
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Taken together, the silencing of VDR confirms the receptor-dependent up-regulation 
of the KLK5, 6, 7, 8, 9 genes by 1α,25(OH)2D3 in human non-malignant prostate cells.  
 
4.5. The early VDR-dependent, dynamic response of KLK6 gene 
expression in non-malignant prostate cell line 
 
In order to investigate how fast mRNA of the KLK6 is produced after VDR 
activation, for the subsequent analysis of the expression of the KLK6 gene in response 
to 1α,25(OH)2D3, we performed a detailed time course experiment with RWPE1 
cells. Therefore, mRNA was isolated every 15 min up to 285 min and the levels of 
KLK6 and CYP24 genes were determined by qPCR. CYP24 showed significant 
induction already after 45 min of treatment. Level of induction was higher than 2-fold 
(Fig. 23B). Interestingly, also the expression of KLK6 changed very early and was 
doubled already after 45 min of 1α,25(OH)2D3 treatment and significantly increased 
after 75 min, suggesting a direct regulation of KLK6 by VDR. The gene expression 
increased constantly with the time in a linear fashion, while after 285 min an 
induction of 25-fold was achieved (Fig. 23B). 
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Figure 23. The early dynamic response of the KLK6 gene. The induction of the 
genes KLK6 (A) and CYP24 (B) was measured by qPCR from an extended time 
series after stimulation of RWPE1 cells with 1α,25(OH)2D3. The mRNA expression of 
KLK6 was calculated relative to the housekeeping RPLPO gene. The fold inductions 
compared to control (EtOH) stimulated cells are displayed with significance using a 
two-tailed students t-test from three independent experiments as shown in the figure 
(* p < 0.05, ** p < 0.01, *** p < 0.001).  
 
The mRNA levels may depend on regulation of their decay rate and altered RNA 
production can activate the process of its degradation and thus may prevent its 
translation into a functional protein (Doma, 2007). Therefore, in order to analyze 
whether VDR-dependent, highly induced mRNA expression of KLK6 is stable, after 
analyzing the mRNA synthesis of this gene upon 1α,25(OH)2D3 stimulation we 
looked on the degradation of KLK6 mRNA. To determine the stability of KLK6’s 
mRNA non-malignant prostate cells were stimulated with 1α,25(OH)2D3 or with 
EtOH for 2 h. This was followed up by incubation with a transcriptional inhibitor that 
blocks RNA Pol II activity, actinomycin D, for 2, 3, 4, 5, 6 h, respectively, and 
mRNA levels were measured by qPCR. We observed that the KLK6 expression level 
remained unchanged upon actinomycin D treatment at selected time intervals, both in 
 
A 
B 
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solvent-and 1α,25(OH)2D3-treated samples (Fig. 24A). As a positive control for the 
actinomycin D treatment we also tested the stability of the IL8 gene. IL8 is a fast 
response immune cytokine and its mRNA is quickly degraded. In the microarray this 
gene was more than 2-fold induced at 4 h by 1α,25(OH)2D3. Already after 2 h of 
actinomycin D treatment (Fig. 24B) the mRNA of IL8 was reduced in both, the EtOH 
and 1α,25(OH)2D3-treated samples. Therefore we can conclude that the mRNA of 
KLK6 is a stable mRNA, giving a possible explanation of the consistent accumulation 
of KLK6 mRNA in the long-term 1α,25(OH)2D3 treatment. 
 
 
Figure 24. mRNA stability of KLK6 gene. (A) Measurement of the KLK6 mRNA 
stability was performed for RWPE1 cells stimulated for 2 h with 1α,25(OH)2D3
 or 
solvent control (ETOH) followed by treatment with 1 M actinomycin D for different 
periods of time. The level of KLK6 mRNA normalized to the control gene RPLPO 
was determined by qPCR. Data points show the means of three independent 
experiments and the error bars indicate SEM. A two-tailed student’s t-test was 
performed to specify the significance of ligand-dependent regulation of KLK6 gene 
compared to ETOH control (* p < 0.05, ** p < 0.01, *** p < 0.001). The mRNA 
expression of (B) IL8 gene served as a reference. 
 B 
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Taken together, KLK6 was rapidly and strongly induced by the VDR ligand in the 
RWPE1 cell line, indicating that KLK6 is a direct target gene of VDR. Moreover, we 
showed that the mRNA of KLK6 was stable for more than 5 h, indicating that this 
gene has long-term rather than short-term functions.  
4.6. Identification of putative binding sites for VDR within the 
human KLK cluster 
 
In order to investigate potential VDREs one can use in silico screening to predict the 
affinity of the binding of VDR to DNA. Several programs based on biological data 
have been established and are available online, e.g. JASPAR (www.jaspar.cgb.ki.se). 
According to the specificity of VDR for its response elements, these algorithms 
screen the genome based on alignments of known binding sites. Nevertheless, the 
most accurate method to locate NR regulatory elements are in vitro assays like the 
chromatin immunoprecipitation assay (ChIP), combined with in silico analysis 
(Meyer, 2010). The ChIP technique enables to cross-link the protein of interest (e.g. 
VDR) directly to the associated chromatin using formaldehyde; the protein-chromatin 
complex is subjected to fragmentation of the DNA to fragments of 300-1000 base 
pairs and the protein of interest is then selectively immunoprecipitated. The 
associated DNA fragments are then purified and serve for further quantitative 
analysis. Since the in silico screening methods deliver putative binding sites and in 
vitro studies verify them, it is important to combine these two methods as they 
complement one another. In this way it is possible to discover VDREs across the 
whole genome in a cell-specific manner.  
 
4.6.1. In silico screening for putative VDREs in the human KLK cluster 
based on datasets tracks  
The analysis of mRNA expression levels of five of the KLKs after stimulation with 
1α,25(OH)2D3 in RWPE1 cells showed their regulation by VDR.  Especially the rapid 
up-regulation of KLK6 gene that was noticeable already after 45 min of treatment, 
which suggested that they are likely to be direct target genes for VDR. Thus, our 
results implied that there should be VDR response elements (RE) within the 
regulatory regions of the KLK genes. In order to get an overview of the possible 
functional elements in KLK locus we analyzed different datasets from the ENCODE 
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regulation tracks in the UCSC Genome Browser (Kent, 2002) through utilization of 
selected ENCODE tracks that represent biological data from 8 different cell lines 
(The ENCODE Project Consortium, 2007). To investigate the open chromatin regions 
we have chosen three “open” chromatin markers: H3K4me3 associated with 
transcriptional initiation that is found near TSSs and H3K4me1 together with 
H3K27Ac that are more linked to enhancer rather than to promoter activity. We 
observed that H3K4me3 was distributed in surroundings of KLK1, KLK15, KLK5, 
KLK8 and KLK10, whereas the H3K4me1 and H3K27Ac were found at the regions 
close to KLK1, KLK15, KLK6 and KLK9 and in between KLK2 and KLK4, KLK4 and 
KLK5, KLK5 and KLK6, KLK7 and KLK8  (Fig. 25B).  
Thus, relying on the supplied data we selected regions from the potential enhancers 
marked by H3K4me1 and H3K27Ac to find putative VDREs (chosen VDR REs 
across the selected regions are shown as red vertical lines in Figure 25A). Using ChIP 
assays with a specific antibody against VDR we analyzed eight potential VDREs on 
chromatin extracted from RWPE1 cells that were either untreated or incubated for 60 
min with 1α,25(OH)2D3. The experiment was based on pooling over 50 independent 
collections of immunoprecipitates (IPs) in order to obtain sufficient amount of DNA 
and to minimize the error between IPs. Analysis was conducted by real-time 
quantitative PCR. Five of the eight tested REs showed a binding of VDR: the RE1, 
RE2, RE3, RE4 and RE5 (Fig. 25C). The activation of VDR for one hour led to 
increase of VDR binding on these response elements. At the same time, negative 
control IgG did not show enriched binding after 1α,25(OH)2D3 treatment indicating 
specificity of VDR antibody. For three REs (RE6, RE7, RE8) no binding of VDR 
could be detected. As a positive control, we could identify a ligand-dependent VDR 
enrichment on a well-described VDRE located in close proximity to another VDR 
target, the IGFBP3 gene (Fig. 25D).  
Therefore, the in silico analysis followed by ChIP analysis revealed 8 putative 
VDREs from which 5 were VDR-enriched in the KLK cluster region of RWPE1 cells.  
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Figure 25. An overview of the KLK genes densely clustered on chromosome 19. (A) The genomic region of KLK locus spans ~265 KB 
uninterrupted with non-KLK genes. (B) The UCSC genome browser was used to display several regulatory regions of this genomic area using 
data from the ENCODE consortium: enhancer regions identified by H3K4me1 and H3K27ac markers and active promoters identified by 
H3K4me3 are displayed from the regulation track. The peaks represent data from 8 different cell lines, each associated with a  specific color. 
Putative active regions (RE1-8) labeled by chromatin activity markers were selected (A) and marked as red vertical line. (C) Regions were 
tested in follow-up experiments using ChIP assay in RWPE1 cells treated with 1α,25(OH)2D3
 for 60 min. RE1-RE5 showed binding of VDR 
whereas at RE6-RE8 the binding could not be detected. ChIP was performed by pooling over 50 independent IPs with the antibody against 
VDR and analyses were conducted by qPCR. The non-specific antibody IgG served as a specificity control. Numbers represent fold 
enrichments relative to IgG. NP, not present, n=1. (D) The VDRE near the IGFBP3 gene was used as a positive control.  
 
RE8RE7RE5RE4RE3RE2RE1
0 60 0 60 0 60 0 60 0 60 0 60 0 60 0 60
0
0.2
0.4
0.6
0.8
%
 o
f 
IN
P
U
T
time (min)
IgG
VDR
RE6
NP NP NP
H3K4Me1 
H3K27Ac 
H3K4Me3 
 
IGFBP3(8)
0 60
0
2
4
%
 o
f 
IN
P
U
T
time (min)
hK3 
chr19: 56,279,314 
hK4 hK5 hK6 hK7 
hK8 hK9 hK10 hK11 hK12 
hK13 hK14 
chr19: 56,014,216 
hK15 hK2 hK1 
RE1 RE2 RE3 RE4 RE5 RE6 RE7 RE8 
A 
B 
C D 
x2.3 
x5.1 
x5.2 
x3.1 
x5.3 
 
IGFBP3(8)
0 60
0
2
4
%
 o
f 
IN
P
U
T
time (min)
RE 
50 kb 
4. Results 
 
 70 
4.6.2. Recruitment of VDR to the TSS regions of KLK genes 
The closer look into the genomic region of the KLKs revealed that the 1α,25(OH)2D3-
responsive KLKs are positioned at a short distance from each other (Fig. 25A). As we 
observed in the ENCODE tracks an association of the H3K4me3 marker of 
transcriptional initiation close to KLKs’ promoters, we proceeded to verify VDR 
binding on the TSS regions of the KLK genes using ChIP assays. Performed qPCR on 
obtained chromatin templates enabled us to detect the presence of VDR upon 60 min 
of ligand treatment on the TSS regions of KLK5, KLK6, KLK7A and KLK9 in RWPE1 
cells which was in consistence with the mRNA data. The most prominent enrichment 
of VDR was identified on the three regions of KLK6 located in surroundings of its 
TSSs, with an up to 15-fold enrichment over unspecific IgG. Other regions associated 
with VDR showed enrichments as follows: KLK5 3.4-fold, KLK7 6.3-fold and KLK9 
3.6-fold. The rest of the analyzed regions did not show significant enrichment for 
VDR binding after 1α,25(OH)2D3 treatment (KLK4, KLK7B, KLK8, KLK10-KLK12) 
(Fig. 26). 
 
 
 
 
 
 
Figure 26. The analysis of VDR association with KLK gene promoters. Ligand-
dependent recruitment of VDR to KLK genes TSSs in RWPE1 cells was tested using 
ChIP assay. Chromatin was extracted from RWPE1 cells treated with 1α,25(OH)2D3
 
for 60 min. More than 50 independent immunoprecipitations with anti-VDR antibody 
or control non-specific anti-IgG antibody were pooled and the analysis of VDR 
recruitment to the KLK TSSs was performed by qPCR. A published VDRE close to 
IGFBP3 gene served as a positive control (see Fig. 25D). Columns represents fold 
enrichments relative to IgG. Note, that n=1.  
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We concluded that the TSSs of the genes from the central part of the KLK region 
exhibited association with VDR and that the KLK6 TSS regions were the most 
enriched ones for binding of VDR.  
4.6.3. Identification of functional VDREs in close proximity to the 
KLK6 promoter 
As we identified binding of the VDR to the selected chromatin regions marked by 
modified histones, next we scanned in silico those “open” genomic sequences in the 
KLK locus using the JASPAR VDR specific weight matrix (with 80% cut-off) to look 
for the presence of further putative VDR binding sites. We selected 7 potential 
VDREs that overlapped with the histone marks (Fig. 27A): one was corresponding to 
the VDR-associated region carrying RE1, two were in surroundings of VDR enriched 
binding sites RE2 and RE3, and three were found close to the regions not associated 
with VDR in RWPE1 cells: RE4, RE5 and RE7. Interestingly, one VDRE was 
situated in close proximity to the most prominent KLK6 promoter, located -101 bp 
away from TSSs of KLK6 variant B and C, and +781 bp from variant A. This region 
was marked by H3K4me1 and H3K27Ac in ENCODE tracks, suggesting the presence 
of an enhancer (Fig. 27A). Moreover, it was located 50 bp away from the amplified 
by qPCR region of KLK6B TSS, which suggested functionality of the identified VDR 
binding site. In addition, the recognized VDRE was evolutionary conserved across 
multiple mammalian genomes, i.e. human, rhesus, mouse and dog. The sequence and 
the conservation of the VDRE are given in Figure 27B. 
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Figure 27. Association of VDR with the genomic region containing a highly conserved putative VDRE near KLK6 TSS variants. (A) 
The region with 7 putative VDREs selected from the JAPSAR database (red vertical line indicated by red arrow) overlapped with active 
chromatin markers identified from the ENCODE tracks. One VDRE was located near the most prominent TSS of KLK6. (B) The conservation of 
the selected VDRE between human and multiple vertebrate species is shown from the UCSC multi conservation track. Letters in blue indicate 
differences in the sequence across species. 
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To validate direct binding of VDR to the selected regulatory region located in the vicinity of 
the TSSs of the KLK6 transcripts B and C variants, we conducted additional ChIP assays 
followed by qPCR from five independent experiments on RWPE1 cells. 60 min after 
stimulation with 1α,25(OH)2D3 the KLK6 promoter showed increased enrichment of VDR. 
This result was highly reproducible and clearly significant compared to the non-specific IgG 
control (Fig. 28A-B). The VDRE located near the IGFBP3 promoter served as positive 
control (Fig. 28A, C).  
This observation leads us to conclude that the identified conserved VDRE next to the KLK6 
promoter must be active and functional in RWPE1 prostate cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Recruitment of VDR to the proximal VDRE at the KLK6 promoter in a ligand-
dependent manner. The region with a putative VDRE near the TSS of KLK6 transcript 
variant B and C was selected for further validation by ChIP assay with antibody against VDR. 
Chromatin was extracted from RWPE1 cells stimulated with 1α,25(OH)2D3
 for 60 min. 
Analyses were conducted by qPCR and the association of VDR at 0 and 60 min after ligand 
stimulation was calculated relative to the control, non-specific antibody IgG (A) or in 
comparison to the control IgG (B, C). The previously verified VDRE near the IGFBP3 gene 
served as a positive control. Significance as calculated using a paired students t-test from 
five independent experiments is shown in the figure (* p < 0.05, ** p < 0.01, *** p < 0.001). 
Error bars indicate SEM. 
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Since H3K4me1 and H3K27Ac marked the VDRE next to the KLK6 promoter region we also 
analyzed the presence of acetylation of histone 4 (H4Ac) at the KLK6 TSS in order to confirm 
the authenticity of an open state of chromatin in this region. For this purpose, we performed 
additional ChIP assays with a specific antibody against H4Ac in RWPE1 cells using the same 
parameters as for VDR analysis. The level of general H4Ac antibody compared to the non-
specific IgG control was significantly high in both 0 and 60 min time points upon 
1α,25(OH)2D3 stimulation (Fig. 29). Our results suggest that acetylated H4 is present at the 
KLK6 promoter and is increased in ligand-dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Ligand-dependent and -independent association of acetylated H4 with the 
KLK6 promoter. For ChIP analysis with an anti-H4Ac antibody, chromatin was extracted 
from RWPE1 cells treated for 60 min with 1α,25(OH)2D3
 and the results were determined by 
qPCR. Data points were analyzed as the mean of three independent biological replicates 
and the error bars indicate SEM. VDR recruitment at 0 and 60 min after ligand stimulation 
was calculated relative to the control IgG antibody (A) or in comparison to the control IgG (B) 
and was used for significance calculation with the paired students t-test  (* p < 0.05, ** p < 
0.01, *** p < 0.001).  
 
Taken together, we conducted in silico screening for putative regulatory regions within the 
KLK locus and performed ChIP analysis from non-malignant prostate cells. Thereby, we 
validated KLK TSSs and 8 putative VDREs for the presence of VDR. Our results showed 
VDR recruitment to the TSSs of the KLKs from the central region of their locus with the 
highest enrichment for KLK6. The VDRE located near the KLK6 promoter was found to be 
highly conserved. Moreover, this genomic region was associated with the presence of 
H3K4me1 and H3K27Ac and the validation of the presence of H4Ac showed VDR-
dependent increased occupancy.  
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4.7. Association of VDR and H4Ac with the KLK6 promoter in 
malignant prostate cells 
 
We deduced that the different mRNA expression levels of KLKs in non-malignant and cancer 
prostate cell lines are linked with regulation of their transcription. Therefore, we analyzed the 
promoter of KLK6 in RWPE2 prostate cancer cells using ChIP assay with antibodies against 
VDR and H4Ac compared to non-specific IgG control. The chromatin was isolated after 60 
min of treatment with 1α,25(OH)2D3. We observed that the level of VDR binding to the 
KLK6 promoter was minor and not significant, in fact it did not change after stimulation with 
1α,25(OH)2D3 (Fig. 30A). The acetylation of H4 upon VDR ligand treatment as well 
remained unchanged  (Fig. 30B). In addition, due to differences in the induction of IGFBP3 
mRNA by VDR ligand in both types of prostate cell lines, we tested the VDR association to 
the known IGFBP3 VDRE in RWPE2 cells. Interestingly, we observed that in contrast to 
RWPE1 cells the recruitment of VDR in RWPE2 was minor and was not influenced by 
treatment with 1α,25(OH)2D3 (Fig. 30C).  
These results suggest that the binding of VDR to its regulatory regions occurs in a cell-
specific manner and that it is enhanced in non-malignant compared to malignant prostate 
cells. 
4. Results 
 
 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Analysis of the KLK6 promoter activity in the RWPE2 cancer cell line. 
RWPE2 cells were treated with 1α,25(OH)2D3 for 60 min and subjected to ChIP analysis 
using antibodies against VDR, acetylated H4 or non-specific IgG, which served as a control. 
Analysis was performed by qPCR and the VDR association with the KLK6 TSS was 
determined by comparison to the control IgG (A, C), whereas acetylation of H4 was 
calculated relative to the control, non-specific IgG (B). The VDRE located close to the 
IGFBP3 gene serves as a control. Data points stand for one biological replicate that 
represent 9 pooled independent immunoprecipitations. 
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4.8. Distribution of CTCF binding sites and their activity within the 
KLK locus 
 
Next, we were interested in possible cause of the common mRNA expression pattern of the 
five KLKs located next to each other on chromosome 19. To investigate the presence of 
putative chromatin boundary insulators we used the ENCODE tracks using the UCSC 
Genome Browser. Interestingly, we found that five potential CTCF binding sites located 
inside the KLK locus separated the central region from the rest of the KLKs (Fig. 31A). Three 
of them were located around the KLK4 gene (CTCF1, CTCF2, CTCF3) and two were in the 
vicinity of the KLK10 gene (CTCF4 and CTCF5). Using ChIP-qPCR analysis with antibody 
against CTCF or a non-specific IgG control, we demonstrated that the insulators surround the 
KLK5, -6, -7, -8 and -9 in RWPE1 cells. Surprisingly, stimulation with the 1α,25(OH)2D3 for 
60 min enhanced association of CTCF with the binding sites CTCF1, CTCF2, CTCF4 and 
CTCF5 (Fig. 31B), whereas a negative control region (KLK6 TSS) shows no binding (Fig. 
31C).  
Taken together, the up-regulated KLKs were situated between the two boundaries of CTCFs 
that were additionally enriched in a VDR-dependent manner. Thus, we conclude that CTCF 
distribution agrees with the regulation of KLKs genes from the central region of their locus by 
1α,25(OH)2D3 stimulation. 
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Figure 31. Distribution of insulators identified within the KLK cluster from multiple cell 
types indicate a separation of KLK5-KLK9 to an isolated chromatin domain. (A) 
Extracted track from the ENCODE datasets displayed at the KLK gene cluster area 
represent ChIP-seq peak data from HeLa cells for CTCF binding sites, which indicate 
potential chromatin boundaries. Selected putative active regions (CTCF1-5) were labeled by 
insulators occupancy. (B) Regions were tested using ChIP assay in RWPE1 cells treated 
with 1α,25(OH)2D3
 for 60 min. ChIP was performed by pooling over 10 independent 
collections with antibody against CTCF and analysis was performed by qPCR. A non-specific 
IgG served as a specificity control. Columns represent fold enrichments relative to IgG. Note 
that n=1 and was consisting of more than 10 independent immunoprecipitations with anti-
CTCF antibody. (C) A region empty in CTCF binding sites, the KLK6 TSS, was used as a 
negative control. 
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4.9. Effect of CTCF silencing on 1α,25(OH)2D3 stimulation 
 
CTCF is one of the proteins involved in formation of a higher-order chromatin structures and 
influence on regulation of gene expression (Philips, 2009). Loss of CTCF can be related to 
concomitantly increased mRNA expression of specific genes like the pro-apoptotic PUMA 
gene (Gomes, 2010). To test whether the VDR-dependent regulation of KLKs located in the 
central part of their locus can be extended to the entire cluster, we knocked-down CTCF and 
validated the response to VDR ligand treatment for all KLKs. RWPE1 cells transfected for 48 
h with CTCF-specific siRNAs or control siRNAs were stimulated for 4 h with 1α,25(OH)2D3. 
CTCF mRNA was successfully knocked-down by 84% (Fig. 32A). However, its depletion did 
not alter the pattern of KLK inducibility by VDR ligand. Indeed, the expression of the KLK6 
gene was similarly elevated after 4 h of 1α,25(OH)2D3 treatment. Likewise, the mRNA level 
of the other genes continued to be modestly up-regulated or did not change upon CTCF 
suppression, i.e. the KLKs situated at the borders of the locus remained inert after stimulation 
with 1α,25(OH)2D3 (Fig. 32B).  
These data showed, that CTCF depletion did not affect the induction of the KLK genes both 
inside the central area and on the border of the locus, suggesting the influence of additional 
factors taking part in the maintenance of barriers in the KLK locus in RWPE1 cells. 
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Figure 32. Effect of CTCF depletion on KLKs stimulated with VDR ligand. To determine 
whether CTCF knockdown expands the ability of VDR to induce the whole KLK cluster, 
RWPE1 cells were transfected with specific siRNA oligonucleotides against CTCF or control 
siRNAs, and were stimulated with 1α,25(OH)2D3
 for 4 h. qPCR was performed to verify the 
effect of CTCF inhibition (A) and to analyze the expression of the KLK gene family (B) in the 
insulator-depleted condition. All genes were normalized to the control RPLPO gene and the 
fold inductions were determined in relation to solvent control (EtOH). Data points show the 
means of three independent experiments, each done in triplicate and the error bars 
represent SEM. The significance was calculated using the paired student’s t-test for the 
siRNA silencing effect on the ligand-inducibility in relation to unspecific control siRNA (ctrl) or 
not transfected (no) samples (* p < 0.05, ** p < 0.01, *** p < 0.001) and no significant 
changes was observed. NE, not expressed. 
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4.10. The correlation between KLK substrates and VDR action. 
 
To explore the relation between VDR-regulated genes and possible KLK enzymatic effects in 
the prostate we selected, based on the literature (Lawrence, 2010), around 100 known KLK 
substrates and compared their expression in our microarray data. Next, we identified and 
selected the GO terms referring to the biological processes to which both, genes significantly 
regulated by VDR as well as genes expressed in RWPE1 cells encoding potential substrates 
for the KLK enzymes were assigned (Table 7). Interestingly, we could distinguish enriched 
GO terms like “cell adhesion”, “regulation of cell motion” and also “response to wounding”, 
“defense response” or “regulation of cell proliferation” that suggest a role of KLK enzymes in 
important VDR-related vital processes. Regulation of KLK gene expression by VDR may 
contribute to indirect, secondary or tertiary effects of this NR. The KLKs as proteases can 
activate or deactivate their substrates that may belong to the biological process in which VDR 
directly controls expression of different set of genes. Thus, VDR through up-regulation of 
KLKs from the central part of their cluster, additionally may influence the selected biological 
process. Moreover, we noticed several overlapping genes when comparing VDR target genes 
and the KLK substrates group within a given GO terms. We were able to select 15 genes 
encoding ascribed KLK substrates significantly up- or down-regulated by 1α,25(OH)2D3 after 
4 or 24 h of stimulation.  
 
 
ID GO TERM 
VDR-
REGULATED 
GENES 
KLKs 
SUBSTRATES OVERLAPP 
ING GENES 
Count P Value Count P Value 
GO:0007155 cell adhesion 39 2.25E-04 18 1.56E-11 LAMB3, CDH1 
GO:0051270 regulation of cell motion 20 6.06E-04 9 2.06E-06 IGFBP3, F3 
GO:0007398 ectoderm development 25 1.19E-07 8 8.41E-06 
KLK5, LAMB3, 
PTHLH, KLK7 
GO:0032989 
cellular component 
morphogenesis 
23 3.07E-02 8 6.84E-04  
GO:0009611 response to wounding 49 1.80E-11 11 7.19E-06 
KLK6, PLAT, 
IL1B, F3 
GO:0042127 
regulation of cell 
proliferation 
59 2.74E-06 11 1.29E-03 
PTHLH, 
IGFBP3, F3 
GO:0048878 chemical homeostasis 30 6.52E-04 9 1.68E-04 
PTHLH, KLK6, 
IL1B, MBP 
GO:0006952 defense response 32 3.05E-04 7 6.26E-03 
IL1B, F3, 
CAMP 
GO:0007166 
cell surface receptor linked 
signal transduction 
70 1.84E-05 11 1.03E-02 PTHLH, PLAT 
Data taken from DNA microarray
Table 7. The enrichment analysis of the relation between genes significantly 
regulated by VDR and putative KLK substrates expressed in the RWPE1 cells 
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Figure 33. Models representing a link between VDR action and KLK activity. KLKs as 
VDR targets may contribute to effects elicted by this NR. Several genes were both VDR 
target genes and KLKs substrates. There are four interactions between VDR and KLK 
enzymes. These proteins can act independently, or both can activate/deactivate the same 
targets (coherent feedforward loop), or they can act in opposition (incoherent feedforward 
loop). A green arrow represents up-regulated/activated targets while red marks show down-
regulated/inactivated targets. 
 
Among the identified overlapping genes there were members of the KLK family, and two 
genes from the insulin-like growth factor binding protein family. Our data suggest a 
correlation between KLK substrates and VDR effects elicited after ligand stimulation in non-
malignant prostate cells. The observed four types of interactions between KLK substrates and 
their regulation by VDR in common biological processes could be associated with the 
transcriptional dynamic (Fig. 33). Thereby, expression of some substrates activated by KLKs 
like KLK5, KLK6, CAMP (Morizane, 2010) is increased by 1α,25(OH)2D3 treatment, and 
the expression of substrate inactivated by KLKs like PTHLH is decreased by stimulation with 
1α,25(OH)2D3. These patterns are called coherent feedforward loops. They consist of 
regulators like VDR or KLKs that together regulates same targets (Alon, 2007). In addition, 
we noticed that identified VDR target genes, IGFBP3 and IGFBP6 are known to be 
inactivated by the KLKs including KLK5. These are incoherent feedforward loop motifs that 
comprise a pulse generator like VDR and a response accelerator like KLKs, where one 
activates a target while the second one represses it (Alon, 2007). This shows that VDR and 
KLKs may also act in opposition.  
 Moreover, these genes were associated with GO terms such as: “extracellular region and 
space”, “homeostatic process” and “cell-cell signaling” (Table 8).  
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Data taken from DNA microarray  
 
 
Taken together, the VDR ligand rapidly induces the KLK6 gene and influences the expression 
of KLKs from the central part of their locus. We showed, based on GO analysis, the 
noticeable communication between KLK enzyme substrates and VDR-regulated genes in 
several biological processes. Moreover, the microarray data showed the impact of 
1α,25(OH)2D3 on known KLKs substrates, implying a crosstalk between regulation of mRNA 
expression of KLK substrates by VDR ligand and potential functions of KLKs as proteases. 
 
ID GO TERM Count 
GENES 
P Value FDR 
Up-regulated Down-regulated 
GO:0005576 extracellular region 11 
KLK9, IGFBP6, 
CAMP, KLK5-
KLK7, IGFBP3, 
PLAT, IL1B, 
COL4A5 
IL1B 2.17E-07 1.03E-04 
GO:0005615 extracellular space 6 
IGFBP3, IGFBP6, 
KLK5, PLAT 
IL1B, PTHLH 1.17E-04 2.25E-04 
GO:0042592 homeostatic process 5 KLK6, MB 
IL1B, MBP, 
PTHLH 
1.42E-04 1.21E-01 
GO:0007267 cell-cell signaling 4 PLAT 
IL1B, MBP, 
PTHLH 
4.90E-04 7.32E-01 
Table 8. GO analysis of putative KLK substrate genes significantly regulated by VDR 
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5. DISCUSSION 
 
5.1. Identification of VDR-regulated genes in human prostate cells 
 
The activation of VDR triggers a cascade of cellular events resulting in various effects 
involved in anti-inflammatory, anti-proliferative, pro-apoptotic and differentiative functions 
(Sproul, 2005). These features can be correlated with a protective role of 1α,25(OH)2D3 
against cancer development. As the tumor develops progressively, it is very important to 
study the ways to prevent its growth already in non-malignant cells.  
In order to explore the role of VDR in human prostate epithelial cells, we performed a 
microarray analysis in the human prostate RWPE1 cell line. To conduct a classification of the 
genes in early-responding, primary and late-responding, secondary target genes, we treated 
these cells for 4 or 24 h with 1α,25(OH)2D3. Among the 87 genes regulated at an early time 
point, only 11 genes were down-regulated, suggesting that VDR preferentially controls genes 
by their stimulation rather than inhibition after a short-term treatment. The broad action of 
VDR across many different genes was seen at the late time point of treatment where a bulk of 
more than 400 genes was significantly regulated. Among the induced genes at both time 
points we recognized well-known VDR targets like CYP24A1 and IGFBP3, members of the 
DUSP and KLK gene families, but also genes involved in the immune response (CD14, IL8, 
FOS). Among the early down-regulated targets, genes were identified that are implicated in 
promotion of angiogenesis (VEGFC, THBS1), inhibition of apoptosis (IER3, BIRC3) and 
TGFβ signaling (FST). These data indicate that the activation of VDR and the reduction in 
expression of these target genes could contribute to the possible anti-cancer effects by 
inhibiting the angiogenesis of a developing tumor and by the reduced inhibition of apoptosis.  
Furthermore, the GO enrichment analysis revealed biological processes in which VDR plays 
an important role also in prostate cells. We noted that VDR activation influences the 
“regulation of cell cycle” by inducing genes such as p21 and GADD45A known as growth 
arrest and DNA-damage-inducible gene, or BCL6 encoding a protein that acts as transcription 
repressor suppressing genes like CDK1, MYC, UBEC2 that are crucial in cell cycle 
progression, pointing at the role of 1α,25(OH)2D3 in cell cycle arrest. In addition, the up- 
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regulated genes involved in “cell differentiation” including BMP2, BMP6, and JUN, may 
potentially induce differentiation, suggesting that VDR also promotes cell differentiation in 
prostate cells. Interestingly, “regulation of apoptosis” was assigned to 52 genes from which 
60% were induced by 1α,25(OH)2D3 such as BOK, BNIP3 and BNIP3L, genes with pro-
apoptotic functions that belong to the BCL2 protein family. On the other hand, the inhibitors 
of apoptosis like ANGPTL4, BIRC3, BIRC5 were down-regulated, which clearly indicates a 
VDR effect also on this process. These results suggest that activation of VDR may possibly 
act as a preventive guard against uncontrolled proliferation.  
Interestingly, the transcriptome analysis revealed that the second most induced gene in the 
non-malignant prostate cell line after 1α,25(OH)2D3 stimulation was kallikrein 6 (KLK6) that 
belongs to the largest continuous cluster of genes encoding serine proteases. This information 
was exciting as another member of this family, KLK3, also known as prostate specific antigen 
(PSA), is widely used as a prostate cancer biomarker (Lilja, 2008). A detailed look on the 
KLK genes revealed that several additional KLKs (KLK5, KLK7, KLK8, KLK9) were also 
expressed in non-malignant prostate cells and can be up-regulated by the activation of VDR. 
Aberrant regulation of KLKs has been associated with many diseases like inflammation, skin 
disorders, neurodegeneration and cancer (Sotiropoulou, 2009). It has been suggested that the 
KLK5, -6 and -8 genes in non-malignant keratinocyte cells (Lu, 2005) and the KLK6 gene in 
breast cancer cells (Vannoirbeek, 2009) can be regulated by 1α,25(OH)2D3 stimulation. As the 
exact mechanism of their activation by VDR remained unsolved, this study presents for the 
first time a detailed analysis of VDR function in the regulation of the kallikrein gene cluster. 
 
5.2. Selectively regulated genes from the KLK cluster in prostate cells 
 
Several members of the KLK gene family were expressed (KLK3 and KLK5-11) in the non-
malignant prostate cell line but few of these genes were directly regulated by 1α,25(OH)2D3 
(KLK3, KLK5-9) based on the microarray results. Interestingly, the induced genes are located 
in the central region of the KLK locus. However, the PSA was not located in this central part 
of the cluster, which might separate this gene from the VDR-specific transcriptional 
regulatory network. This may probably explain why the KLK3 gene was slightly responding 
to 1α,25(OH)2D3 in the microarray analysis which however, could not be confirmed by qPCR. 
Interestingly, KLKs can be co-expressed together in many different tissues, like in breast 
(KLK5-8, KLK10, KLK11, and 14) or cervix (KLK4-11), which suggest that they may be 
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 regulated in a coordinated manner (Debela, 2008, Borgono, 2004). The presented results 
showed that several genes from central part of KLK locus can be also jointly induced upon 
1α,25(OH)2D3 stimulation in prostate, which implies a common transcriptional mechanism.  
As 1α,25(OH)2D3 could differently affect the induction of the KLK genes in RWPE1 cells the 
question raised whether mRNA expression of genes from the central KLK region could also 
be stimulated by the VDR ligand in the malignant prostate cells. KLKs are often deregulated 
in tumor and their expression pattern differs from cancer to cancer (Borgono, 2004). For 
instance, in prostate cancer mRNA levels of some KLK genes like KLK5, KLK6, KLK8, 
KLK10, KLK12 was found to be decreased in relation to non-malignant prostate (Lawrence, 
2010; Yousef, 2002; Petraki, 2003).  
Intriguingly, our series of time course experiments revealed that the highest induction of the 
KLK6 gene upon 1α,25(OH)2D3 stimulation was more than 10 times lower in cancer cell lines 
compared to the non-malignant prostate cell line. KLK7, KLK8 and KLK9, which were 
modestly but significantly induced in non-malignant prostate cells by VDR activation, could 
not be significantly induced in the cancerous PC3 and DU145 cells. Only the RWPE2 cancer 
cells showed a small significant induction of KLK5, -7, -8 and -9 upon 1α,25(OH)2D3 
treatment. These observations led to the assumption that the KLKs may be a direct target of 
VDR in non-malignant prostate cells but not in cancer cells. Moreover, the relative expression 
of the KLK genes from the central part of their cluster was lower in cancer when compared to 
a non-malignant prostate cells. The exception was the KLK6 gene; here the expression level 
remained unchanged across different prostate cell lines. KLKs expression in malignant versus 
non-malignant prostate was also studied by others, and the results have shown a similar 
outcome. For example, KLK5 gene expression was lower in cancer than in normal cells 
(Yousef, 2002). Perhaps the accessibility of these genes to the transcriptional machinery is 
limited in cancer cells. We observed a similar effect for the known VDR target gene IGFBP3 
that showed decreased up-regulation by VDR ligand in malignant prostate cells compared to 
non-malignant cells. Interestingly, Zhang et al. have shown that the VDR protein levels in 
RWPE1 and RWPE2 cells were equal upon 1α,25(OH)2D3 treatment. However, the 
transcription in RWPE2 after VDR stimulation was blunted as a result of phosphorylation of 
RXR in the AF1 domain that decreased binding of co-activators. It would possibly explain 
lower response of the VDR to its ligand in malignant prostate cells (Zhang, 2010).  
To further deduce the role of VDR in the regulation of the KLKs in non-malignant prostate 
cells, we analyzed the central region of the KLKs also under conditions of depleted VDR. We 
verified the effectiveness of VDR silencing via gene-specific siRNAs by showing inhibition 
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of CYP24A1 expression, the best-known direct VDR target gene, by around 90% after 
1α,25(OH)2D3 treatment. Silencing of VDR alters the transcription of KLKs differently, 
depending on their localization, confirming the idea that only the KLKs of the central region 
are VDR-responsive. The highest responsive gene was KLK6 whose expression was impaired 
up to 90% upon 1α,25(OH)2D3 stimulation, whereas the second most up-regulated gene, 
KLK5, showed ~45% of knockdown suggesting that it might be regulated by additional 
factors. The slight up-regulation of KLK7, -8 and -9 was completely abolished after VDR 
silencing, showing that VDR may have been involved in their expression. Thus, VDR 
depletion in the non-malignant prostate cell line demonstrated that the up-regulation of the 
KLK6, -7, -8 and -9 genes is dependent on the presence of VDR and not induced through an 
unspecific ligand effect.  
These results are particular interesting since KLK6 was assigned as a tumor suppressor gene 
that plays a protective role against breast cancer development (Pampalakis, 2009).  
In addition, the mRNA of KLK6 after 1α,25(OH)2D3 treatment in RWPE1 cells was 
continuously accumulating in a time-dependent manner. The induction of KLK6 was 
detectable already after 45 min of 1α,25(OH)2D3 stimulation and was accumulating thereafter 
in a linear fashion. The time and rate of the mRNA transcription should harmonize with the 
mRNA degradation rate since both determine the actual amount of mRNA designated for 
protein production (Houseley, 2009). The consistent accumulation of KLK6 mRNA was in 
agreement with the stability of its mRNA in certain time interval. The KLK6 mRNA half-life 
was higher than 5 hours, the time span covered by the experimental set-up. The rapid and 
high VDR-dependent induction of the KLK6, correlated with rather stable mRNA indicates 
that the KLK6 gene is a primary VDR target gene in non-malignant prostate cells. 
5.3. Organization of the KLK gene locus, and implications of the VDR in 
its regulation 
 
In order to further investigate the gene regulation of the KLK locus we looked at the whole 
KLK gene region, first to determine sites enriched with a marker of chromatin 
decondensation. The UCSC Genome Browser tools provided us a set of diverse binding 
patterns of the H3K4me1, H3K4me3 and H3K27Ac markers from 8 different cell lines. These 
histone modifications were associated with an open chromatin state (Heintzman, 2009). 
Thereby, we were able to identify the location of these indicators of chromatin relaxation at 
the TSSs of some genes and in intergenic sites that indicate potential accessibility for the 
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transcriptional machinery at the KLK locus. On this basis, 8 putative VDREs located inside 
the cluster and in proximity to KLKs TSSs were analyzed, in non-malignant prostate cells 
upon 1α,25(OH)2D3 stimulation, using the chromatin immunopecipitation (ChIP) assay. The 
results revealed the strongest binding of VDR to the TSS region of the KLK6, which 
indicates the presence of VDRE close to the promoter of this gene. In contrast, the rest of 
analyzed TSSs showed minor or no association with VDR. Intriguingly, the potential VDREs, 
selected based on histone modification markers also demonstrated diverse association with 
the VDR protein. Since genes located close to these binding sites were not regulated by VDR, 
one can assume that predicted response elements may be involved in transcription of other, 
perhaps distinct VDR target genes. However, detailed analyses are required to verify their 
function. It would be especially valuable for the RE4 and RE5 located between KLK4 and 
KLK5, since the mRNA expression of the second gene was increased after 1α,25(OH)2D3 
treatment. In general, the REs were considered to be located in close proximity to the 
promoter of targeted gene to activate transcription. However, emerging studies have shown 
that distal REs can also participate in gene regulation. For instance, it was shown that multiple 
ER binding sites situated both distal and in close proximity from the regulated gene, can 
cooperate via long-range chromosomal interactions (Pan, 2008). Moreover, the well-known 
VDR target gene, CYP24A1 was shown to be regulated by a several VDREs located both at 
distant and proximal sites from the promoter, connected by a chromatin loop formed in a 
ligand-dependent manner (Matilainen, 2010). Nonetheless, the exact mechanism on how 
multiple REs act jointly is not yet clear. 
For further analysis, we conducted an in silico screening with “the high-quality transcription 
factor binding profile database” called Jaspar that revealed a number of putative VDR 
response elements inside the KLK locus, one of which was located at position -101 bp of the 
KLK6 promoter. Despite the presence of a considerable number of putative VDREs within the 
KLK cluster, majority of TSSs in the locus except KLK6 showed minor or no VDR 
recruitment, which suggests selectivity of VDR for its response elements in prostate cells, 
perhaps due to differential attraction to the VDREs. One binding site flanking the TSS of 
KLK6 gene showed significant association with the VDR after 1α,25(OH)2D3 stimulation. 
Interestingly, this VDRE was evolutionary conserved and showed similarities across multiple 
species. The 15 nucleotides are highly similar between mammalian species (human, rhesus, 
mouse and dog) with only one nucleotide change in human and two changes in dog. The high 
conservation may reflect the functionality of this VDRE across species. The VDRE sequence 
inside the KLK cluster remained unchanged throughout the evolution, which suggests its 
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unique value. Moreover, the KLK6 gene together with the other kallikrein family members 
(except KLK2 and -3), are highly conserved, since they are present in all placental mammals. 
That suggests they have an important biological function (Lawrence, 2010). Nevertheless, 
their potential roles in co-operation with VDR are poorly understood. Intriguingly, Wang et 
al. using their in silico screening for predicting VDREs have found another binding site 
located -489 bp away from the promoter of KLK6 gene (Wang, 2005). However this RE could 
not be confirmed by the Jaspar screening. 
The comparison of the KLK6 promoter binding site in non-malignant and cancer cells 
regarding presence of the VDR, reflected differences in the mRNA expression level of the 
KLK6 gene between those two kinds of cells. The smaller enrichment for VDR binding to its 
promoter resulted in a lower mRNA expression of the KLK6 that was seen in the cancer cell 
line, whereas strong and significant VDR binding to the KLK6 promoter in the non-malignant 
prostate cell line may be a sign of a higher mRNA expression of the gene. The differences 
between induction of KLK6 might be due to variations in chromatin remodeling affecting the 
genes’ accessibility for the transcriptional machinery and ability of the VDR to bind to the 
potential VDREs, which might differ in non-malignant and cancer cells. Moreover, possible 
loss-of-function mutations in VDR may impair ligand binding, heterodimerization and thus 
transactivation in cancer (Haussler, 2011).  
In order to confirm the authenticity of the regulatory regions in non-malignant and cancer 
cells near the TSS of KLK6 gene, we examined the presence of H4Ac, which reflects the 
activation state of transcription. It is a marker for the relaxation and open state of chromatin 
structure, and therefore its accessibility for the transcriptional machinery (Zella, 2009). 
Interestingly, its high levels in the absence and increased levels in the presence of 
1α,25(OH)2D3 in non-malignant prostate cells suggested that histone acetyltransferases are 
associated with the KLK6 gene induction. This underlines the authenticity of the regulatory 
region and suggests that the KLK6 TSS is permissive and allows VDR to bind. The histone 4 
was also acetylated at the promoter site of KLK6 in malignant cells, but its level remained 
unchanged after induction with 1α,25(OH)2D3. Nevertheless, this also can be a possible sign 
of euchromatin formation, which might suggest that VDR cooperates with other transcription 
factors and thereby takes part in chromatin decondensation, allowing other proteins bind to 
the DNA. However, the presence of H4Ac may also relate to the situation observed with 
trimethylated histones, which reside at silent promoters, and take part in maintenance or 
priming the chromatin for the future activation or act as a memorizer of a previous 
transcriptional activation (Heintzman, 2007).  
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In addition, data taken from the UCSC Genome Browser showed that among several different 
cell lines, the surrounding of the KLK6 TSS is covered with H3K4 monomethylation, which 
is supposed to be enriched in active genes and to have possibly a function in transcriptional 
activation (Barski, 2007). Also presence of acetylated H3K27 was detected, which is thought 
to augment the transcription (Kim, 2011). These results also suggest that the KLK6 gene may 
be active across many cell lines.  
 
5.4. Role of insulators in the KLK cluster  
 
The datasets from the ENCODE tracks in the UCSC Genome Browser helped us to notice that 
the KLK cluster is separated by putative insulators marked by CTCF binding sites. The 
different expression patterns for the regions of the KLK family members were compatible 
with the presence of CTCFs on the borders of the central region of the KLK cluster that would 
separate KLK5, -6, -7, -8, -9 from the rest of the family. In general, insulators may regulate 
the transcription of specific genes by several mechanisms including restricting the enhancer-
promoter interactions (Gomes, 2010) and by obstructing heterochromatin from spreading 
(Witcher, 2009). Interestingly, upon 1α,25(OH)2D3 stimulation of the prostate cells, the 
strength of CTCF binding in the KLK locus increased. This indicate VDR role in recruitment 
of CTCFs, which in turns may augment the transcription, limited to the central region of the 
KLK locus. Intriguingly, three out of five VDREs, predicted based on “open” chromatin 
markers, were located outside the CTCF-restricted region, while the other two were 
positioned in close proximity to the CTCF binding sites. These results would indicate the 
possibility of KLK genes regulation by distal and close (situated near KLK6 gene promoter) 
response elements to happen only inside the loop, formed by flanking insulators (Philips, 
2009). Perhaps VDR-dependent recruitment of CTCFs to their binding sites in the KLK locus 
could also influence the accessibility of functional VDREs, located outside the loop, to the 
active KLK genes.  
CTCF, being a highly conserved protein, has also a crucial role in the chromatin architecture. 
It was proposed that CTCF can be “a leading candidate as a global genome organizer” to 
control chromatin organization and gene expression (Handoko, 2011). The VDR-related 
enriched association of CTCF with the KLK locus suggests a link between these two proteins 
in regulation of KLK genes. Since insulators may modify the chromatin conformation to 
control gene regulation we inhibited CTCF mRNA expression to investigate whether VDR 
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may then expand its action on the whole KLK gene cluster possibly by utilizing the active 
VDREs located on the border of the KLK locus. Surprisingly, our data did not show changes 
in the VDR-mediated regulation of the KLK locus. The genes were similarly induced in 
control samples as well as in samples treated with siRNA against CTCF, which indicate that 
loss of this insulator did not disturb the KLK genes induction by 1α,25(OH)2D3 in non-
malignant prostate cells.  
Perhaps, additional mechanisms might be involved in the control of the KLK gene expression 
e.g. the promoters of inactive genes may contains CpG islands that can be hypermethylated 
and result in formation of transcriptionally inactive state of chromatin (Esteller, 2007). An in 
silico analysis has shown that the KLK locus hold 16 CpG islands, interestingly absent in the 
region of KLK6, -7, -8 and -9 genes (Pampalakis, 2006, Pasic, 2012). The presence of CpG 
island in the regions of the KLKs not regulated by VDR may suggest their association with 
the DNA methylation and formation of heterochromatin structure.  
Another argument why the CTCF inhibition did not broaden the VDR-mediated induction of 
the whole KLK cluster can be related to the fact that cohesin proteins may reside in CTCF 
sites and can have a role in insulator functions. Cohesin has been implicated to participate in 
gene regulation and this may also contribute to the CTCF positioning (Wendt, 2008). For 
instance, RAD21, a cohesin protein, was found to co-occupy many CTCF binding sites.  
Mishiro et al. have shown that inhibition either of CTCF or RAD21 was followed by 
disturbance in the chromatin structure and by expression of the apolipoprotein (APO) gene 
cluster (Mishiro, 2009).  
Preliminary data have shown that CTCF silencing did not alter the expression profile of 
RAD21 in non-malignant prostate cells, however upon 1α,25(OH)2D3 stimulation in CTCF-
depleted conditions, RAD21 gene was induced (see Appendix III). 
Another study showed that CTCF silencing also did not reduce chromatin-bound cohesin 
level; likewise CTCF was also not reduced by depletion of RAD21 or other cohesins. This led 
to the conclusion that CTCF may not be required for binding of RAD21 on DNA regions 
(Wendt, 2008), which could also suggest an involvement of cohesin protein complex in 
maintaining the DNA boundaries in the KLK locus. However, the exact mechanism of 
insulator-dependent chromatin loop formation that enables selective gene regulation through 
connection with distant regulatory elements to their promoters is not well known and is still 
under investigation. 
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5.5. Potential functions of VDR and KLKs in human non-malignant 
prostate cells 
 
The enrichment analysis performed on data from non-malignant prostate cells stimulated with 
1α,25(OH)2D3 provided also a representation of different pathways in which VDR may be 
involved, and the most enriched ones were “arachidonic acid metabolism”, “p53 signaling 
pathway” and “cancer pathway”. These data were consistent with the observation of 
Kovalenko et al., showing that 1α,25(OH)2D3 affects processes involved in cancer 
development in prostate cells. The 1α,25(OH)2D3  target genes may have biological functions 
related to VDR’s preventive impact on tumor growth (Kovalenko, 2010). Thus, we identified 
significantly up-regulated genes in the “cancer pathway” that act as tumor suppressors or 
transcription factors that control proliferation. Down-regulated genes were involved in 
angiogenesis, inhibition of apoptosis or they belonged to transcription factors over-expressed 
in cancer. Thus, the functional analysis of genes significantly regulated by 1α,25(OH)2D3 
pointed at biological processes that encompass the anti-proliferative, pro-apoptotic and pro-
differentiating role of VDR, which may be a prominent preventive factor against prostate 
cancer development. 
Regarding the interactions between VDR-regulated genes and the potential KLKs substrates 
(obtained from the literature (Lawrence, 2010)), we identified several common and 
overlapping biological processes that might indicate a synergistic relationship between VDR 
and KLK proteins. The association of both groups of the selected genes with “cell adhesion”, 
“response to wounding” or “regulation of cell proliferation” may implicate a common 
function in controlling these processes. For instance, KLKs are known for their role in 
degradation or remodeling of extracellular matrix by digestion of its components like collagen 
IV, fibronectin or laminin (Lawrence, 2010). This may affect the adhesion of cells, especially 
since KLKs cleave cell-cell adhesion molecules like desmoglein or E-cadherin (Borgono, 
2007). Interestingly, Sung et al. have shown that in prostate cancer cells 1α,25(OH)2D3 can 
decrease the tumor invasion by reducing cell adhesion to the basement membrane protein 
laminin, in part via suppression of laminin receptors i.e. α6 and 4 integrins (Sung, 2000). 
Our study implicates that VDR-dependent activation of KLKs from the central part of their 
locus, triggers a cascade of events that may be also correlated with a function of a direct VDR 
target genes in a cellular processes. It would suggest a possibility of secondary or tertiary 
effect of this NR.  
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Further, we wondered if VDR, additionally to the induction of KLKs, also regulates KLK 
substrates in order to boost the KLK processes. Indeed, we observed that some of potential 
KLK substrates overlapped with the VDR-regulated genes. Moreover, we have noticed that 
VDR may intensify the KLKs function by inducing or repressing their substrates and VDR 
up-regulates substrates that are deactivated by KLK proteolysis. This observation implies a 
broad cellular response to 1α,25(OH)2D3 treatment. The conducted GO analysis showed 
relation to “the extracellular space and region” where we identified two members of IGFBP 
family. Intriguingly, the IGFBP3 protein encoded by a well-known VDR target gene may be 
cleaved and inactivated along with other IGFBP members by the KLK5 enzyme (Michael, 
2006). Both, the IGFBP3 and KLK5 genes, are elevated upon 1α,25(OH)2D3 stimulation in 
prostate cells. The simultaneous up-regulation of IGFBP3 and its deactivator indicate an 
important function since this gene has a multifunctional role e.g. in promoting apoptosis or 
inhibiting the growth of prostate cancer cells (Liu, 2007). The IGFBP3 is also regulating the 
bioactivity of IGFs and its proteolysis may result in reduced affinity for IGF, which can make 
IGFs more available to the cell (Jerome, 2003). Perhaps KLK5 cleaves IGFBP3 in order to 
liberate the IGFs to exercise control of normal regulation of cell differentiation and 
proliferation in non-malignant prostate cells.  
Importantly, KLK pro-proteins can be cleaved by other KLKs. For example, KLK7 is a 
substrate of KLK5. In our microarray analyses we identified KLK5 as an early responding 
gene, while its substrate KLK7 was late responding to 1α,25(OH)2D3. This data indicate that 
the activation of VDR is boosting the KLK5-KLK7 biochemical process. Furthermore, the 
KLK activity may be enhanced by the activation of VDR that mediates the mRNA down-
regulation of the serine protease inhibitor SERPINB2.  
Deregulated in tumor environment KLKs, excessive activate substrates like MMPs, PAR, 
uPA or TGF1 that are correlated with cancer development and progression (Avgeris, 2012; 
Kessenbrock 2011). Moreover, the KLKs ability to degrade ECM proteins (e.g. fibronectin) 
that act as a barrier for tumor cells to spread enables to facilitate angiogenesis and metastasis 
(Borgono, 2004). In accordance with these studies it was thought that extracellular proteases 
including MMPs and KLKs are involved in tumorigenesis (Egeblad, 2002). However, clinical 
studies on MMP inhibitors failed to show anti-cancer effect, on contrary, in some cases it was 
associated with promoting of tumor growth (Overall, 2002). This suggest more complex role 
of extacellular proteases in biological processes. Since then studies have shown that proteases 
can exhibit anti-tumor functions (Rodriguez, 2010). Interestingly, it was previously shown 
that the expression of KLK6 in non-malignant and in cancer breast cell lines differs. 
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Moreover, this serine protease has anti-tumor properties that inhibit epithelial-mesenchymal 
transition in tumor cells and was proposed to be classified as a tumor suppressor (Pampalakis, 
2009).  
Our closer look into the KLK6 substrates has revealed some of the genes regulated by VDR 
in prostate. Intriguingly, myelin that may be cleaved by KLK6 is down-regulated by VDR in 
prostate cells. However, KLK6 may also take part in E-cadherin shedding in epidermal 
keratinocytes, which is a mark for the extracellular matrix degradation. In contrast, the gene 
encoding E-cadherin is induced upon VDR activation in prostate cells. The diversity of 
effects elicited by the KLK6 enzyme and members of its family may suggest that they can 
demonstrate a variety of functions. Therefore, the functional meaning of KLK6 up-regulation 
by 1α,25(OH)2D3  in non-malignant prostate cells needs to be further explored.  
5.6. Conclusions  
 
In this study we conducted a genome-wide expression profiling to reveal the most responsive 
target genes of VDR in non-malignant human prostate cells. Our data suggest that the second 
most responsive target under these conditions was the KLK6 gene, a member of the largest 
contiguous cluster of genes encoding peptidases in human. Moreover, several other genes 
belonging to this family were also regulated by 1α,25(OH)2D3 in non-malignant prostate cells, 
while their induction in cancer cells was decreased or was abolished. 
We showed that the expression of the central region of the KLK gene cluster depends on VDR 
activation and that KLK6 is a direct target of VDR. Moreover, the transcriptional activation of 
KLK6 gene begins rapidly upon 1α,25(OH)2D3 stimulation and the mRNA stability remained 
unchanged for indicated time. 
The central region of the KLK cluster in prostate cells is separated from the other KLK 
members by CTCF insulators, whose occupancy is enhanced after 1α,25(OH)2D3  stimulation. 
The CTCF insulators may create boundaries allowing the selective regulation of the central 
KLK genes. Furthermore, from several putative VDREs we identified six functional ones 
from which three were located on the border of the KLK locus and the other three were 
situated in the central part of the KLK cluster and were encompassed by CTCFs. One 
evolutionary conserved VDRE was located close to the KLK6 promoter, which indicated the 
direct action of VDR on this gene. This was also reflected in chromatin decondensation that 
occurred in a presence of histone modification like H4Ac, in non-malignant prostate cells. In 
contrast, the selected VDRE was not active in the cancer cell line, which affects the mRNA 
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expression profile. Looking on genomic context, basal expression level, responsiveness to 
VDR ligand we proposed a model that present formation of chromatin loop in the nucleolus. 
 
 
Figure 34. Model of kallikrein cluster organization in prostate cells upon 1α,25(OH)2D3 
treatment in non-malignant prostate cells (adapted from Yang & Corces, 2012). 
 
Therefore, our study for the first time provides insight into the transcriptional regulation of 
the expression on KLK gene family after VDR activation in prostate cells. 
 
5.7. Future perspective 
 
To further explore the regulation of expression of the whole KLK cluster, the silencing of 
RAD21 alone and together with CTCF could provide detailed insights into the boundaries 
within the KLK locus. Additional ChIP experiments under CTCF and RAD21 depletion 
conditions along with the analysis of chromatin markers such as H3K4me3 would possibly 
show abolition of VDR restriction in the KLK gene regulation. To investigate the 
functionality of VDREs located at the border of a cluster and close to the CTCF binding sites 
it would be necessary to perform chromosome conformation capture (3C) assays in order to 
verify long-distance interactions between regulatory elements and TSS regions. In addition, it 
would be a great of interest to analyze the responsiveness to 1α,25(OH)2D3  treatment of the 
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KLK genes located outside the central part of their locus and to analyze the presence of 
insulators in a malignant prostate cells. 
Furthermore, it would be very interesting if the VDR-dependent mRNA regulation of the 
central KLK genes is also translated on the KLK protein level and whether the augmented 
proteins stay in the cell or are secreted immediately. 
To broaden the investigation of gene regulation by VDR in human prostate, one could 
perform a genome-wide profiling of DNA-binding proteins and histone modifications as an 
epigenetic study, in both non-malignant and cancer cells, using ChIP-Seq experiments. The 
data would contribute to delineate the number of binding sites for selected nuclear receptors 
that might assist in regulation of genes involved in prostate cell function. Hence, the 
identification of RNA pol II, VDR, AR, histone acetylation (H4Ac, H3K27Ac), methylation 
(H3K4me1, H3K4me3) and of the presence of insulators would help to discover the 
complexity of the regulation of the human genome and its expression in prostate cells. For 
instance, it could allow identifying the functional distal and proximal response elements to 
which attracted VDR would bind and thus modulate expression of target genes.   
In order to understand wide connections of VDR effects on the protein level in non-malignant 
and cancer prostate cells, it would be of great interest to perform a proteome analysis to 
investigate proteins interactions upon 1α,25(OH)2D3 treatment, using mass spectrometry 
technique, and compare them with both prostate cell lines. This challenging approach would 
also reveal possible differences in the modulated expressions of the genes mRNA and 
modulated expressions of their corresponding proteins. 
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7. APPENDIX I 
 
A tables that representing primer list of selected genes (Table 9) and the predicted VDREs 
using JASPAR dataset (Table 10) are shown below. 
 
Table 9. A primer list of selected genes  
Primer pair Sequence 
KLK3 
F - TGCTGTGAAGGTCATGGACC 
R - CCAGCACACAGCATGAACTTG 
KLK4 
F - CGGTGGTGTCTGAGGAGGTCTGC 
R - TTCCTTCCGCAGGATGTATTTGG 
KLK5 
F - CTGGATGTGGGTGCTCTGTGCTC 
R - GATGCGGCTGCTGCTGTCATC 
KLK6 
F - GTGATTTCCCTGACACCATCCAGTG 
R - TGGCTTCTCCTTTGATCCACAGG 
KLK7 
F - TGGCATCCCCGACTCCAAGA  
R - TTAACTCAGTGTGGCGTTAGCGATG 
KLK8 
F - ATGGTCTGTGCAGGCAGCAGC 
R - TGCTTATCCTAGAATCAGCCCTTGCT 
KLK9 
F - GCATCCTGGAGAACAAACTCTGTCACT 
R - CCAGTCAAGGTAGTGGCATACGCTG 
KLK10 
F - CAGCATCACTATCCTGAGCCCTAAAGA 
R - AGCTGGAGCGTAGCATCTGGATC 
KLK11 
F - ACCATCATTGAGCACCAGAAGTGTGAG 
R - CCAGTCCACATATTTGCAGACTTTCGTG 
KLK12 
F - CTCCATCGTCTCCCATGCCACCT 
R -CCAGGGATGCCATCTTGTCCACAG 
KLK13 
F - CGGCACAAAAGAGGGTGGCAAAGAC 
R - AGGGCTAAGCAGACCATGTGAGGAAG 
KLK14 
F - TGGTCTGTGCAGGAGTTCCCCAGG 
R - CTCCATTCCCCAAGACACGAGGC 
KLK15 
F - CTCCCAGATACGTTGCATTGTGCCA 
R - CAGGCTTGGTGGTGTTGTCACAAGG 
RPLPO 
F - AGATGCAGCAGATCCGCAT 
R - GTGGTGATACCTAAAGCCTG 
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IGFBP3 
F - AAGTTGACTACGAGTCTCAG 
R - AATCAGTTCACCACAAACAGA 
CYP24 
F - GACTACCGCAAAGAAGGCTAC 
R - CATCACTTCCCCTGGTTTCATTA 
IL8 
F - TAGCAAAATTGAGGCCAAGG 
R -AAACCAAGGCACAGTGGAAC 
VDR 
F - AGATGACCCTTCTGTGACCC 
R - AGCTTCTTCAGTCCCACCTG 
CTCF 
F - CAG-ATC-TGG-ACG-ACA-ATG-AGG  
R - AAC-ACA-GCC-CAG-AGA-AGT-CC 
RAD21 
F - GAGTCAGCTATGCCTCCAC 
R -CCTGATGCATCTTCATCCTC 
KLK4_TSS 
F - CCCAGACACGGCTAAGTCTC 
R -AGATACCTGCGACACCAAGG 
KLK5_TSS 
F - GCTATTGCTAAGGCCCGATA 
R -CTCAGCCGCAGACTTCTCAG 
KLK6_TSS1 
F - CTGCTGGGAGCATGGCACTG 
R -CTCTGTGTGCTGCCTGCCGA 
KLK6_TSS2 
F - GCCTGGGTAAGGAGGAAAAG 
R -TGGAAGAGGCTGGTTCTGTC 
KLK6_TSS3 
F - AAAGGACGTTCCAGAAGCAT 
R - GCCGTGAGGAGAGAAGACAC 
KLK7_TSS1 
F - CCAGCAGAGGGATGAAGAT 
R - GAGCAGAGTCAGGCTTGGAG 
KLK7_TSS2 
F - CCAGCAGAGGGATGAAGAT 
R - CCCAAATTGCAGACTTCCAG 
KLK8_TSS 
F - TCCTCCCTCAAGATTTCACG 
R - ACTGGGAATCTCCACCTCC 
KLK9_TSS 
F - GAAGGAGATGGCATGGCTTA 
R - CAGCAGAGAGAGCAGAGCAC 
KLK10_TSS1 
F - TCCCATTGATTTCCTCTTGC 
R -GCCCTGGAATACAGGCTTC 
KLK10_TSS2 
F - CCTCACCCACGGTACAATTAG 
R - GAGTCGCCGATAGGAAGGAG 
KLK10_TSS3 
F - CACACACAGAGCTCACTCACG 
R - CAGGTTGAGTAGGAGGGACAG 
KLK11_TSS1 F - GGGACGTGGCTTTGTTCTAA 
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R - TCCCAGTGGAGACAGAATCC 
KLK11_TSS2 
F - CCCACGTCATAAGGGTAGTCA 
R -ATTCCTGCTTCTCCCAGCTTG 
KLK12_TSS 
F - GCCAGGTGCAGAGTGGTAG 
R - CCTCTACGTGGCTGTCACTG 
KLK13_TSS 
F - GAGTGAATGAGGCGAGGAGA 
R - CGCATTCTTACCTCCTGACAA 
KLK14_TSS 
F - GCATCTCCAGCTCTCACTTTG 
R - AGATACCTGGACCTGGAGCA 
IGFBP3_RE8 
F - CTGGAGTGACTCACCAGAGTC 
R - CTTGCCTGCCTCTCTCAGCTG 
KLK_RE1 
F - GAGCCGTGTCCTACCTAAGC 
R - AGACCTCGGGTGCTATTCCT 
KLK_RE2 
F - GAGGAAACTGAGGCCCAGAC 
R - GTGTCCCCGTCTGTATCAGG 
KLK_RE3 
F - CCCATACACACGTCATACGG 
R - CACCCTCACAACCTCAGCTA 
KLK_RE4 
F - CCACTCTCCCTCAGTCCTACA 
R - CGCCATGAAGTTCCTATGC 
KLK_RE5 
F - GATCTTCAGCCAATTCTGTGC 
R - GGCCACCTTCTGATGCTGTT 
KLK_RE6 
F - GGCTCACGCCTGCTATCCCAAC 
R - GTCTCAGAGTCTCACTCTGTCACC 
KLK_RE7 
F - GGTTCTGATGGCCCATTGTTTC 
R - CACTGATCTTGTTGACTTGGA 
KLK_RE8 
F - CGAGACTGGTCACTGCACTC 
R - GACTACAGGTGTGCAACAGCA 
CTCF_1 
F - CCAGATAGGGAAATGCGACC 
R - GCGGTCCAATGCCACCTAG 
CTCF_2 
F - GGAGTCATCCATCACCCTGAC 
R - CACAGTTGTAGGCGCACTTG 
CTCF_3 F - CTGACCTCAAGTGATCCAC 
R - ATAAGATCCCCTGGTGTTTCG 
CTCF_4 
F - CTAATCCAGCCACCACCAGT 
R -AGCAAGGATCTGAAGCAAGG 
CTCF_5 
F - GCCATCTAACTCAGTGCTGCT 
R - AAGAAGTCAGTTAGCCTGCACA 
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Table 10. A list of potential VDREs predicted by JASPAR inside the KLK locus. 
According to the JASPAR VDR weight matrix (80% cut offs) there were detected 30 
putative VDREs, one of which was located in close proximity to KLK6 TSS.  
JASPAR VDRE sequences 
 
 
Position at 
chromosome 19 
 
GGGTCACAGGGATTC 56033320 56033338 
GGGTGTCTGAGTTCA 56039257 56039275 
GGGTCATAGAGTCAA 56045445 56045463 
GGGTCTTGGAGTGCA 56049642 56049660 
AGGTGACCAAGTTCA 56053606 56053624 
GGGTCCACGAGGACA 56054785 56054803 
AGGGCACATGGTTCA 56055103 56055121 
GGGTTGATAGGTACA 56057298 56057316 
AGGTCAGGAGTTTCA 56060696 56060714 
GGGTCACTGACTACA 56062825 56062843 
GGGACACTGGATTCA 56066602 56066620 
GGGTCAGGGGGATCA 56062825 56069777 
AGGTGACAGAGTTCA 56072019 56072037 
GGGTCCTGAGTTTCA 56079652 56079670 
AGGTCACTGGATACA 56069759 56087294 
GGGCCACAGAGTTTC 56101291 56101309 
GGGTCATAGAGCTTA 56103489 56103507 
GTGTCAAATGGTTCA 56121828 56121846 
GGGTGAAGGGGTTCT 56122078 56122096 
GGGTCTAAAGGTTGA 56139382 56139400 
AGGTAAATGAGTTAA 56141351 56141369 
GGGTCACCAAGAGCA 56163960 56163978 
VDRE close to the 
KLK6 TSS 
GGGTCATTGGGTTGG 56172672 56172690 
GAGTCATCAGCTTCA 56174257 56174275 
GGGTCACTGAGGCCA 56175289 56175307 
GGGTCACAGTGTTCA 59187219 56187237 
GGATCAAGAAGATCA 56191145 56191163 
GAGTTATAGGGTTCA 56250950 56250968 
GGGTCATCCAGTAGA 56257290 56257308 
AGGTCCATGGGTTCC 56276369 56276387 
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APPENDIX II 
 
The Volcano Plots showed below visualize the fold change of genes stimulated with 
1α,25(OH)2D3  for 4 h (Fig. 35A ) or 24 h (Fig. 35B) in non-malignant prostate cells. Data are 
taken from the RWPE1 microarray. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Volcano plot of significantly expressed genes after 4 h (A) or 24 h (B) of 
1α,25(OH)2D3
  stimulation of non-malignant prostate RWPE1 cells. 
 
A 
B 
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Tables presented below represents fold changes of genes regulated by 1α,25(OH)2D3 after 4 h 
(Table 11) or 24 h (Table 12) of treatment in RWPE1 cells. Table 12 shows top 100 genes 
both significantly up- or down-regulated.  
 
Table 11. List of top significantly up- or down-regulated genes after 4 h of treatment 
with 1α,25(OH)2D3 in RWPE1 cells 
 
Gene symbol Gene name 
Fold 
change 
Up-regulated genes 
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 32.35 
HAS3 hyaluronan synthase 3 5.27 
CD14 CD14 molecule 4.35 
IGFBP3 insulin-like growth factor binding protein 3 3.48 
KLK6 kallikrein-related peptidase 6 3.34 
PADI3 peptidyl arginine deiminase, type III 3.25 
C9ORF169 chromosome 9 open reading frame 169 3.11 
FAM83A family with sequence similarity 83, member A 2.85 
ANGPTL4 angiopoietin-like 4 2.83 
PTGES prostaglandin E synthase 2.77 
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1 2.75 
DHRS3 dehydrogenase/reductase (SDR family) member 3 2.71 
DUSP1 dual specificity phosphatase 1 2.45 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 2.43 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 2.42 
ARSI arylsulfatase family, member I 2.32 
TMEM156 transmembrane protein 156 2.27 
TINAGL1 tubulointerstitial nephritis antigen-like 1 2.25 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 2.17 
BAIAP2L2 BAI1-associated protein 2-like 2 2.15 
IL8 interleukin 8 2.09 
ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 2.06 
NRIP1 nuclear receptor interacting protein 1 2.04 
NET1 neuroepithelial cell transforming 1 1.94 
ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 1.90 
DHRS9 dehydrogenase/reductase (SDR family) member 9 1.89 
TRIM6 TRIM6-TRIM34 readthrough transcript; tripartite motif-containing 6 1.89 
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 1.87 
KRT15 keratin 15 1.83 
AKAP12 A kinase (PRKA) anchor protein 12 1.80 
TXNRD1 thioredoxin reductase 1; hypothetical LOC100130902 1.77 
IL1RL1 interleukin 1 receptor-like 1 1.75 
FBXO32 F-box protein 32 1.72 
FAM84B family with sequence similarity 84, member B 1.70 
  RP5-1022P6.2 glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae) 1.63 
FAM20C family with sequence similarity 20, member C 1.63 
HS.551538  1.61 
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 1.58 
DUSP10 dual specificity phosphatase 10 1.58 
NINJ1 ninjurin 1 1.57 
FHL2 four and a half LIM domains 2 1.57 
NAV2 neuron navigator 2 1.56 
KLK5 kallikrein-related peptidase 5 1.56 
EMP1 epithelial membrane protein 1 1.56 
THBD thrombomodulin 1.56 
SMAD3 SMAD family member 3 1.55 
TFCP2L1 transcription factor CP2-like 1 1.55 
C20ORF100 chromosome 20 open reading frame 100 1.55 
FOXQ1 forkhead box Q1 1.54 
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TMEM91 transmembrane protein 91 1.52 
FAM129A family with sequence similarity 129, member A 1.51 
C2CD2 C2 calcium-dependent domain containing 2 1.50 
IL1B interleukin 1, beta 1.50 
FOXA1 forkhead box A1 1.50 
PTPN1 protein tyrosine phosphatase, non-receptor type 1 1.49 
ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 1.49 
GRB7 growth factor receptor-bound protein 7 1.49 
TACSTD2 tumor-associated calcium signal transducer 2 1.49 
FAT2 FAT tumor suppressor homolog 2 (Drosophila) 1.48 
RFFL ring finger and FYVE-like domain containing 1 1.48 
MBP myelin basic protein 1.47 
KRT13 keratin 13 1.47 
CA2 carbonic anhydrase II 1.46 
SNRK SNF related kinase 1.46 
ASB1 ankyrin repeat and SOCS box-containing 1 1.46 
HOXA5 homeobox A5 1.46 
MMD monocyte to macrophage differentiation-associated 1.46 
BHLHB2 basic helix-loop-helix family, member e40 1.45 
UPP1 uridine phosphorylase 1 1.45 
FAM43A family with sequence similarity 43, member A 1.44 
RASSF5 Ras association (RalGDS/AF-6) domain family member 5 1.43 
STAT4 signal transducer and activator of transcription 4 1.43 
CRABP2 cellular retinoic acid binding protein 2 1.43 
HRCT1 histidine rich carboxyl terminus 1 1.42 
INPP1 inositol polyphosphate-1-phosphatase 1.41 
BTBD11 BTB (POZ) domain containing 11 1.41 
Down-regulated genes 
ZBED2 zinc finger, BED-type containing 2 0.70 
FOXA2 forkhead box A2 0.69 
IER3 immediate early response 3 0.69 
LOC652235 thioredoxin reductase 1; hypothetical LOC100130902 0.66 
VEGFC vascular endothelial growth factor C 0.64 
BIRC3 baculoviral IAP repeat-containing 3 0.64 
PHACTR3 phosphatase and actin regulator 3 0.61 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 0.57 
FST follistatin 0.55 
PTHLH parathyroid hormone-like hormone 0.53 
THBS1 thrombospondin 1 0.39 
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A heat map shown in a Figure 36 represents genes regulated after 24 h of 1α,25(OH)2D3 
treatment in RWPE1 cells. There were 663 genes significantly up- or down-regulated in a 
VDR-dependent manner.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Microarray analysis revealed secondary VDR target genes in RWPE1 cells. 
Heat map displaying the gene expression profile of differential expressed genes according to 
applied cut offs (p<0.01, log2FC>0.5 or <-0.5). There were 467 genes significantly up-
regulated and 196 significantly down-regulated genes upon 24 h of 1α,25(OH)2D3  
stimulation. Red indicates up-regulation and blue down-regulation.  
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Table 12. List of top 100 significantly up- or down-regulated genes after 24 h of 
treatment with 1α,25(OH)2D3  in RWPE1 cells. 
 
Gene 
symbol 
Gene name 
Fold 
change 
Up-regulated genes 
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 60.21 
KLK6 kallikrein-related peptidase 6 38.28 
PADI3 peptidyl arginine deiminase, type III 31.99 
CD14 CD14 molecule 28.18 
CA9 carbonic anhydrase IX 15.63 
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1 15.44 
DHRS9 dehydrogenase/reductase (SDR family) member 9 10.74 
BAIAP2L2 BAI1-associated protein 2-like 2 9.09 
TMEM91 transmembrane protein 91 7.51 
TCEA2 transcription elongation factor A (SII), 2 7.00 
IGFBP3 insulin-like growth factor binding protein 3 6.18 
MGC102966 keratin 16 pseudogene 3 5.18 
DUSP10 dual specificity phosphatase 10 5.18 
CALB2 calbindin 2 5.13 
KLK5 kallikrein-related peptidase 5 5.07 
G6PD glucose-6-phosphate dehydrogenase 5.03 
DNER delta/notch-like EGF repeat containing 5.00 
DUSP1 dual specificity phosphatase 1 4.87 
ACOT11 acyl-CoA thioesterase 11 4.74 
CTSD cathepsin D 4.65 
CST6 cystatin E/M 4.62 
MALL mal, T-cell differentiation protein-like 4.51 
TMEM79 transmembrane protein 79 4.49 
ANKRD33 ankyrin repeat domain 33 4.44 
KRT13 keratin 13 4.06 
CAMP cathelicidin antimicrobial peptide 3.90 
FTH1 ferritin, heavy polypeptide 1; ferritin 3.84 
FTHL3 ferritin, heavy polypeptide-like 3 pseudogene 3.83 
FTHL8 ferritin, heavy polypeptide-like 8 3.76 
LYPD5 LY6/PLAUR domain containing 5 3.68 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 3.66 
FTHL12 ferritin, heavy polypeptide-like 12 3.59 
HES5 hairy and enhancer of split 5 (Drosophila) 3.54 
ZNF185 zinc finger protein 185 (LIM domain) 3.54 
RASSF5 Ras association (RalGDS/AF-6) domain family member 5 3.44 
AKR1C3 
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type 
II) 3.39 
CDA cytidine deaminase 3.27 
ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 3.26 
NDRG1 N-myc downstream regulated 1 3.20 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 3.20 
BGN biglycan 3.15 
SHE Src homology 2 domain containing E 3.11 
TXNRD1 thioredoxin reductase 1; hypothetical LOC100130902 3.11 
FTHL2 ferritin, heavy polypeptide-like 2 3.09 
FTHL11 ferritin, heavy polypeptide-like 11 3.08 
ALOX5 arachidonate 5-lipoxygenase 3.06 
AKR1C4 aldo-keto reductase family 1, member C4 (dihydrodiol dehydrogenase 4) 2.99 
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2) 2.99 
CA12 carbonic anhydrase XII 2.92 
LOC729252 keratin 16 pseudogene 1 2.91 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 2.90 
NINJ1 ninjurin 1 2.90 
PLA2G10 phospholipase A2, group X 2.90 
CA2 carbonic anhydrase II 2.88 
LOX lysyl oxidase 2.88 
FAM116B family with sequence similarity 116, member B 2.83 
PDPN podoplanin 2.82 
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KRT15 keratin 15 2.74 
SEMA4B 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4B 2.72 
ETNK2 ethanolamine kinase 2 2.69 
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 2.69 
MVK mevalonate kinase 2.68 
IL1RL1 interleukin 1 receptor-like 1 2.65 
MTSS1 metastasis suppressor 1 2.64 
SGPP2 sphingosine-1-phosphate phosphotase 2 2.64 
ADM adrenomedullin 2.64 
SERPINE1 
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 
member 1 2.61 
SLC47A2 solute carrier family 47, member 2 2.59 
ASS1 argininosuccinate synthetase 1 2.57 
PTGS2 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase) 2.56 
COL16A1 collagen, type XVI, alpha 1 2.56 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 2.56 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 2.55 
ADSSL1 adenylosuccinate synthase like 1 2.54 
TRIML2 tripartite motif family-like 2 2.53 
BTBD11 BTB (POZ) domain containing 11 2.53 
TNNI2 troponin I type 2 (skeletal, fast) 2.47 
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 2.47 
PTK7 PTK7 protein tyrosine kinase 7 2.45 
FADS1 fatty acid desaturase 1 2.45 
LOC400578 keratin 1 pseudogene 2 2.44 
KRT6B keratin 6B 2.42 
TUBB3 tubulin, beta 3; melanocortin 1 receptor 2.41 
LAMB3 laminin, beta 3 2.41 
KRT80 keratin 80 2.39 
ERRFI1 ERBB receptor feedback inhibitor 1 2.39 
IRX4 iroquois homeobox 4 2.38 
MFGE8 milk fat globule-EGF factor 8 protein 2.38 
GDPD3 glycerophosphodiester phosphodiesterase domain containing 3 2.36 
BMP6 bone morphogenetic protein 6 2.36 
PKP1 plakophilin 1 (ectodermal dysplasia/skin fragility syndrome) 2.32 
PYCARD PYD and CARD domain containing 2.31 
SEMA3B 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 
3B 2.31 
ULK1 unc-51-like kinase 1 (C. elegans) 2.30 
TMEM40 transmembrane protein 40 2.30 
TRPV6 transient receptor potential cation channel, subfamily V, member 6 2.30 
FAM46A family with sequence similarity 46, member A 2.30 
RHPN2 rhophilin, Rho GTPase binding protein 2 2.27 
C14ORF78 chromosome 14 open reading frame 78 2.25 
CD9 CD9 molecule 2.21 
Down-regulated genes 
IL1A interleukin 1, alpha 0.24 
IL1B interleukin 1, beta 0.25 
FST follistatin 0.31 
IER3 immediate early response 3 0.31 
PTHLH parathyroid hormone-like hormone 0.35 
BIRC3 baculoviral IAP repeat-containing 3 0.37 
CAV1 caveolin 1, caveolae protein, 22kDa 0.37 
NUDT1 nudix (nucleoside diphosphate linked moiety X)-type motif 1 0.39 
THBS1 thrombospondin 1 0.39 
PHLDA1 pleckstrin homology-like domain, family A, member 1 0.4 
F2R coagulation factor II (thrombin) receptor 0.43 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 0.43 
PHACTR3 phosphatase and actin regulator 3 0.45 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 0.46 
LEPREL1 leprecan-like 1 0.48 
DUSP6 dual specificity phosphatase 6 0.49 
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ALDH1A3 aldehyde dehydrogenase 1 family, member A3 0.49 
HERC5 hect domain and RLD 5 0.5 
CCL20 chemokine (C-C motif) ligand 20 0.5 
IFIT3 interferon-induced protein with tetratricopeptide repeats 3 0.51 
AXL AXL receptor tyrosine kinase 0.51 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 0.51 
DKK3 dickkopf homolog 3 (Xenopus laevis) 0.52 
LOC653820  family with sequence similarity 72, member B 0.52 
CAV2 caveolin 2 0.52 
CPA4 carboxypeptidase A4 0.52 
FAM83A family with sequence similarity 83, member A 0.53 
FGFBP1 fibroblast growth factor binding protein 1 0.53 
CCNA2 cyclin A2 0.54 
CDC20 cell division cycle 25 homolog C (S. pombe) 0.54 
VEGFC vascular endothelial growth factor C 0.54 
FJX1 four jointed box 1 (Drosophila) 0.54 
GAL galanin prepropeptide 0.55 
DLK2 delta-like 2 homolog (Drosophila) 0.55 
CCNB1 cyclin B1 0.55 
DHRS3 dehydrogenase/reductase (SDR family) member 3 0.56 
HMMR hyaluronan-mediated motility receptor (RHAMM) 0.56 
STAMBPL1 STAM binding protein-like 1 0.56 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 0.57 
LPAR1 lysophosphatidic acid receptor 1 0.57 
ODC1 ornithine decarboxylase 1 0.57 
DLGAP5 discs, large (Drosophila) homolog-associated protein 5 0.58 
CKS2 CDC28 protein kinase regulatory subunit 2 0.59 
CKS1B CDC28 protein kinase regulatory subunit 1B 0.59 
SLC39A10 solute carrier family 39 (zinc transporter), member 10 0.59 
CLEC2D C-type lectin domain family 2, member D 0.59 
PAAF1 proteasomal ATPase-associated factor 1 0.6 
LOC652235  hypothetical protein LOC652235 0.6 
CENPA centromere protein A 0.6 
LHX6 LIM homeobox 6 0.6 
CKAP2L cytoskeleton associated protein 2-like 0.6 
HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 0.61 
CDKN3 cyclin-dependent kinase inhibitor 3 0.61 
OASL 2'-5'-oligoadenylate synthetase-like 0.61 
DKK1 dickkopf homolog 1 (Xenopus laevis) 0.61 
SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), member 13 0.61 
IL7R interleukin 7 receptor 0.61 
TRIP13 thyroid hormone receptor interactor 13 0.61 
KIF14 kinesin family member 14 0.61 
PBK PDZ binding kinase 0.62 
CCNB2 cyclin B2 0.62 
CTGF connective tissue growth factor 0.62 
KIF20A kinesin family member 20A 0.62 
CEP55 centrosomal protein 55kDa 0.62 
ADORA2B hypothetical LOC100131909; adenosine A2b receptor 0.62 
DDX10 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 0.63 
CLCC1 chloride channel CLIC-like 1 0.63 
PTTG3P pituitary tumor-transforming 3 0.63 
CCDC86 coiled-coil domain containing 86 0.63 
CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 0.63 
BIRC5 baculoviral IAP repeat-containing 5 0.63 
CCND2 cyclin D2 0.63 
FAM3C family with sequence similarity 3, member C 0.63 
TIMM10 translocase of inner mitochondrial membrane 10 homolog (yeast) 0.63 
ITPRIPL2 inositol 1,4,5-triphosphate receptor interacting protein-like 2 0.63 
TTK TTK protein kinase 0.63 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1); karyopherin alpha-2 subunit like 0.64 
CENPF centromere protein F, 350/400ka (mitosin) 0.64 
AURKB aurora kinase B 0.64 
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CENPN centromere protein N 0.64 
RABEPK Rab9 effector protein with kelch motifs 0.64 
GAS6 similar to growth arrest-specific 6; growth arrest-specific 6 0.64 
CYP27B1 cytochrome P450, family 27, subfamily B, polypeptide 1 0.64 
DLEU2 
deleted in lymphocytic leukemia 2 (non-protein coding); deleted in lymphocytic 
leukemia 2-like 0.64 
F3 coagulation factor III (thromboplastin, tissue factor) 0.64 
FAM83D family with sequence similarity 83, member D 0.65 
DEPDC1B DEP domain containing 1B 0.65 
MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) 0.65 
SOCS2 suppressor of cytokine signaling 2 0.65 
GPSM2 G-protein signaling modulator 2 (AGS3-like, C. elegans) 0.65 
ARL9 ADP-ribosylation factor-like 9 0.65 
PLD6 phospholipase D family, member 6 0.65 
FEZ1 fasciculation and elongation protein zeta 1 (zygin I) 0.65 
C13ORF34 chromosome 13 open reading frame 34 0.65 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 0.65 
PDCD2L programmed cell death 2-like 0.65 
LOC731049  similar to Ubiquitin-conjugating enzyme E2S 0.65 
FAM64A family with sequence similarity 64, member A 0.65 
PTTG1 pituitary tumor-transforming 1; pituitary tumor-transforming 2 0.65 
RAB3IL1 RAB3A interacting protein (rabin3)-like 1 0.66 
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APPENDIX III 
 
Interestingly, the reported data illustrate that CTCF and cohesin may bind the same DNA 
regions independently and thus may share the function as insulators (Wendt, 2008). To 
analyze the differences in CTCF and RAD21 (that is a subunit of cohesin complex and 
encodes the double-strand-break repair protein) we compared their relative expression levels 
in non-malignant prostate cells using qPCR analysis. As shown in the Figure 37A, the 
expression of RAD21 gene was more than 25-times higher than that of the CTCF gene. Based 
on our previous data showing the relation between CTCF stronger associations to its binding 
sites upon VDR ligand stimulation, we tested whether VDR influences the expression of 
RAD21 gene in CTCF depletion condition. Therefore, after CTCF knockdown we stimulated 
non-malignant prostate cells with 1α,25(OH)2D3 for 4 h and we noticed that RAD21 was 
induced (Fig. 37B). Inhibition of CTCF had no effect on the transcript level of RAD21 (Fig. 
37C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. CTCF knockdown causes 1α,25(OH)2D3-dependent changes in mRNA 
expression level of RAD21 gene. The basal expression levels of RAD21 and CTCF (A) 
were analyzed by qPCR in relation to housekeeping gene RPLPO. RWPE1 cells transfected 
with specific siRNAs oligonucleotides against CTCF and control siRNA or not transfected, 
were stimulated for 4 h with 1α,25(OH)2D3 (B) and the fold inductions were determined 
relative to the solvent (EtOH). (C) The basal expression levels of RAD21 after CTCF 
depletion were analyzed according to the RPLPO gene. Columns indicate a mean of three 
independent experiments, each done in triplicate and the error bars stand for SEM. 
 
Taken together, our data suggests that in non-malignant prostate cells the mRNA level of 
RAD21 gene was strikingly higher than the level of CTCF gene. Moreover, after knockdown 
of CTCF gene, relative expression level of RAD21 did not change however this gene was 
induced by 1α,25(OH)2D3 in CTCF-depleted condition, which may suggest VDR contribution 
in regulation of that gene. 
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